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ii. Summary 
Background: Campylobacteriosis is a zoonotic disease caused 
by an infection with bacteria from the genus 
Campylobacter spp. In humans, it manifests clinically as acute 
gastroenteritis (AG) of short duration i.e. a few days. The 
syndrome AG is mainly characterised by diarrhoea (>3 
unformed stools per day), vomiting, nausea, dehydration and 
abdominal cramps and pain. Also other infectious intestinal 
diseases (IID) caused by a wide range of bacterial, viral or 
parasitic pathogens can lead to AG. Campylobacteriosis and 
many other IID are diagnosed by stool diagnostics (stool 
cultures, polymerase chain reactions). Major risk factors for an 
infection with Campylobacter spp. are foreign travel, eating 
undercooked chicken meat and exposure through 
environmental routes e.g. contaminated drinking water. 
Campylobacteriosis is the most prevalent bacterial zoonotic 
disease in European countries and other high-income countries 
around the world. Close to 230,000 cases were recorded in 
Europe in 2015, 7000 thereof from Switzerland. AG due to IID 
is a prevalent disease and 0.25 – 1.4 disease episodes per 
person per year are observed in high-income countries. In 
Switzerland, laboratory-confirmed cases of campylobacteriosis 
are registered in the National Notification System for 
Infectious Diseases (NNSID) at the Federal Office of Public 
Health. In line with the rest of Europe case numbers show an 
increasing and unexplainable trend since 2005. Human 
Campylobacter infections in Switzerland show a clear 
seasonality with a peak of infections during summer time and a 
second peak during winter time at the turn of the year. 
Determinants leading to the observed epidemic peak of 
campylobacteriosis case numbers in Switzerland in winter time 
Summary 
xxvi 
are unknown. The disease burden of campylobacteriosis 
measured by the NNSID is supposedly only the tip of the 
iceberg. Many cases suffering from a mild episode of AG 
which could be due to an infection with Campylobacter spp. do 
not seek health care, are never tested and hence not reported. 
Yet, only laboratory-confirmed cases of notifiable IID such as 
campylobacteriosis are registered in the NNSID. The paradigm 
of the burden-of-illness pyramid describes the chain of events 
that have to occur for a case of IID in the community to be 
reported to the surveillance system. These are: (i) affected 
individual seeks health care (ii) a stool test is performed and 
(iii) a positive result is reported to the surveillance system. It is 
unclear which determinants lead to health care seeking of 
campylobacteriosis and AG cases and which processes lead to 
the initiation of stool testing i.e. to registration in the NNSID. 
Objectives: This work aimed at contributing to a better under-
standing of the epidemiology of human campylobacteriosis and 
AG and improving the interpretation of routine surveillance 
data from the NNSID. It seeks (i) to describe how campylobac-
teriosis and AG presents as disease and illness in the Swiss 
population and within the Swiss health care system and (ii) to 
create a basis for an improved interpretation and validity of 
routine surveillance data from the NNSID. 
Methods: Six research components were conducted to assess 
the epidemiology of human campylobacteriosis and AG and 
the associated disease and economic burden from different per-
spectives along the burden-of-illness pyramid. Determinants of 
the campylobacteriosis winter peak in Switzerland were inves-
tigated conducting a matched case-control study at the turn of 
the year 2012/2013. Cases were recruited among laboratory-
confirmed cases registered in the NNSID and controls matched 
Summary 
xxvii 
for sex, age group and canton of residence from the general 
Swiss population. Participants were interviewed by telephone 
using a sent-before photo illustrated questionnaire about differ-
ent food and non-food exposures and cases were additionally 
questioned regarding their illness experience. Risk factors were 
assessed applying a pair-matched analysis. Results of the case-
control study lead to an additional assessment of transmission 
dynamics of Campylobacter spp. in Europe. For this work 
case-based surveillance data for selected European countries 
were descriptively analysed with a focus on winter peaks as 
observed in Switzerland. Long-term epidemiological trends 
observed in campylobacteriosis and salmonellosis surveillance 
data of the NNSID were investigated by assessing laboratory 
positivity rates and merging case notification data and laborato-
ry test data from eight large Swiss diagnostic laboratories. The 
retrospective analysis of positivity rates (positive tests divided 
by total tests conducted) included data on stool tests conducted 
between 2003 and 2012. The clinical presentation of campylo-
bacteriosis cases, case management and disease burden of 
campylobacteriosis and AG at the primary care level were in-
vestigated using a mixed methods approach. First, general 
practitioners (GPs) managing cases of the aforementioned 
case-control study were interviewed with a semi-structured 
questionnaire on clinical presentation, case management and 
disease burden. Interviews were analysed by inductive content 
analysis based on Grounded Theory. Study results provided 
valuable inputs for the design of the following prospective 
quantitative study embedded in the Swiss Sentinel Surveillance 
Network Sentinella. Some 170 physicians practicing in primary 
care and paediatrics provided information on the number and 
aetiology of AG cases and also on the associated case presenta-
tion and management over one year. Data were descriptively 
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analysed and initial consultations due to AG per 100,000 popu-
lation were estimated. This work portfolio finally provided data 
needed to estimate direct health care costs caused by campylo-
bacteriosis and AG. Direct health care costs were estimated 
using expert opinions, official cost rates for health care and 
results of the preceding research components. 
Results: The multivariable analysis of data from the case-
control study identified the consumption of meat fondue 
(matched odds ratio [mOR] 4.0, 95 % confidence interval [CI] 
2.3–7.1) and travelling abroad (mOR 2.7, 95 % CI 1.1–6.4) as 
major risk factors for an infection with Campylobacter spp. 
over Christmas and New Year. The consumption of meat 
fondues with chicken meat was associated with a significantly 
increased risk of disease compared to meat fondue without 
chicken meat (mOR 3.8, 95 % CI 1.1–13.5). Around 60% of 
campylobacteriosis cases received an antibiotic therapy and 
14% were hospitalised. The assessment of transmission 
dynamics with national case-based surveillance data on 
Campylobacter spp. from several European countries showed 
that winter peaks similar to Switzerland can be observed in 
Austria, Belgium, Finland, Germany, Luxembourg, The 
Netherlands and Sweden. Disease onsets reported for cases 
point towards risk exposures around Christmas and New Year, 
and meat fondue or table top grilling also posing such a risk are 
prominent in several of these countries at this time of the year. 
The analysis of laboratory positivity rates from 
Campylobacter spp. and Salmonella spp. showed an increase of 
annual test numbers for both infections of 51% from 2003 to 
2012. Positivity rates of Campylobacter spp. increased from 
7.6% to 11.1% during the same time period while rates of 
Salmonella spp. decreased from 2.7% to 1.5%. A distinct 
Summary 
xxix 
seasonality of test numbers and positivity rates was observed 
whereby the rate for Salmonella spp. peaked in autumn and for 
Campylobacter spp. in summer as well as at the turn of the 
year. The qualitative study among GPs revealed that a 
considerable proportion of AG patients consults and receives 
medical advice by telephone only. Interviewed physicians 
reported an estimated average disease burden of two AG cases 
per week and five campylobacteriosis cases per year. Four 
distinct strategies for the application of stool diagnostics 
(“test”) and antibiotic therapy (“treat”) were observed: “Wait & 
See”, “Treat & See”, “Treat & Test”, and “Test & See”. The 
subsequent quantitative study within the Sentinella network 
estimated the incidence of AG at the primary care level for 
2014 at 2146 first consultations per 100,000 population. Stool 
diagnostics were performed for 11.6% of patients and 
Campylobacter spp. was the most frequently diagnosed 
pathogen. Antibiotics were prescribed for 8.5% of cases and 
86.3% were on sick leave for a median duration of 4 days. 
Estimated 311,192 – 707,255 patients consult a physician due 
to AG or campylobacteriosis annually resulting in direct health 
care costs of €29 to €45 million. 
Conclusions: The importance of human campylobacteriosis 
and AG due to IID for public health has been clearly underes-
timated in Switzerland so far. Both diseases cause a high 
disease and health system burden leading to remarkable health 
care costs. Cases are often severely affected by the disease and 
the proportion requiring hospitalisation and/or antibiotic thera-
py is considerable. Human exposure to chicken meat 
contaminated with Campylobacter spp. at meat fondues plays a 
major role for the epidemic increase of case numbers during 
winter time. The NNSID accurately reflects epidemiological 
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trends of campylobacteriosis and salmonellosis in the Swiss 
population. Public health authorities should regularly assess 
determinants of the burden-of-illness pyramid to maintain the 
system’s validity. This work has significantly increased the 
knowledge on the disease burden of human campylobacteriosis 
and AG in Switzerland but the exact burden of disease in the 
community still needs to be further investigated. 
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1. Introduction including literature review 
Campylobacteriosis is a zoonotic bacterial disease in humans 
leading to acute gastroenteritis (AG) and is caused by 
Campylobacter spp. Its disease burden increased continuously 
in Europe during the last decade. Switzerland was no exception 
and Campylobacter spp. got more attention from public health 
authorities. As a result, the Swiss Federal Food Safety and 
Veterinary Office (FSVO) founded the “Campylobacter 
platform” together with other authorities and partners from 
academia and the industry to address this public health problem 
in a One Health approach in December 2008
1
. The aim was to 
launch the control of Campylobacter spp. based on scientific 
evidence and thereby reduce the human disease burden. 
Therefore, the platform initiated several research projects 
regarding campylobacteriosis to close existing knowledge gaps 
in Switzerland.  
Various risk assessments from abroad showed that the con-
sumption of chicken meat contaminated with 
Campylobacter spp. is the main source of infection for humans. 
Consequently, a focus of the research was laid on the transmis-
sion pathway of Campylobacter spp. along the food chain 
including poultry production, food safety, consumer behaviour 
and risk exposures. Other sources of infection and routes of 
exposure than via poultry were investigated by source attribu-
tion studies with Campylobacter spp. isolates from animals, 
food, humans and the environment. The disease burden of 
campylobacteriosis and the associated health care costs in 
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Switzerland were largely unknown except case numbers regis-
tered by the National Notification System for Infectious 
Diseases (NNSID) of the Federal Office of Public Health 
(FOPH). The NNSID case numbers represent merely the tip of 
the iceberg in terms of disease burden. Only laboratory-
confirmed cases are registered and not all cases suffer from 
severe disease and have stool diagnostics performed. Undiag-
nosed campylobacteriosis cases are clinically categorised as 
AG patients. Hence, estimating the disease burden and health 
care costs of campylobacteriosis need to take AG into account. 
This work contributes to the endeavours of the Campylobacter 
platform by providing an understanding of the epidemiology of 
campylobacteriosis and AG in Switzerland. The disease bur-
den, potential risk factors for infection, case management and 
health care costs associated with campylobacteriosis and AG 
were investigated from a human and health system’s perspec-
tive. The subsequent introduction and literature review 
provides an overview on (i) campylobacteriosis and AG as 
diseases including risk factors for infection, (ii) the associated 
case management, (iii) the current knowledge on their disease 
burden and cost of illness in high-income countries and (iv) 
surveillance systems for campylobacteriosis and other gastroin-
testinal diseases in Switzerland. 
1.1. Campylobacteriosis 
1.1.1. Pathogenesis 
Human campylobacteriosis is a zoonotic disease that is mainly 
caused by the bacteria Campylobacter jejuni and a smaller pro-
portion by Campylobacter coli (Gillespie et al. 2002, Man 
2011, Schielke et al. 2014, EFSA and ECDC 2016). The rela-
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tionship of both species with the occurrence of diarrhoea in 
humans was first described by Skirrow as “Campylobacter 
enteritis” (Skirrow 1977). Other Campylobacter species caus-
ing gastrointestinal and extragastrointestinal infections include 
C. concisus, C. upsaliensis, C. ureolyticus, C. lari or C. fetus 
but their importance for humans and public health is largely 
unknown (Lastovica 2006, Man 2011, Kaakoush et al. 2015). 
However, traditional culture methods – which are still widely 
deployed in routine diagnostics - underestimate the prevalence 
of non-C. jejuni/C. coli spp. and recent studies suggest a higher 
importance of non-C. jejuni/C. coli spp. in human campylobac-
teriosis than previously assumed (Lastovica 2006, Bullman et 
al. 2012, On 2013, Underwood et al. 2016). 
Campylobacter spp. is transmitted by the faecal-oral route and 
the intake of as little as 500 organisms is sufficient to acquire 
an infection (Robinson 1981, Black et al. 1988, Kothary and 
Babu 2001). Following an incubation period of approximately 
3 days the onset of campylobacteriosis is often marked by 
strong abdominal cramps and later includes diarrhoea (bloody, 
watery), fever, nausea, vomiting and abdominal and joint pain 
(Skirrow 1990, Kapperud et al. 1992, Ketley 1997, Braam 
2004). A variety and mix of signs and symptoms occur in dif-
ferent combinations and severities. The disease manifests 
clinically as AG of short duration i.e. a few days and is usually 
self-limiting with an unproblematic recovery (Kapperud et al. 
1992, Ketley 1997, Wassenaar and Blaser 1999, Zilbauer et al. 
2008).  
Rare complications of an infection with Campylobacter spp. 
include gastrointestinal and extragastrointestinal complications 
such as reactive arthritis, cholecystitis, pancreatitis, meningitis, 
bacteraemia, inflammatory bowel disease (IBS) or febrile con-
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vulsions (Skirrow et al. 1993, Smith 1995, Allos 2001, Hannu 
et al. 2002). The so called Guillan-Barré syndrome (GBS) is an 
important and severe complication after an infection 
(Nachamkin et al. 1998, Allos 2001, Nachamkin 2001, 
Poropatich et al. 2010). GBS, an acute autoimmune-mediated 
disorder affecting the peripheral nervous system, results in neu-
romuscular paralysis such as weakness of limbs and respiratory 
muscles (Smith 1995, Hughes and Rees 1997, Nachamkin et al. 
1998). An annual increase of 7% of cases with Campylobacter-
associated GBS was observed in France between 1996 and 
2007 while the number of GBS cases in New Zealand de-
creased due to campylobacteriosis control (Baker et al. 2012, 
Sivadon-Tardy et al. 2014). 
1.1.2. Risk factors for contracting campylobacteriosis 
Reservoirs for Campylobacter spp. are different domestic or 
wildlife birds and mammals where the human pathogen lives 
commensally in the intestine (Blaser et al. 1980, EFSA Panel 
on Biological Hazards 2010). As a result animal faeces con-
taminate the environment or carcasses - especially poultry - 
during the slaughter process (Engberg 2006, EFSA Panel on 
Biological Hazards 2010, Whiley et al. 2013, Kaakoush et al. 
2015). Hence, the pathogen can be transmitted from its reser-
voir to humans over direct routes e.g. close contact with 
domestic animals or indirect routes such as contaminated 
drinking water or meat (EFSA Panel on Biological Hazards 
2010, Whiley et al. 2013). A meta-analysis of case-control 
studies on risk factors for a sporadic Campylobacter spp. infec-
tion identified the following exposures being associated with 
an elevated risk for infection: foreign travel, eating under-
cooked chicken meat, exposure through environmental routes 
e.g. contaminated drinking water, direct contact with farm an-
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imals and having a pre-existent chronic disease (Domingues et 
al. 2012). 
Several studies have identified travelling abroad as one of the 
most important risk factor for contracting human 
campylobacteriosis (Schorr et al. 1994, Neimann et al. 2003, 
Friedman et al. 2004, Mossong et al. 2016). Concomitantly, 
high proportions of campylobacteriosis were reported among 
returning travellers suffering from bacterial diarrhoea 
(Swaminathan et al. 2009, Ravel et al. 2011, Zenner and 
Gillespie 2011, Kendall et al. 2012). The risk of infection 
depends on the destination of travel and is generally lower for 
travels to Northern and Western Europe and North America 
while it increases for travels to Asia, Africa or South America 
(Charlett et al. 2003, Ekdahl and Andersson 2004, Mughini-
Gras et al. 2014). However, travel per se is not considered a 
source of infection or route of exposure as travellers are likely 
exposed to Campylobacter spp. by the common routes e.g. 
eating chicken meat (Pires et al. 2009, Domingues et al. 2012, 
Mughini-Gras et al. 2014). 
The most important source for the foodborne transmission de-
scribed in the literature is poultry whereas beef and pork seem 
to play a secondary role (Mullner et al. 2009, Sheppard et al. 
2009, EFSA Panel on Biological Hazards 2010, Boysen et al. 
2014). Poultry and cattle mainly harbour Campylobacter jejuni 
and to a lesser extent Campylobacter coli which is more com-
mon among pigs (Inglis et al. 2004, Milnes et al. 2008, Hannon 
et al. 2009, EFSA Panel on Biological Hazards 2010).  
Especially carcasses of broilers become easily contaminated 
during the slaughter process and chicken meat often contains 
high loads of Campylobacter spp. when it reaches the retail 
level (EFSA Panel on Biological Hazards 2010, Ellerbroek et 
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al. 2010, Guerin et al. 2010, Hardy et al. 2013). Different risk 
assessments in high-income countries indicate that the con-
sumption of poultry meat especially when undercooked is the 
main risk factor for an infection with Campylobacter spp. 
(Schorr et al. 1994, Neimann et al. 2003, Friedman et al. 2004, 
Mughini Gras et al. 2012, Mossong et al. 2016). Genetic stud-
ies investigating the sources of human Campylobacter spp. 
infections showed that exposure to chicken meat accounts for 
around 50-70% of human campylobacteriosis cases (Sheppard 
et al. 2009, Kittl et al. 2013a, Boysen et al. 2014, Jonas et al. 
2015, Mossong et al. 2016).  
The important role of poultry as an infection source could be 
observed 1999 in Belgium and 2003 in the Netherlands 
(Vellinga and van Loock 2002, van Pelt et al. 2004). Domesti-
cally produced poultry products and eggs were withdrawn from 
the retail market in Belgium due to the contamination of poul-
try products with dioxin (Vellinga and van Loock 2002). The 
number of human campylobacteriosis cases dropped by 40% 
during the two weeks following the withdrawn and returned to 
previous levels afterwards (Vellinga and van Loock 2002). An 
outbreak of avian influenza and the associated culling of poul-
try in the Netherlands from March to May 2003 resulted in 
higher prices for and consequently a lesser consumption of 
poultry meat (Friesema et al. 2012). A 10% - 70% reduction of 
reported campylobacteriosis cases was observed among public 
health laboratories until December 2003, with the largest re-
duction in areas where the culling took place (Friesema et al. 
2012). 
Beef, pork, sheep meat or game play also a role in in foodborne 
transmission of Campylobacter spp. e.g. if consumed raw as 
tartare (Mullner et al. 2009, Taylor et al. 2013, Whiley et al. 
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2013). While pigs, sheep and wild animals are the a source of 
infection for only a minority of human infections cattle account 
for around 20% of human cases (Sheppard et al. 2009, Kittl et 
al. 2013a, Boysen et al. 2014, Jonas et al. 2015). 
Campylobacter strains from cattle are mainly linked to 
campylobacteriosis outbreaks where contaminated 
unpasteurized milk or drinking water was identified as the 
source of infection (Clark et al. 2003, Heuvelink et al. 2009, 
Taylor et al. 2013, Fernandes et al. 2015). 
Although Campylobacter spp. are generally perceived as food-
borne pathogens other transmission pathways also contribute. 
Noteworthy are direct contact (e.g. petting) with infected do-
mestic animals or pets and contaminated vegetables or fruits 
eaten raw (Neimann et al. 2003, Verhoeff-Bakkenes et al. 
2011, Mughini Gras et al. 2012, Gras et al. 2013). However, 
the consumption of raw vegetables in relation to contracting 
campylobacteriosis is controversial and has also been identified 
as a protective factor (Neimann et al. 2003, Doorduyn et al. 
2010, Mughini Gras et al. 2012, Whiley et al. 2013). 
1.1.3. Risk factors for contracting campylobacteriosis in 
Switzerland 
In Switzerland the major risk factors for a sporadic infection 
with Campylobacter spp. were already described more than 20 
years ago by a case-control study using a ‘close-friend’-control 
sampling (Schorr et al. 1994). It showed that travelling abroad 
followed by the consumption and handling of poultry and poul-
try liver are the most important risk factors in Switzerland. 
Risk exposures and risk factors could have changed and likely 
vary during the year considering the increase of human cam-
pylobacteriosis cases since the 1990s (Schmutz et al. 2016). 
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It appears as travelling abroad was surpassed by poultry con-
sumption as the main risk factor in Switzerland. One of the 
Swiss genotyping studies which distinguished between domes-
tic and travel-associated human cases counted only 18% of 
travel-associated cases (Niederer et al. 2012). The population 
attributable fractions of travelling abroad and poultry consump-
tion in Switzerland were equal (27%) in a risk attribution 
model using exposure modelling (Büttner et al. 2010). 
In Switzerland several genotyping studies attributed human 
campylobacteriosis cases to different sources of infection. The 
comparison of human isolates with environmental isolates re-
vealed that 40 – 84% of the human cases originated from the 
poultry reservoir (Kittl et al. 2011, Kittl et al. 2013a, Jonas et 
al. 2015). However, another study on domestic and travel-
associated human isolates showed a much lower genetic over-
lap with poultry isolates (Niederer et al. 2012). Further, poultry 
as main cause of infection leading to human campylobacterio-
sis in Switzerland is supported by a risk attribution model 
which estimated a population attributable fraction of 27% for 
poultry consumption (Büttner et al. 2010). 
Indeed Swiss broiler flocks show high levels of colonisation 
with Campylobacter spp. (BLV and BAG 2017). A Swiss 
study between autumn 2003 and summer 2004 found that 
35.7% of broiler flocks were colonised by Campylobacter spp. 
whereby the five colonised flocks were tested positive in sum-
mer (Ring et al. 2005). Another study revealed a 
Campylobacter spp. prevalence of 29% among faecal swab 
samples collected from chickens of 100 Swiss poultry farms. 
This corresponds to a flock prevalence of 54% and on the farm 
level up to 69% of included farms were tested positive depend-
ing on the type of farm (Wittwer et al. 2005). On farms, the 
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pathogen is often transferred from chickens to other farm ani-
mals and vice versa (Zweifel et al. 2008). The latest available 
data from 2016 shows a flock prevalence for broiler chickens 
of 35% (BLV and BAG 2017). 
The prevalence of Campylobacter in broilers at slaughter has a 
direct effect on the prevalence of campylobacteriosis in 
humans after two weeks (Wei et al. 2015). Campylobacter 
strains of broilers at slaughter were found at high levels in 
chicken meat at the Swiss retail level (Wirz et al. 2010, Kittl et 
al. 2013b). The contamination rate of chicken meat with 
Campylobacter spp. depends on the season of the year (higher 
in summertime) and can reach up to a 100% e.g. for chicken 
liver (Baumgartner and Felleisen 2011, BLV and BAG 2017). 
Domestic chicken meat products are significantly more often 
contaminated than chicken meat products imported from 
abroad (Baumgartner and Felleisen 2011). Hence, the indirect 
transmission of Campylobacter spp. from broilers to humans 
by chicken meat could play a major role for human 
campylobacteriosis in Switzerland. 
Bovine Campylobacter spp. strains are also a source for human 
campylobacteriosis in Switzerland. Around 10-20% of human 
Campylobacter spp. isolates can be attributed to cattle 
(Wieland et al. 2006, Kittl et al. 2013a, Jonas et al. 2015). 
However, an earlier study did not find any Campylobacter spp. 
in bulk-tank milk samples from 206 different Swiss dairy farms 
(Stephan and Buhler 2002). Campylobacter spp. can also be 
found in pigs, dogs and cats but these seem to play a minor part 
as sources for human campylobacteriosis (Wieland et al. 2005, 
Keller et al. 2007, Kittl et al. 2013a, Amar et al. 2014). 
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1.1.4. Measures to reduce the burden of campylobacteriosis 
The burden of human campylobacteriosis can be most 
effectively reduced by an interdisciplinary One Health 
approach along the food chain including all relevant 
stakeholders (Golz et al. 2014). Of special interest herein is 
chicken meat given it is deemed the main source of human 
infections in Europe (EFSA Panel on Biological Hazards 
2010). Intervention methods and control measures should be 
implemented at different stages along the farm-to-fork chain 
i.e. from broiler farms over slaughter and retail levels to the 
consumer level (Wagenaar et al. 2013, Golz et al. 2014). The 
colonization of broiler flocks with Campylobacter spp. can 
theoretically be prevented with strict biosafety measures on 
farms (Wagenaar et al. 2013, Golz et al. 2014). Yet, 
Campylobacter spp. is ubiquitous in the environment of farms 
significantly hindering any prevention of its introduction into 
broiler flocks (Wagenaar et al. 2013). Promising control 
measures are the irradiation (e.g. gamma radiation) or chemical 
decontamination (e.g. by lactic acids, acidified sodium chlorite, 
peracetic acid) of broiler carcasses at the end of the slaughter 
process which aim at reducing the contamination rate and the 
load of Campylobacter spp. on broiler carcasses (EFSA Panel 
on Biological Hazards 2011). Today, these interventions and 
measures aim at lowering Campylobacter contamination levels 
of poultry products to an acceptable low risk as it is hardly 
possible to completely eliminate Campylobacter spp. from the 
poultry production (Wagenaar et al. 2013). 
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1.2. Acute gastroenteritis and infectious intestinal diseases 
caused by Campylobacter spp. and other gastrointes-
tinal pathogens 
1.2.1. Acute gastroenteritis 
Gastroenteritis also named gastrointestinal illness or diarrhoeal 
disease is a common and widespread disease worldwide espe-
cially among children (Majowicz et al. 2008, Fischer Walker et 
al. 2012, GBD 2015) (see Chapter 1.3). In general, gastroenter-
itis is physiologically characterised by inflammatory processes 
of the stomach or intestinal mucosal surface leading to enteric 
symptoms - predominantly diarrhoea (Tam et al. 2012a, 
DuPont 2014, Morgan et al. 2015). General characteristics of 
diarrhoea are increased water content, volume or frequency of 
stools (Guerrant et al. 2001). A frequent definition of diarrhoea 
is the passage of ≥3 unformed or liquid stools per day (in 24h) 
likewise accompanied by other enteric symptoms such as vom-
iting (Guerrant et al. 2001, WHO 2005, DuPont 2014). 
Diarrhoea can be categorised based on its duration as acute 
(<14 days), persistent (14 - 29 days) and chronic (≥30 days) 
(DuPont 2014). 
AG usually last for less than 2 weeks and typical symptoms 
include diarrhoea (watery, with blood, mucus), vomiting, ab-
dominal cramps and pain, fever, dehydration, nausea and loss 
of appetite occurring in various combinations (Guerrant et al. 
2001, Thielman and Guerrant 2004, Majowicz et al. 2008, 
Morgan et al. 2015). Causes of AG include a range of gastroin-
testinal infections e.g. campylobacteriosis, non-infectious 
causes such as food poisonings (bacterial toxins, chemicals) or 
chronic conditions e.g. Crohn’s disease, ulcerative colitis or 
food intolerance (Tam et al. 2012a). Yet, not all gastrointesti-
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nal infections or food poisonings e.g. Helicobacter pylori or 
botulism lead to enteric symptoms (Tam et al. 2012a).  
1.2.2. Infectious intestinal diseases 
The term infectious intestinal diseases (IID)
2
 generally refers to 
an infection with a gastrointestinal pathogen causing AG and is 
also known as acute infectious diarrhoea (Guerrant et al. 2001, 
Tam et al. 2012a, DuPont 2014, Morgan et al. 2015) (Figure 
1.1). A wide range of pathogenic bacteria, viruses and protozoa 
mainly transmitted by the faecal-oral route have been identified 
as causes of IID (de Wit et al. 2001a, Huhulescu et al. 2009, 
Tam et al. 2012b, Morgan et al. 2015). Many of them are part 
of the ICD-10 group “Intestinal infectious diseases” (A00–
A09) and are also summarised under the term food- and water-
borne diseases. 
The largest proportion of IID is caused by viruses whereby the 
main cause of viral IID at a global scale is considered to be 
norovirus accounting for nearly a fifth of all AG cases (Hall et 
al. 2013, Ahmed et al. 2014, Kirk et al. 2015, Pires et al. 
2015). Other disease causing viruses include rotavirus, adeno-
virus, astrovirus and others (de Wit et al. 2001a, Huhulescu et 
al. 2009, Tam et al. 2012b, Morgan et al. 2015). Bacterial 
pathogens commonly causing IID are mainly food- and water-
borne including, among others, Campylobacter spp., 
Salmonella spp., Shigella spp., Clostridium spp., Vibrio spp., 
Yersinia spp. or pathogenic E. coli (de Wit et al. 2001a, 
DuPont 2009, Tam et al. 2012b). However, also bacterial path-
ogens potentially resulting in systemic infections with little 
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enteric symptoms (e.g. Salmonella typhi/paratyphi, Listeria 
spp.) are often included (DuPont 2009, Tam et al. 2012a).  
Parasitic pathogens such as Giardia spp., Cryptosporidium 
spp., Blastocystis spp. or Entamoeba spp. are of less im-
portance in high-income countries (de Wit et al. 2001a, 
Huhulescu et al. 2009, Tam et al. 2012b). In these countries 
they are often found in travellers returning from the tropics and 
sub-tropics (Shah et al. 2009, Majer and Neumayr 2015, 
Herbinger et al. 2016). Also other IID are frequently diagnosed 
in travellers with traveller’s diarrhoea returning from low- and 
middle-income countries to high-income countries (Shah et al. 
2009, Kendall et al. 2012, Herbinger et al. 2016). 
Figure 1.1: Graphical illustration of the term infectious intes-
tinal disease in relation to similar terms. 
Source: Tam et al. (2012a) 
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1.3. Disease burden and epidemiology of acute gastroen-
teritis and human campylobacteriosis 
1.3.1. Disease burden and epidemiology of acute gastroenter-
itis in high-income countries 
An estimated 2.8 billion cases of diarrhoeal diseases occurred 
on a global level in 2013 according to the Global Burden of 
Disease Study (GBD 2015). Pires et al. (2015) estimated that 
Campylobacter spp., Cryptosporidium spp., Salmonella spp., 
Shigella spp., enterotoxigenic E. coli, enteropathogenic E. coli, 
Entamoeba histolytica, Giardia lamblia and norovirus trans-
mitted by food in concert caused globally 1.8 billion cases of 
diarrhoeal disease and 599,000 deaths in 2010. Children under 
the age of 5 years accounted for around 40% of cases and 
deaths (Pires et al. 2015). The highest disease burden is ob-
served in low- and middle income countries (LMICs) (GBD 
2015, Pires et al. 2015) 
In high-income countries incidences of AG on population level 
range from 0.3 to 3.5 episodes per person-year (Roy et al. 
2006). In Europe, reports indicate that an individual experienc-
es 0.5 to 1.4 episodes of AG on average per year. Specifically 
the number of episodes per person-year – often referred to as 
‘annual incidence’-, was estimated at 0.27 for the United King-
dom (UK) (Tam et al. 2012c), 0.29 for the Netherlands 
(Havelaar et al. 2012), 0.33 for France (van Cauteren et al. 
2012), 0.42 for Malta (Gauci et al. 2007b) 0.60 for Ireland 
(Scallan et al. 2004), 0.90 for Poland (Baumann-Popczyk et al. 
2012), 0.95 for Germany (Wilking et al. 2013), 1.08 for Italy 
(Scavia et al. 2012), 1.2 for Norway (Kuusi et al. 2003) and 1.4 
for Denmark (Muller et al. 2012). The disease burden in the 
United States of America (US), Canada, Australia and New 
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Zealand was estimated at 0.60, 0.63, 0.92 and 1.11 episodes per 
person-year, respectively (Hall et al. 2006, Jones et al. 2007, 
Adlam et al. 2011, Thomas et al. 2013). Comparisons between 
countries should be interpreted with caution. Often, different 
study designs and case definitions were used leading to re-
markable differences in the estimated disease burden (Scallan 
et al. 2005, Majowicz et al. 2008). By 2017 no such estimate 
was available for Switzerland. 
These high incidences result in a high annual AG disease bur-
den and significant health system use in these countries: In 
2009, an estimated 16.9 million cases in the UK resulted in 18 
physician consultations per 1000 person-years (Tam et al. 
2012c). In the Netherlands, an estimated 4.8 million cases of 
AG result in 13 primary care attendances per 1000 person-
years and 1.3 hospitalisations per 1000 person-years (Havelaar 
et al. 2012). Norwegian estimates assume 5.4 million cases, 
200 consultations per 1000 person-years and 50 hospital ad-
missions per 1000 person-years resulting in 800,000 hospital 
days (Kuusi et al. 2003). The disease burden for France was 
estimated at 21 million cases and 110 physician consultations 
per 1000 person-years (van Cauteren et al. 2012). The estimate 
for Poland is 33.3 million cases, 266 physician consultations 
per 1000 person-years and 40 hospitalisations per 1000 person-
years (Baumann-Popczyk et al. 2012). In Italy, an estimated 48 
million cases and 389 physician consultations occur per 1000 
person-years (Scavia et al. 2012). A study in Germany estimat-
ed 64.9 million cases, 395 physician consultations per 1000 
person-years and 32 admissions to hospital per 1000 person-
years resulting in 19.9 million hospital days per year for the 
adult population only (Wilking et al. 2013).  
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Studies in high-income countries showed that the disease bur-
den is generally highest in children and decreases with age 
(Baumann-Popczyk et al. 2012, Doorduyn et al. 2012, Muller 
et al. 2012, Tam et al. 2012c, van Cauteren et al. 2012). The 
incidence of AG in Danish children aged <9 years was 2.3 epi-
sodes per person-year compared to an all-age incidence rate of 
1.4 (Muller et al. 2012). In France, children aged <5 years had 
an incidence rate of 0.76 episodes per person-year which was 
more than double the rate of all study participants (van 
Cauteren et al. 2012). The incidence rate of AG among Polish 
children was higher for those aged 5-14 years than for those 
aged <5years (1.4 vs. 1.1 episodes per person-year) (Baumann-
Popczyk et al. 2012). The disease burden among children is 
comparable to Europe in Australia, Canada, New Zealand and 
the US (Scallan et al. 2005, Hall et al. 2006, Jones et al. 2007, 
Adlam et al. 2011). 
The disease burden of AG in Europe generally peaks in winter 
and decreases at the beginning of spring (Huhulescu et al. 
2009, Muller et al. 2012, Scavia et al. 2012, van Cauteren et al. 
2012, Wilking et al. 2013). In Poland as an example, the high-
est rate was observed for January (1.48 episodes per person-
years) and lowest in June (0.35 episodes per person-years) 
(Baumann-Popczyk et al. 2012). Interestingly, in Malta a 
slightly different seasonality with peaks in June–July and Oc-
tober–November is observed (Gauci et al. 2007b). The disease 
burden of AG in Australia peaks also in summer (Hall et al. 
2006). 
In some countries such as Austria, Italy, Norway or Poland an 
additional peak in late summer (July-September) can be ob-
served (Kuusi et al. 2003, Huhulescu et al. 2009, Baumann-
Popczyk et al. 2012, Scavia et al. 2012). Studies indicate that 
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the peak in winter is associated with viral gastrointestinal in-
fections e.g. norovirus or rotavirus and the one in late summer 
with enteropathogenic bacteria e.g. Campylobacter spp. or 
Salmonella spp. (Huhulescu et al. 2009, Karsten et al. 2009, 
Baumann-Popczyk et al. 2012). The disease burden of specific 
bacterial and viral IID in Denmark shows a distinct seasonality 
(Muller et al. 2012). Norovirus infections are more prevalent in 
winter months, rotavirus infections in late winter and early 
spring and bacterial IID – especially Salmonella spp. – in 
summer (Muller et al. 2012). 
1.3.2. Disease burden and epidemiology of campylobacterio-
sis in high-income countries 
Human campylobacteriosis occurs worldwide (Kaakoush et al. 
2015, Kirk et al. 2015). The global disease burden in 2010 is 
estimated at 166 million cases including 37,600 deaths or at 3.7 
million disability-adjusted life years (DALYs) by the 
Foodborne Disease Burden Epidemiology Reference Group 
(FERG) (Kirk et al. 2015). The Global Burden of Disease 
Study 2010 estimated an even higher global burden of 7.5 
million DALYs (Murray et al. 2012). The disease burden for 
Switzerland in 2013 was estimated at 1751 – 2852 DALYs 
(Babo Martins et al. 2017). 
The available information on the disease burden of campylo-
bacteriosis in high-income countries is diverse and includes 
surveillance data, population-based studies and national burden 
estimates. This information can be influenced by surveillance 
biases, different diagnostic methods and techniques, study de-
signs and methods or population-level immunity (Havelaar et 
al. 2009, Kaakoush et al. 2015, EFSA and ECDC 2016). The 
disease burden of campylobacteriosis should thus be carefully 
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compared between countries and different study characteristics 
need to be considered. 
Since 2005 Campylobacter spp. is the most common gastroin-
testinal bacterial pathogen reported in humans in the European 
Union (EU) and the European Economic Area (EEA) (EFSA 
and ECDC 2016). The annual notification rate of campylobac-
teriosis in the EU increased significantly from 2008 to 2015 but 
has been rather stable in the last 5 years (EFSA and ECDC 
2016). For 2015, an average notification rate of 65.5 laborato-
ry-confirmed cases per 100,000 population corresponding to 
totally 229,213 laboratory-confirmed cases was reported 
(EFSA and ECDC 2016). This is a decrease of 5.8% compared 
to the notification rate of 2014 (69.5 per 100,000 population) 
and comparable with notification rates of 2012 and 2013 (65.4 
and 64.3 per 100,000 population, respectively) (EFSA and 
ECDC 2016). 
Highest national notification rates (>90 cases per 100,000 pop-
ulation) were reported from the Czech Republic, Slovakia 
Sweden and the UK and lowest rates (≤3.7 cases per 100,000 
population) from Bulgaria, Cyprus, Latvia, Poland, Portugal 
and Romania (EFSA and ECDC 2016). In Germany, the notifi-
cation rate of campylobacteriosis has increased considerably 
from 2001 (67 cases per 100,000 population) to 2014 (86 cases 
per 100,000 population) (Schielke et al. 2014, EFSA and 
ECDC 2016). Switzerland reported a notification rate of 85.3 
cases per 100,000 population for 2015 (EFSA and ECDC 
2016)
3
. 
                                                 
3
 Further, annual notification rates of campylobacteriosis for European 
countries  in 2015 are summarised in EFSA and ECDC (2016). 
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Some of the highest notification rates for campylobacteriosis 
were observed in New Zealand in the early 2000s with an aver-
age annual rate of 354 laboratory-confirmed cases per 100,000 
population (Sears et al. 2011). The notification rate dropped to 
162 cases per 100,000 population in 2008 after the successful 
implementation of poultry-focused food safety interventions 
(Sears et al. 2011). The notification rate of neighbouring Aus-
tralia was 117.3 cases per 100,000 population in 2011 and an 
estimated 774,000 cases resulting in 18,200 DALYs occurred 
at the population level in 2010 (Gibney et al. 2014, Gibney et 
al. 2016). 
Laboratory-confirmed cases represent only the tip of the ice-
berg of the total campylobacteriosis disease burden. Individuals 
suffering of campylobacteriosis do not always seek health care 
and if they do, they are not always tested with stool diagnos-
tics. This leads to a considerable number of undetected cases in 
the community and at the healthcare level as often only labora-
tory-confirmed cases are registered in national surveillance 
systems. An estimated 9.25 million cases of human campylo-
bacteriosis corresponding to an incidence rate of 1860 cases 
per 100,000 population occurred in the European community in 
2009 (Havelaar et al. 2013). This means that for each of the 
198,252 cases reported an additional 47 cases occur in the 
community without being registered (Havelaar et al. 2013). 
The annual incidence rate of campylobacteriosis in the UK 
population was estimated at 1100 cases per 100,000 population 
(572,000 cases) and the disease lead to an estimated 80,000 
medical consultations (Tam et al. 2012c). In the Netherlands, 
the estimated number of campylobacteriosis cases at the popu-
lation level for 2009 was around 92,000 (557 cases per 100,000 
population) which resulted in approximately 22,000 medical 
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consultations and 1000 hospitalizations (Havelaar et al. 2012). 
The Dutch disease burden including sequela of campylobac-
teriosis in the same year was estimated at 3250 DALYs 
(Havelaar et al. 2012). The annual incidence rate of campylo-
bacteriosis in the French population was estimated at 842 cases 
per 100,000 population or 528,800 cases (van Cauteren et al. 
2015). Around 327,000 of them consult a physician and close 
to 5200 cases are hospitalised (van Cauteren et al. 2015). An-
nual incidence rates for the German and Swiss population in 
2009 were estimated at 338 and 350 cases per 100,000 popula-
tion (277,000 cases and 26,900 cases), respectively (Havelaar 
et al. 2013)
4
.  
For the US population, 845,000 cases of domestically acquired 
foodborne campylobacteriosis including 8500 hospitalisations 
and 76 deaths were estimated for 2006 which equals 22,500 
DALYs (Scallan et al. 2011, Scallan et al. 2015). In 2016, the 
American Foodborne Diseases Active Surveillance Network 
(FoodNet) notified around 8500 cases of Campylobacter spp. 
infections in its surveillance area which correspond to an inci-
dence of 17.43 cases per 100,000 population (Marder et al. 
2017). The incidence of campylobacteriosis in the US had in-
creased since 2006 and the rate of 2014 was 13% higher 
compared to the average of the period from 2006-2008 (Crim 
et al. 2015). An estimated 213,700 cases of domestically ac-
quired campylobacteriosis occurred in Canada in 2006 and 
145,400 cases thereof were assumed to be foodborne (Thomas 
                                                 
4
 Further population incidence rates for other European countries can be 
found in Havelaar et al. (2013). 
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et al. 2013). However, only 7861 laboratory-confirmed cases 
were recorded in Canada in 2006 (Thomas et al. 2013).  
Sporadic foodborne Campylobacter spp. infections represent 
the majority of cases whereas outbreaks – mainly waterborne 
and foodborne - are responsible for a small proportion of all 
infections (Skirrow 1990, 1991, Engberg 2006, Silva et al. 
2011). Sources of infection for outbreaks are mainly contami-
nated poultry (often chicken liver), unpasteurized cow milk and 
contaminated drinking water (Heuvelink et al. 2009, Gubbels 
et al. 2012, Wensley and Coole 2013, Kaakoush et al. 2015, 
Mungai et al. 2015). In 2015, 385 foodborne outbreaks with 
1421 cases and 2 waterborne outbreaks (unknown case num-
bers) were reported by EU/EEA member states - slightly less 
than in the previous five years (EFSA and ECDC 2016). Milk 
as source of infection was reported for more than half (56%) of 
the 25 foodborne outbreaks with strong evidence while around 
a quarter (24%) of these outbreaks were associated with broiler 
meat and products thereof (EFSA and ECDC 2016). A study 
by Taylor et al. (2013) reported that 86% of Campylobacter 
outbreaks in the US between 1997 and 2008 were foodborne 
and dairy exposures accounted for the majority of outbreaks 
(29%). 
In high income countries the disease burden is generally largest 
among children less than 5 years of age and decreases with 
increasing age (Havelaar et al. 2009, Nichols et al. 2012, 
Schielke et al. 2014, ECDC 2015). Persons aged between 20 
and 30 years are the second most affected group (Nichols et al. 
2012, Schielke et al. 2014, Schmutz et al. 2016). The disease 
burden among older people increased since around 2005 while 
it decreased for young children (Nichols et al. 2012, Schielke 
et al. 2014, Schmutz et al. 2016). In general males are more 
Introduction including literature review 
22 
affected by campylobacteriosis than females (Nichols et al. 
2012, Schielke et al. 2014, ECDC 2015, Schmutz et al. 2016). 
An exception is observed for young adults in their twenties 
where campylobacteriosis is more prevalent among females 
(Nichols et al. 2012, Schielke et al. 2014, Schmutz et al. 2016). 
In LMICs, symptomatic infections affect mainly children less 
than 2 years of age while in high-income countries humans of 
all age groups are affected (Coker et al. 2002, Havelaar et al. 
2009, Platts-Mills and Kosek 2014, ECDC 2015). A possible 
reason is the early and frequent exposure to 
Campylobacter spp. of children in LMICs resulting in 
individual protective immunity and population-level immunity 
(Rao et al. 2001, Havelaar et al. 2009, Amour et al. 2016). As 
a result, the incidence rate of symptomatic infections decreases 
with age and the proportion of asymptomatic carriers is bigger 
than in high-income countries (Havelaar et al. 2009). 
A seasonal trend in human infections with Campylobacter spp. 
is observed in many high-income countries (Kovats et al. 2005, 
Lal et al. 2012). In Europe, the disease burden of campylobac-
teriosis shows a distinct seasonality with higher case numbers 
in all age groups during the summer months (ECDC 2015). 
Generally, case numbers start to increase rapidly at the begin-
ning of April, peak between June and August and are lowest in 
February (ECDC 2015). The incidence of campylobacteriosis 
in Germany starts to increase in May and peaks in August 
(Schielke et al. 2014). An additional small peak of the inci-
dence can be observed at the beginning of January (Schielke et 
al. 2014). In England and Wales case numbers – particularly in 
children - increase between May and June which is related to a 
rise in ambient temperature (Louis et al. 2005, Tam et al. 2006, 
Nichols et al. 2012). Ambient temperature likely acts as an 
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indirect driver of intermediate ecological pathways of trans-
mission (Louis et al. 2005, Tam et al. 2006).  
1.3.3. Disease burden and epidemiology of acute gastroenter-
itis and campylobacteriosis in Switzerland 
In Switzerland the burden of disease of AG at population and 
health care levels are largely unknown. Available information 
is restricted to notifiable IID which are reported to the NNSID 
of the FOPH. Only bacterial IID have to be reported to the 
NNSID including Campylobacter spp., Salmonella spp., Shi-
gella spp., Vibrio cholerae, Listeria spp. and 
enterohaemorrhagic Escherichia coli (EHEC) (EDI 2015). As 
only laboratory-confirmed cases are recorded no numbers or 
even estimates of notifiable IID at population level are availa-
ble. On the other side, information on the epidemiology and 
disease burden of non-notifiable IID caused by viruses or pro-
tozoa is very limited. Case numbers of notifiable IID for the 
year 2016 are summarised in Table 1.1. 
In 2012, 8480 cases of human campylobacteriosis were report-
ed to the NNSID – the highest number of cases since the 
establishment of the NNSID in 1988 (Schmutz et al. 2016). 
This is equivalent to an annual notification rate of 105 cases 
per 100,000 population and higher than the average of EU 
member states (65.4 cases per 100,000 population) in the same 
year (EFSA and ECDC 2016, Schmutz et al. 2016). In the 
1990s, the yearly numbers steadily increased and reached a 
first peak in the year 2000 with 7024 cases (Figure 1.2). 
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Table 1.1: Case numbers of notifiable IID in Switzerland for 2016 
Pathogen Case numbers 
Incidence per 
100,000 popula-
tion 
Campylobacter spp. 7810 93.40 
Salmonella spp. 1508 18.00 
Salmonella typhi/paratyphi 24 0.03 
Shigella spp. 186 2.20 
Enterohaemorrhagic E. coli 478 5.70 
Listeria spp. 51 0.60 
Source: BAG (2017b) 
Thereafter a decline in the yearly numbers was observed reach-
ing the lowest level of 5061 cases in 2006 (Schmutz et al. 
2016). Ever since, the yearly numbers increased steadily and 
campylobacteriosis was the most frequently notified zoonotic 
IID in 2016 (Schmutz et al. 2016, BLV and BAG 2017). The 
reasons still remain unexplained. 
The rise in case numbers concurs with data from the EU where 
an increase in the number of cases was observed as well since 
2005 (EFSA and ECDC 2016). The reasons for these increas-
ing trends in Switzerland and the EU are not fully understood. 
It is assumed that improvements of surveillance systems and of 
diagnostics for campylobacteriosis could contribute to potential 
trends changes (EFSA and ECDC 2015). 
The number of cases in Switzerland exhibits a seasonal pattern 
(Figure 1.3) (Schmutz et al. 2016). Peaks are observed during 
the summer months from June to August and over the festive 
season at the end of December and the beginning of January 
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(Schmutz et al. 2016). The reasons for this seasonal pattern are 
largely unknown. It is assumed that the summer peak is most 
likely related to the frequency of barbequing, thus also known 
as the “BBQ-peak”. However, scientific evidence for this as-
sumption is not available. Yet, chicken meat is more frequently 
contaminated with Campylobacter spp. in Switzerland during 
summer months (Baumgartner and Felleisen 2011). The winter 
peak is also named the “Fondue chinoise-peak” and is accord-
ing to experts related to the consumption of dishes whereby 
raw meat is directly prepared at the table e.g. Fondue chinoise 
(Baumgartner et al. 2012). In agreement with this assumption 
group outbreaks of campylobacteriosis during the festive sea-
son due to Fondue chinoise have already been described 
(Schmid and Baumgartner 2003). 
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Figure 1.2: Notification rates and number of campylobacteriosis 
cases notified to the FOPH, Switzerland, 1988–2016 
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Figure 1.3: Seasonality of human campylobacteriosis and sal-
monellosis case notifications in Switzerland, 2009-
2013. 
Adapted from: Schmutz et al. (2016) 
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Figure 1.4: Notification rates and number of salmonellosis cases 
notified to the FOPH, Switzerland, 1988–2016 
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The situation of human campylobacteriosis in Switzerland 
stands in contrast to human salmonellosis. Salmonella spp. was 
more frequently diagnosed than Campylobacter spp. in clinical 
isolates of AG patients until 1995 (Schmid and Baumgartner 
2012). A decline in the annual case numbers and notification 
rates was observed from the early 1990s until the 2010s (Figure 
1.4) (Schmutz et al. 2016). This development was the result of 
concerted efforts and legal regulations of the poultry- and food-
production industries to reduce the contamination of food with 
Salmonella spp. (Schmutz et al. 2016). As a consequence the 
proportion of travel-associated salmonellosis cases among noti-
fied cases increased from 28.7% in 1993 to 35.7% in 2011/12 
(Schmid and Baumgartner 2013). Case notifications of human 
salmonellosis show a distinct seasonality with an increased 
number of notifications in late summer (July-October) (Figure 
1.3) (Schmutz et al. 2016). Since 2010, the most frequent 
serovars were S. Enteritidis (54.0%) and S. Typhimurium 
(13.7%) (Schmutz et al. 2016). 
1.4. Economic burden of acute gastroenteritis and cam-
pylobacteriosis 
The high levels of disease burden associated with AG and 
campylobacteriosis generate a considerable economic burden. 
This burden is associated with different types of costs incl. 
direct healthcare costs (e.g. medication costs, consultation 
costs, hospital inpatient costs) and direct and indirect non-
healthcare costs (e.g. loss of income and productivity). Eco-
nomic burdens of different countries are difficult to compare as 
case definitions, cost items and approaches included for cost 
estimates vary between studies. Additionally, prices for health 
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care or medicines, loss of income and health care systems in 
general vary from country to country. 
The economic burden of AG due to IID per case in the com-
munity of high income countries ranges from €14 in Australia 
to €1305 in the US (Hellard et al. 2003, Hoffmann et al. 2015). 
The total annual economic burden per country depends on the 
population size and is lowest in Malta (€17 million) and high-
est in the US (€12 billion) (Gauci et al. 2007a, Hoffmann et al. 
2015). Annual health care costs account for €12 million in 
Malta and for €1.4 billion in the US (Gauci et al. 2007a, 
Hoffmann et al. 2015). In terms of direct health care costs per 
case in the community, the costs vary between €3 in Australia 
and €155 in the US (Hellard et al. 2003, Hoffmann et al. 2015). 
Cases of campylobacteriosis result in annual costs (expendi-
tures of public health systems and productivity losses) of €2.4 
billion in the EU (EFSA 2016). Costs estimates for campylo-
bacteriosis cases are highly variable depending on included 
sequela and mode of transmission e.g. foodborne cases only. 
National annual economic burdens range from €9 million in the 
Netherlands to €1.4 billion in the US (van den Brandhof et al. 
2004, Hoffmann et al. 2015). This corresponds to costs of €117 
per case in the Netherlands and of €1,710 in the US (van den 
Brandhof et al. 2004, Hoffmann et al. 2015). Total direct 
health care costs are also highest in the US (€213 million) and 
lowest in New Zealand (€0.6 million) (Scott et al. 2000, 
Hoffmann et al. 2015). Lowest health care costs per case were 
reported for New Zealand (€8) while these costs were highest 
in the Netherlands (€280) (Scott et al. 2000, Mangen et al. 
2015). 
The section above is a summary of the introduction of Chapter 
9. A detailed overview and discussion on costs of illness of AG 
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and campylobacteriosis in high income countries can be found 
in this chapter. 
1.5. Health care seeking of and case management for pa-
tients suffering from campylobacteriosis and other 
infectious intestinal diseases 
1.5.1. Health care seeking of individuals affected by AG 
The onset of AG due to IID can be abrupt or rather slow and 
individual symptoms occur in different combinations, severi-
ties and orders mainly depending on the infectious cause. As a 
result not every individual affected by an IID seeks medical 
care and many manage their illness themselves (DuPont 2014, 
Zollner-Schwetz and Krause 2015). The overall perceived se-
verity of illness by the individual and the resulting need for 
medical care are important factors for health care seeking 
(Herikstad et al. 2002, Gibbons et al. 2014). There is evidence 
that cases with higher disease severity and longer disease dura-
tion are more likely to consult a physician (de Wit et al. 2001b, 
Kuusi et al. 2003, Tam et al. 2003, Hall et al. 2008).  
Individuals with disease duration of ≥3 days were six times 
more likely to consult medical services than individuals with a 
shorter duration (Scallan et al. 2006). Bloody diarrhoea, vomit-
ing, fever and abdominal cramps are important symptoms 
positively associated with medical consultations (de Wit et al. 
2001b, Herikstad et al. 2002, Voetsch et al. 2004, MacDougall 
et al. 2008). Seeking medical care also depends on sex and age 
whereby male, children and elderly seek more frequently med-
ical care than the rest of the population (de Wit et al. 2000, 
Scallan et al. 2006). These differences could be related to edu-
cation and health literacy e.g. disease awareness, severity and 
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duration, previous illness and treatment experiences or when to 
seek care (Tam et al. 2003, Gibbons et al. 2014). Also not di-
rectly disease-related factors of legal, administrative and 
financial origin e.g. having health insurance, income, access to 
health care play a role (Tam et al. 2003, Scallan et al. 2006, 
Gibbons et al. 2014). 
Additional contributing factors can be of cultural or religious 
origin (Gibbons et al. 2014). Health and medical care seeking 
differs e.g. between Bosnian migrants, Turkish/Kurdish mi-
grants and Swiss (Gilgen et al. 2005). Differences were 
observed in the preferred medical outpatient setting (general 
practitioner vs. hospital) and the importance of different health 
care providers (Gilgen et al. 2005). Swiss patients considered 
the biomedical sector more important than self-treatment com-
pared to Bosnian and Turkish/Kurdish patients (Gilgen et al. 
2005). 
1.5.2. Anamnesis and clinical evaluation of patients with AG 
Assessing the medical history and a clinical evaluation of pa-
tients presenting with AG are important first steps for the 
further evaluation of the disease (Guerrant et al. 2001, 
Schweiger et al. 2005, Switaj et al. 2015). A thorough anamne-
sis and evaluation of the patient contributes to cost-effective 
and evidence-based initial diagnostic testing and therapy 
(Guerrant et al. 2001, Thielman and Guerrant 2004). The 
course and magnitude of the disease episode is evaluated by the 
onset, occurrence and severity of diarrhoea, abdominal pain, 
vomiting, nausea, fever and other symptoms (Guerrant et al. 
2001, DuPont 2014). Thereby, the frequency, volume and 
presentation of stools e.g. stool with blood, mucus or pus need 
particular attention (Guerrant et al. 2001). Additionally, pa-
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tient-specific epidemiological risk factors should be collected. 
Of interest are: recent travel activities, diet, contact to animals, 
individuals with similar disease in the environment, previous 
drug intake (antibiotics, immunosuppressive medications), co-
morbidity (immunosuppressive disorders), occupational expo-
sures like working in the food sector or at a day care centre 
(Guerrant et al. 2001, DuPont 2014). 
The clinical evaluation of the patient entails the assessment of 
the abdomen (tenderness, pain localisation), vital signs (fever, 
blood pressure, heart rate and state of consciousness), bacte-
raemia, inflammation parameters (C-reactive protein level, 
blood count), hydration status or hypovolemia (Guerrant et al. 
2001, DuPont 2014, Switaj et al. 2015). The anamnesis and 
clinical evaluation can provide hints about the likely cause of 
disease and some authors have summarised clinical and epide-
miological features of individual IID in detail (Thielman and 
Guerrant 2004, DuPont 2009, Switaj et al. 2015). However, the 
predictive value is generally low due to often similar disease 
patterns among individual IID and other possible non-
infectious causes of AG (Slutsker et al. 1998, Guerrant et al. 
2001). 
1.5.3. Diagnostic tests for infectious intestinal diseases in 
patients with AG 
Specific diagnostic tests for IID should be considered if the 
clinical features of the disease and the epidemiological setting 
point towards an infectious cause or if possible public health 
implications are likely (Thielman and Guerrant 2004, DuPont 
2009, 2014). Patients with mild symptoms or a recent disease 
onset (<24h) do usually not require microbiological investiga-
tions as AG episodes are often self-limiting and frequently last 
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less than a day (Herikstad et al. 2002, Thielman and Guerrant 
2004, DuPont 2014). General indications for diagnostic tests 
are: severe diarrhoea with blood, mucus or pus (dysentery), 
protracted diarrhoea, profuse cholera-like watery diarrhoea, 
fever, dehydration or the suspicion of an outbreak (Guerrant et 
al. 2001, DuPont 2009, 2014). Immunocompromised and el-
derly patients and patients working in the food industry, health 
care sector and at day care centres should be tested as their 
diseases could point towards an outbreak in these settings 
(Guerrant et al. 2001, DuPont 2014). 
In the past, medical laboratories applied mainly culture-based 
methods, microscopy, antigen detection or individual real-time 
multiplex polymerase chain reaction (PCR) assays for routine 
diagnostics of IID (Binnicker 2015, Humphries and Linscott 
2015). Since a few years so-called syndromic panels or PCR 
panels for the diagnosis of IID-causing pathogens are used for 
routine diagnostics (de Boer et al. 2010, Allerberger 2015, 
Humphries and Linscott 2015). In the meantime such panels 
are also frequently deployed in diagnostic laboratories of high-
income countries including Switzerland (DuPont 2014, Hächler 
and Stephan 2015). Some of these panels are able to detect 
more than 20 gastrointestinal pathogens in one test with higher 
sensitivity than conventional methods (Khare et al. 2014, 
Binnicker 2015, Buss et al. 2015, Spina et al. 2015). A reduced 
need for labour and timeliness of diagnosis are additional bene-
fits compared to conventional methods (Binnicker 2015). 
The usefulness in daily routine diagnostics and in regard to 
clinical practice and disease surveillance are currently dis-
cussed (Langley et al. 2015, Schreckenberger and McAdam 
2015). Multiple infections are more often detected with panels 
and the detection of DNA does not allow distinguishing be-
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tween viable disease-causing pathogens and non-viable or pas-
sage pathogens (Khare et al. 2014, Binnicker 2015, Buss et al. 
2015). It is currently unclear how to meaningfully interpret 
such results for an appropriate treatment in clinical practice 
(Binnicker 2015). Pathogens are often not isolated when panels 
are applied and hence, isolates for antimicrobial susceptibility 
testing or subtyping for outbreak detection can be lacking 
(Hächler and Stephan 2015, Humphries and Linscott 2015, 
Langley et al. 2015). As a result, conventional methods are still 
needed and will likely remain the gold standard for antimicro-
bial susceptibility testing, strain characterisation and public 
health purposes such as outbreak investigations (Guerrant et al. 
2001, Hächler and Stephan 2015, Langley et al. 2015). 
In the near future whole genome sequencing (WGS) with next-
generation sequencing technologies is likely to become a solid 
and fast method for the routine diagnostic and surveillance of 
infectious diseases incl. IID (Deng et al. 2016, Tang et al. 
2017). Together with bioinformatics tools it opens a whole 
range of new possibilities for disease surveillance and outbreak 
detection compared to older technologies such as pulsed-field 
gel electrophoresis (PFGE). Thereby sequenced genomes of 
pathogens from humans, food items or the environment are 
stored in a central database and through the comparison of dif-
ferent isolates by bioinformatics tools foodborne disease 
outbreaks and their sources can be discovered and investigated. 
A recent study in Denmark on the routine typing, surveillance, 
and outbreak detection of verocytotoxin-producing E. coli in-
fections, for example, showed that WGS is indeed suitable for 
routine diagnostics and surveillance and that it is faster and 
cheaper than currently deployed routine methods (Joensen et 
al. 2014). 
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1.5.4. Treatment of acute gastroenteritis and infectious intes-
tinal diseases  
The fundamental therapeutic aim of up most importance for 
AG patients is to maintain their fluid and electrolyte balance to 
avoid dehydration (Guerrant et al. 2001, DuPont 2014). Oral 
fluid and electrolyte replacement by an appropriate and addi-
tional food and liquid intake e.g. through juices or soups is 
often sufficient for patients with mild disease (Guerrant et al. 
2001, Thielman and Guerrant 2004, DuPont 2009). 
Intermediate to severerly dehydrated patients are more likely to 
require glucose-based electrolyte solutions or rehydration by 
intravenous fluids if oral rehydration is not possible (Guerrant 
et al. 2001, Thielman and Guerrant 2004). Antidiarrhoeals play 
a major role in the therapy besides maintenance of patients’ 
fluid and electrolyte balance and antimotility drugs like 
loperamide can be helpful to reduce the frequency of stools 
(DuPont 2009, DuPont 2014). However, their use does not 
shorten the disease duration and they should be used in combi-
nation with antimicrobials for patients with bloody or febrile 
diarrhoea (Thielman and Guerrant 2004, DuPont 2009, 2014). 
Antimicrobials or antibiotics can be important for the treatment 
of inflammatory and invasive bacterial IID. However, they are 
indicated in only a small proportion of patients as the disease is 
mostly self-limiting and symptomatic therapy is usually suffi-
cient (DuPont 2009, 2014, Zollner-Schwetz and Krause 2015). 
Empirical treatment of patients is mainly indicated if the an-
amnesis and the clinical evaluation reveal a severe course of 
disease pointing towards a bacterial cause. Indicators are 
bloody stools, fever, signs of systemic infection, immunocom-
promised patients or watery and severe traveller diarrhoea 
(Guerrant et al. 2001, DuPont 2014, Zollner-Schwetz and 
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Krause 2015). In these urgent cases an empirical treatment with 
azithromycin (macrolide) is recommended nowadays while in 
the past often quinolone antibiotics (e.g. ciprofloxacin) were 
used (Guerrant et al. 2001, Zollner-Schwetz and Krause 2015).  
The initiation of a targeted antimicrobial therapy is indicated in 
only a small number of patients with a laboratory-confirmed 
bacterial infection (DuPont 2014). The macrolides azithromy-
cin and erythromycin are recommended antimicrobial agents 
for the treatment of human campylobacteriosis (DuPont 2009, 
2014). Further detailed recommendations for targeted antimi-
crobial therapies of bacterial IID have been summarised by 
DuPont (2009, 2014). Specific national guidelines for Switzer-
land are not available so far. 
Antibiotic resistance rates are increasing in gastrointestinal 
bacterial pathogens such as Campylobacter spp. or 
Salmonella spp. and local resistance patterns should be 
considered for a successful antimicrobial therapy (Guerrant et 
al. 2001, Zollner-Schwetz and Krause 2015). Campylobacter 
spp. one of the most common causes of bacterial IID in Europe 
shows high levels of resistance to fluoroquinolones (EFSA and 
ECDC 2016, 2017). In 2015, the level of resistance to 
ciprofloxacin (fluoroquinolone) among human Campylobacter 
jejuni isolates ranged from 96.6% in Portugal to 27.4% in 
Norway while the European average was at 60.8% (EFSA and 
ECDC 2017). Resistance to erythromycin (macrolide) of the 
same human isolates was on average very low (1.5%) with the 
highest rate observed in Romania (8.7%) (EFSA and ECDC 
2017). Fluoroquinolones are not anymore recommended for the 
empirical treatment of human campylobacteriosis by the 
European Food Safety Authority (EFSA) and the European 
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Centre for Disease Prevention and Control (ECDC) (EFSA and 
ECDC 2017). 
The situation in Switzerland is similar and resistance levels of 
58.0% for fluoroquinolones and of 1.2% for erythromycin were 
observed among Campylobacter jejuni isolates from humans 
undergoing routine susceptibility testing in 2015 (FOPH and 
FSVO 2016). A comparison of domestic and travel-associated 
C. jejuni and C. coli isolates showed that quinolone-resistant 
strains were more prevalent in travellers (56% vs. 39%) 
(Niederer et al. 2012). An earlier analysis of C. jejuni isolates 
from campylobacteriosis patients revealed a proportion of 
quinolone-resistance of 37.5% (Kittl et al. 2011). However, 
only two out of the total 603 isolates tested in both studies were 
resistant to macrolides. 
1.6. Surveillance of infectious intestinal diseases 
Infectious disease surveillance like the surveillance of IID is 
part of public health surveillance and corresponding data is 
nowadays often collected through voluntary or mandatory re-
ports of diagnostic laboratories, physicians and other health 
care providers (Chorba et al. 1990, Choi 2012). The concept of 
mandatory reporting of infectious diseases was introduced 
when the colony of Rhode Island in North America passed a 
law on the mandatory reporting of smallpox, yellow fever and 
cholera in 1743 (Thacker and Berkelman 1988, Choi 2012). 
William Farr coined the modern concept of surveillance by his 
work on vital statistics in the 19
th
 century (Langmuir 1976, 
Choi 2012). The systematic reporting of various diseases by 
physicians on a weekly basis was first introduced in Massachu-
setts, US (1874) and later mandatory reporting was also 
implemented in Europe (Italy 1888, UK 1890) (Chorba et al. 
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1989, Choi 2012). Surveillance data on infectious diseases re-
ported by diagnostic laboratories and physicians in Switzerland 
was published for the first time in 1894 (Schmid and 
Baumgartner 2012). 
In 1963, Alexander Langmuir - chief epidemiologist of the US 
Centers for Disease Control (CDC, Atlanta, US) - defined dis-
ease surveillance as: 
“Surveillance, when applied to a disease, means the continued 
watchfulness over the distribution and trends of incidence 
through the systematic collection, consolidation and evaluation 
of morbidity and mortality reports and other relevant data. 
Intrinsic in the concept is the regular dissemination of the 
basic data and interpretations to all who have contributed and 
to all others who need to know.” (Langmuir 1963) 
The definition of Langmuir let to today’s broad concept of pub-
lic health surveillance which is defined by the World Health 
Organisation (WHO 2017) as: 
“Public health surveillance is the continuous, systematic col-
lection, analysis and interpretation of health-related data 
needed for the planning, implementation, and evaluation of 
public health practice. Such surveillance can: 
 serve as an early warning system for impending public 
health emergencies; 
 document the impact of an intervention, or track progress 
towards specified goals; and 
 monitor and clarify the epidemiology of health problems, 
to allow priorities to be set and to inform public health 
policy and strategies.” 
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1.6.1. Laboratory surveillance systems for infectious intesti-
nal diseases 
Public health surveillance systems are ongoing data systems 
which collect data on health from populations (individuals and 
communities), healthcare providers (physicians, hospitals, la-
boratories) and governmental agencies (Thacker and Stroup 
1994). Their data is linked directly to the practice of public 
health at different levels and can be used for research, public 
policies, decision making, treatment, and prevention and inter-
vention programs (Thacker and Stroup 1994). “An ideal 
surveillance system is representative of the population, flexible, 
economic, and resilient, with timely reporting and validation of 
its outputs (Declich and Carter 1994, Thacker and Stroup 
1994)” (Simonsen et al. 2016). Multiple surveillance data 
streams capturing the whole range of clinical outcomes and 
laboratory data are needed to be fully aware of the situation 
(Simonsen et al. 2016). Laboratory surveillance systems are the 
core of infectious disease surveillance (Simonsen et al. 2016). 
The Foodborne Diseases Active Surveillance Network (Food-
Net) is a collaborative effort of the CDC and other partners that 
conducts laboratory-based surveillance of foodborne diseases 
including IID in several states in the US (Allos et al. 2004). For 
this purpose the FoodNet introduced a paradigm which is now-
adays known as the surveillance or burden-of-illness pyramid 
(Allos et al. 2004). It considers the chain of events which have 
to occur for an episode of IID in the community to be recorded 
by the laboratory-based surveillance system (Figure 1.5). 
For Campylobacter spp. and other IID the chain of events that 
have to occur are: (i) being exposed to and infected by a gastro-
intestinal pathogen (ii) experience of symptomatic disease i.e. 
AG (iii) seek medical care e.g. at general practitioner (iv) phy-
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sician requests a faecal specimen (v) positive test result i.e. 
laboratory-confirmed case (vi) reported to notification system 
(Allos et al. 2004, Gibbons et al. 2014). Obviously a case of 
IID will only be recorded by the notification system if every 
event of the chain arrives (Allos et al. 2004, Scallan et al. 
2006, Gibbons et al. 2014). As a consequence, passive notifica-
tion systems often underestimate the true burden of disease in 
the community resulting in an uncertainty around the popula-
tion incidence of campylobacteriosis and other IID derived 
from the system (Wheeler et al. 1999, Gibbons et al. 2014). 
Underestimation is an indicator of the extent to which notifica-
tion systems fail to describe the real burden of disease in a 
given population i.e. the number of cases occurring in the pop-
ulation that are not captured by the system in relation to the 
number of notified cases (Gibbons et al. 2014). It consists of 
two components at different levels of the burden-of-illness pyr-
amid: under-ascertainment of cases occurring at the population 
level and underreporting of cases occurring at the healthcare 
level (Gibbons et al. 2014). 
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Figure 1.5: Burden-of-illness pyramid showing the chain of events 
required for a case of IID to be ascertained in the sur-
veillance system  
Adapted from Allos et al. (2004) 
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Notification systems capture only cases attending health care 
and hence, under-ascertainment can be seen as the proportion 
of cases not attending health care to cases attending health care 
(Gibbons et al. 2014). Reasons for not attending health care 
include asymptomatic infection, mild symptoms, the 
knowledge on the self-limiting nature of many IID and more 
(see 1.5.1). Underreporting refers to cases attending health care 
but not being recorded by the notification system and can be 
quantified as the proportion of cases attending healthcare to 
cases being recorded in the system (Hardnett et al. 2004, 
MacDougall et al. 2008, O'Brien et al. 2010, Gibbons et al. 
2014). Under-diagnosis (pathogen is not diagnosed or misdiag-
nosed, see 1.5.3) and under-notification (failure to report) are 
both reasons for underreporting (Hardnett et al. 2004, 
MacDougall et al. 2008, Gibbons et al. 2014). The opposite of 
underreporting is referred to as reporting completeness which 
refers to the proportion of cases correctly diagnosed and re-
ported among cases attending health care (Doyle et al. 2002). 
The extent to which cases are underestimated in a notification 
system i.e. the extent of under-ascertainment and underreport-
ing can be quantified by different study designs e.g. 
community-based studies, serological surveys, returning travel-
ler studies, capture-recapture studies or modelling (Gibbons et 
al. 2014). Community-based studies such as the recent IID-2 
study in the UK are frequently used to estimate the extent of 
underestimation in a notification system (Tam et al. 2012c, 
Gibbons et al. 2014). 
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1.6.2. Surveillance of campylobacteriosis and other infec-
tious intestinal diseases in Europe 
EU member states, Iceland, Liechtenstein and Norway report 
national surveillance data on a total of 52 communicable dis-
eases to the ECDC. The ECDC coordinates the EU-wide 
surveillance of communicable diseases and enters the data in 
its database system, known as The European Surveillance Sys-
tem (TESSy) (ECDC 2015). The surveillance of the seven 
priority food- and waterborne diseases non-typhoidal salmonel-
losis, typhoid and paratyphoid fever, campylobacteriosis, Shiga 
toxin/verocytotoxin-producing E. coli, listeriosis, yersiniosis, 
and shigellosis is carried out by the ECDC Food- and Water-
borne Diseases Network (FWD-Net) within the Programme of 
Food- and Waterborne Diseases and Zoonoses (FWD) (ECDC 
2015). 
In 2012, surveillance of campylobacteriosis was done by man-
datory notification systems with full population coverage in 21 
countries and by voluntary systems in six countries while three 
did not report at all. Surveillance data of campylobacteriosis 
reported to TESSy entails 27 variables common to all moni-
tored communicable diseases (such as patient characteristics 
and diagnostics) and eight variables specifically for campylo-
bacteriosis (for details see ECDC (2015)). The national 
notification systems vary among countries in regard to case 
definitions for campylobacteriosis, population coverage or di-
agnostic methods and hence a direct comparison of countries is 
hampered. A common case definition for the EU exists but 
further harmonisation of surveillance systems is needed for 
comparable surveillance data on national levels (ECDC 2015). 
Surveillance of infectious intestinal diseases 
45 
1.6.3. Surveillance of campylobacteriosis and other infec-
tious intestinal diseases by the NNSID in Switzerland 
In Switzerland, human campylobacteriosis and other IID are 
monitored through the NNSID run by the FOPH (Der 
Schweizerische Bundesrat 2015, EDI 2015). Only laboratory-
confirmed bacterial IID including Campylobacter spp., 
Salmonella spp., Shigella spp., Vibrio cholerae (incl. clinical 
report), Listeria spp. (incl. clinical report) and EHEC (incl. 
clinical report) have to be reported to the NNSID (EDI 2015). 
Until 2015, laboratories reported confirmed cases to the FOPH 
and the cantonal physician of the cases’ canton of residence 
within 24 hours or one week according to the Epidemics Act of 
1970 and its related ordinances (Die Bundesversammlung 
1970, Der Schweizerische Bundesrat 1999, EDI 1999).  
The reporting period for laboratory-confirmed cases of all these 
diseases was set to 24 hours when the new Epidemics Act was 
implemented in 2016 (Die Bundesversammlung 2012, EDI 
2015). Additionally, the total number of tests conducted for 
Campylobacter spp. and Salmonella spp., including the number 
of positive results, must now be reported annually as aggregat-
ed numbers, stratified by month and test method (EDI 2015) 
(reporting form see Appendix 14.1). Personal information on 
cases such as name, address, sex or date of birth has also to be 
reported but varies between notifiable pathogens. For cases of 
campylobacteriosis only initials, place of residence, date of 
birth and sex are required while e.g. full name, address, tele-
phone number, whereabouts, date of birth, nationality and 
occupation have to be reported for cases infected with EHEC 
(EDI 2015) (reporting form see Appendix 14.2). Surveillance 
data on IID are made publically available on the website 
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(https://www.bag.admin.ch) and the weekly BAG-Bulletin of 
the FOPH. 
Cases of campylobacteriosis and other notifiable IID are only 
diagnosed and later registered in the NNSID after a patient has 
consulted a physician, stool testing has been conducted and the 
stool test rendered a positive result. Consequently, patients 
registered in the NNSID represent only a (self-)selected pro-
portion of all cases occurring in the population. This 
underestimation is thus, intrinsically linked to individual illness 
experience when suffering from an AG episode and related to 
individual steps in health care seeking and case management 
(see 1.6.1). The paradigm of the burden-of-illness pyramid 
introduced by FoodNet could be applied within the NNSID to 
interpret campylobacteriosis case numbers in regard to the dis-
ease burden in the general population. Unfortunately, required 
surveillance parameters e.g. the ratio of the campylobacteriosis 
rate in the community to the national surveillance rate are not 
available for Switzerland. Other European countries like the 
UK can do such interpretations based on country-specific sur-
veillance parameters (Tam et al. 2012c).  
1.6.4. The Swiss Sentinel Surveillance Network Sentinella 
Established in 1986, the Swiss Sentinel Surveillance Network 
Sentinella is a cooperative voluntary surveillance and research 
network of primary care physicians and the FOPH which is 
operated and funded by the FOPH. The network’s aim is to 
perform surveillance of non-notifiable infectious diseases and 
to conduct research in primary care. Sentinella consists of 
around 170 general practitioners, internists and paediatricians 
allocated to six geographical regions covering entire Switzer-
land. Approximately 2.5% of all physicians practicing in the 
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ambulatory care sector participate. The lead is with a steering 
committee consisting of representatives of the six regions, the 
Division of Communicable Diseases of the FOPH, the medical 
faculties of Basel, Bern, Geneva, Lausanne and Zurich plus 
individual primary care physicians. A biannual newsletter in-
forms participating physicians about the latest administrative 
news, research projects and (scientific) publications of the net-
work. 
The network performs sentinel surveillance of influenza-like 
illness (ILI), mumps, pertussis, tick bites, Lyme disease, herpes 
zoster and post herpetic neuralgia. Additionally, research pro-
jects selected by the steering committee are included in the 
annual program of the network each year. Case numbers and 
the number of physician-patient contacts are reported weekly 
on a standard form with a unique identifier for each physician 
(paper-based or online). The standard form and/or paper-based 
supplementary forms or questionnaires are used for data collec-
tion in research projects. Further, physicians report detailed 
information on physician-patient contacts including age, sex 
and region twice a year during two weeks. This information 
together with reported case numbers is used to extrapolate the 
number of first consultations (“Erstkonsultationen”) due to a 
disease or health condition per 100,000 inhabitants. A detailed 
description of the extrapolation method can be found in 
Altpeter et al. (2013). Latest results of the surveillance are pub-
lished weekly in the BAG-Bulletin of the FOPH and its website 
(https://www.bag.admin.ch). Results from research projects are 
published in scientific journals. For more information see 
www.sentinella.ch. 
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2. Context and background for this work 
2.1. Rationale and identified research needs 
There is an unclear observed increase in campylobacteriosis 
case notifications in Switzerland since 2006. The interpretation 
of routine NNSID data is challenged given insufficient 
knowledge of how campylobacteriosis disease and illness pre-
sents in the general population and which determinants lead to 
health care seeking and case registration in the NNSID. The 
existing routine NNSID data do not allow estimating the annu-
al incidence of campylobacteriosis in the Swiss general 
population. It allows only calculating the annual notification 
rate per 100,000 population. This clearly underestimates the 
incidence in the Swiss population as not all individuals affected 
by campylobacteriosis seek health care and have stool diagnos-
tics performed. 
Risk factors to contract campylobacteriosis are generally well 
described yet short-lived and transient risk factors relevant for 
the Swiss setting are unknown. The consumption of fondue 
chinoise is supposed to be relevant for Switzerland (Schmid 
and Baumgartner 2003). However, its importance as a risk 
factor during the observed campylobacteriosis winter peak is 
unclear. Similarly, the relationship of travelling and 
Campylobacter infections could play a role over Christmas and 
New Year considering that travelling is a risk factor in several 
countries and has been described more than 20 years ago as a 
cause for human campylobacteriosis in summer time in 
Switzerland (Schorr et al. 1994). Also, specific determinants 
for the apparent differences in age- and sex distributions of 
campylobacteriosis as observed in the NNSID are not fully 
understood. 
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It is actually unknown if the observed increase in campylobac-
teriosis case notification represents a real epidemiological 
increase or is only the result of an increased stool diagnostic 
rate and disease awareness on the part of the physicians and/or 
patients. A similar phenomenon has already been described 
with data from the NNSID on Chlamydia trachomatis infec-
tions (a sexually transmitted disease). The epidemic upward 
trend of case numbers observed in NNSID data could not be 
confirmed by analysing positivity rates using laboratory data 
(Schmutz et al. 2013). 
Moreover, the burden of disease, aetiology and economic bur-
den of AG in general, and due to IID in particular, are 
unknown at the population and the health system level in Swit-
zerland. This is largely driven by the fact that individuals 
experiencing an episode of AG are not formally recorded nei-
ther at the health care level nor in other routine health 
information or surveillance systems apart from the NNSID. 
Consequently, interpretation of data from the NNSID, specifi-
cally from the case numbers published by the FOPH is limited 
and does not allow drawing inference on the burden of disease 
of AG in the community. There is a clear need to have a closer 
look at the NNSID data quality and relate and better explain it 
in regard to the corresponding burden of disease in Switzer-
land. 
Also our understanding of the aetiological pattern of AG and 
the frequency of the pathogens at the primary care level and in 
the general Swiss population is equally hampered, i.e. only 
known from the “self-selected” subgroup of cases that is seek-
ing medical care and that is registered in the NNSID. 
Information on the aetiology of AG in Switzerland is crucial to 
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establish interventions which reduce the burden of AG caused 
by IID. 
The full economic burden of AG consisting of direct medical 
costs and direct and indirect non-medical costs is neither 
known from an individual patient-case nor from a national 
macro-economic perspective. Given the potentially significant 
nation-wide burden of AG there is a clear need to calculate the 
total monetary costs of an episode of AG due to IID arising 
from direct healthcare costs (medication costs, consultation 
costs, hospital inpatient costs) and direct and indirect non-
healthcare costs (e.g. loss of income and productivity). It is 
likely that those diseases generate a considerable portion of 
national health expenditure and a substantial productivity loss 
in Switzerland that may be partially preventable. 
2.2. Aim and objectives 
2.2.1. Overall aim 
The overall aim of the PhD thesis is to contribute to a better 
understanding of the epidemiology of human campylobacterio-
sis and AG and to improve the interpretation of routine 
surveillance data from the Swiss NNSID. 
2.2.2. General objective 1 
To describe how campylobacteriosis and AG present as diseas-
es and illnesses in the Swiss population and within the Swiss 
health care system. 
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Specific objectives: 
1) To assess the relative importance of alimentary, behav-
ioural and environmental determinants to acquire a 
Campylobacter infection in Switzerland 
2) To estimate the burden of AG and campylobacteriosis 
at the primary care level 
3) To estimate direct health care costs associated with 
campylobacteriosis and AG in Switzerland 
2.2.3. General objective 2 
To create a basis for an improved interpretation and validity of 
routine surveillance data from the NNSID. 
Specific objectives: 
4) To analyse the validity of infectious disease surveil-
lance data by assessing laboratory positivity rates of 
Campylobacter and Salmonella infections 
5) To describe medical practitioners’ diagnosis including 
stool testing rate, and treatment approaches for patients 
with AG and campylobacteriosis in particular 
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3. Research concept and methodological 
overview 
This research consists of six research components aiming at a 
better understanding of the epidemiology of campylobacterio-
sis and AG especially in Switzerland and improving the 
interpretation of infectious disease surveillance data from the 
NNSID. The individual research components contributed to 
this aim by generating results at different levels of the burden-
of-illness pyramid (Figure 3.1). Determinants of the transmis-
sion of Campylobacter spp. during winter time and disease 
presentation were investigated by a matched case-control study 
at the turn of the year 2012/2013 (Chapter 4). Transmission 
dynamics of Campylobacter spp. in Europe were analysed with 
a focus on winter peaks as observed in Switzerland using 
TESSy surveillance data for selected European countries 
(Chapter 5). Laboratory positivity rates of Campylobacter spp. 
and Salmonella spp. were analysed to assess the validity of the 
NNSID i.e. if corresponding surveillance data of the NNSID 
reflect what is observed at the laboratory level (Chapter 6). The 
presentation, case management and disease burden of campyl-
obacteriosis and AG at the primary care level were first 
assessed in an explorative manner implementing a qualitative 
study among 69 Swiss general practitioners (GPs) in 2013 
(Chapter 7). Based on these findings a one-year quantitative 
study within Sentinella was designed and implemented (Chap-
ter 8). Additionally, direct health care costs caused by 
campylobacteriosis and AG were estimated for the first time in 
Switzerland (Chapter 9). 
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Figure 3.1: Graphical representation of the research components 
along the burden-of-illness pyramid 
Collaborations 
55 
3.1. Collaborations 
The present PhD thesis was conducted in close collaboration 
with cantonal and federal authorities, diagnostic laboratories, 
internal and external academic partners and the Swiss Sentinel 
Surveillance Network Sentinella. 
The FOPH showed openness to scrutinise the NNSID and to 
assess determinants of campylobacteriosis and AG in the Swiss 
population and health care system. It was the main partner and 
played a major role in many aspects of conducting research by 
providing resources, expertise, surveillance data and its norma-
tive powers to foster collaboration with other stakeholders. In 
particular, it supported the research to understand the transmis-
sion of Campylobacter spp. in winter times (Chapter 4) and to 
describe the disease situation at the primary care level (Chapter 
7 and 8). Contacts with diagnostic laboratories to obtain the 
necessary data to assess the positivity rates of Campylobacter 
and Salmonella were established with the help of the FOPH 
(Chapter 6). 
The Swiss Sentinel Surveillance Network Sentinella under the 
lead of the FOPH provided the framework to conduct the longi-
tudinal study to assess the incidence and aetiology of AG at the 
medical practice level (Chapter 8). Sentinella is managed en-
tirely by the FOPH and our collaborative agreement with the 
FOPH enabled us to work through their channels. 
GPs professional experience with campylobacteriosis and AG 
in regard to case management and disease burden (Chapter 7) 
was investigated together with colleagues from the Swiss 
branch of Pass International, Tessenderlo, Belgium and the 
Medical Anthropology Research Center, Universitat Rovira i 
Virgili, Tarragona, Spain; and with colleagues from the Centre 
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for Primary Health Care, University of Basel, Basel, Switzer-
land. 
Direct health care costs for campylobacteriosis and AG (Chap-
ter 9) were estimated in close collaboration with the Medical 
Services unit and Diagnostics unit of the Department of Medi-
cine, Swiss TPH, Basel and colleagues from the Institute of 
Pharmaceutical Medicine, University of Basel and the Biosta-
tistics and Prevention Institute, University of Zurich, 
Switzerland. 
3.2. Summary of research approaches and study designs 
3.2.1. A tradition and an epidemic: determinants of the cam-
pylobacteriosis winter peak in Switzerland 
A prospective laboratory-based matched case-control study 
was conducted to elucidate risk exposures related to the cam-
pylobacteriosis winter peak such as food consumption or 
journeys abroad between December 2012 and February 2013. 
The principal aim of the study was to identify risk factors for a 
Campylobacter infection and corresponding risk factor patterns 
over the festive season in Switzerland. Secondary outcomes 
included symptomatology, illness perception and -experience, 
morbidity, health seeking behaviour and case management of 
laboratory-confirmed campylobacteriosis patients presenting to 
the health care system. 
The study was performed among males and females aged ≥5 
years living in Switzerland. Controls were selected from a ran-
dom sample of the Swiss population. Cases and Controls were 
sent an information letter with a photo-illustrated questionnaire 
by postal mail and data was collected via computer-assisted 
Summary of research approaches and study designs 
57 
telephone interviews (CATI) working through the photo-
illustrated questionnaire at both participant- and interviewer 
sides. A pair-matched analysis was performed to identify risk 
factors and corresponding matched odds ratios were reported. 
Data on secondary outcomes were descriptively analysed. 
A detailed description of the methods applied for this research 
component can be found in Chapter 4 i.e. Bless et al. (2014). 
3.2.2. The recurrent campylobacteriosis epidemic over 
Christmas and New Year in European countries, 2006-
2014 
This part of the thesis analyses surveillance data of Switzer-
land, neighbouring countries (Austria, Belgium, France, 
Germany, Italy, Luxembourg, and The Netherlands), countries 
of the British Isles (Ireland, United Kingdom) and Nordic 
countries (Denmark, Finland, Norway, Sweden) in regard to 
campylobacteriosis winter peaks at the turn of the year between 
2006 and 2014. Surveillance data was obtained from the 
NNSID for Switzerland and from TESSy for the remaining 
countries.  
A descriptive analysis of country-specific weekly notification 
data (case numbers and notification rates) focusing on the peri-
od of calendar weeks 45 to 8 was performed. Additionally, 
dates of disease onset or diagnosis were analysed for countries 
with an observable winter peak and possible causes for the ob-
served transmission patterns are discussed. 
A detailed description of the methods applied for this research 
component can be found in Chapter 5 i.e. Bless et al. (2017a). 
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3.2.3. Time trends of positivity rates from foodborne patho-
gen testing in Switzerland, 2003-2012 
In this part laboratory positivity rates of Campylobacter spp. 
and Salmonella spp. in Switzerland were calculated to better 
understand their epidemiology. Essential retrospective nomina-
tor (positive tests) and denominator data (total number of tests 
performed) between 2003 and 2012 was collected from 8 Swiss 
medical diagnostic laboratories. The retrospective data collect-
ed included information on test characteristics (test method 
applied, test result, test date) and on tested patients (sex, age, 
canton of residence).  
The positivity rate was defined as number of positive tests di-
vided by all tests performed. The descriptive analysis included 
positivity rates for each of the two pathogens by year, laborato-
ry, sex, age, test month, test week and combinations thereof. 
Additionally, determinants for a positive test result and the 
seasonality of positivity rates were analysed by univariable and 
multivariable regression. Results allowed drawing conclusions 
about the epidemiological situation of campylobacteriosis and 
salmonellosis and were compared with corresponding data of 
the NNSID to evaluate the validity of surveillance data.  
A detailed description of the methods applied for this research 
component can be found in Chapter 6 i.e. Bless et al. (2017b). 
3.2.4. Acute gastroenteritis and campylobacteriosis in Swiss 
primary care: the viewpoint of general practitioners 
A qualitative study was conducted among Swiss GPs who 
treated campylobacteriosis patients invited for the previous 
case-control study (Chapter 5). GPs’ perception of and profes-
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sional experience with campylobacteriosis and AG including 
clinical presentation, case management and disease burden was 
investigated to evaluate the disease situation at the primary 
care level.  
GPs were invited by an information letter explaining the study 
and contacted for an interview appointment by telephone. In-
terviews were conducted face-to-face with a semi-structured 
questionnaire which was pre-tested in a pilot. Data collected 
continuously underwent inductive content analysis based on 
Grounded Theory which allowed adapting the questionnaire for 
the next interviews based on preliminary results. Theoretical 
saturation was reached and results extensively discussed with 
the study team before drawing conclusions. 
A detailed description of the methods applied for this research 
component can be found in Chapter 7 i.e. Bless et al. (2016). 
3.2.5. Acute gastroenteritis in primary care: a longitudinal 
study in the Swiss Sentinel Surveillance Network, Sen-
tinella 
The incidence and aetiology of AG and the routine faecal spec-
imen testing rate among patients with AG at the primary care 
level in Switzerland was assessed by a prospective longitudinal 
study within the Sentinel Surveillance Network Sentinella. 
Over the study period of one year (December 2013 to Decem-
ber 2014) sentinel physicians reported weekly the number of 
consultations per week (denominator data) and the number of 
patients initially consulting with AG including information on 
date of birth, sex, stool diagnostics performed (yes/no) and 
hospitalisation (yes/no). Additional information on cases of AG 
was collected by a supplementary questionnaire covering the 
total number of consultations, clinical presentation, stool test 
Research concept and methodological overview 
60 
result if available, treatment approaches and information on 
sick leave certification, travel activities and suspected risk fac-
tors.  
During the first half of the study period the supplementary 
questionnaire was applied to a third of patients and in the sec-
ond half to every patient due to lower case numbers than 
expected. Consequently, a weighted descriptive analysis was 
applied to the collected data and weighted, univariable logistic 
regression was used to assess the significance of differences. 
The burden of AG at the primary care level was estimated as 
initial consultations due to AG per 100,000 population with the 
established extrapolation method for Sentinella data of the 
FOPH. 
A detailed description of the methods applied for this research 
component can be found in Chapter 8 i.e. Schmutz et al. 
(2017a). 
3.2.6. Estimating health care costs of acute gastroenteritis 
and human campylobacteriosis in Switzerland 
Own (preliminary) research results, official health statistics, 
expert opinions and official rates for medical services were 
used to estimate direct health care costs attributable to campyl-
obacteriosis and AG in Switzerland. Four different patient 
management models (A-D) were developed based on expert 
opinions and data available from previous work: patients con-
sulting a physician without stool testing (A), patients 
consulting a physician with negative Campylobacter stool test 
results (B), patients consulting a physician and having a posi-
tive Campylobacter stool test result (C) and hospitalized 
campylobacteriosis cases (D). Each model was divided in a 
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minimal and extended scenario accounting for the heterogenei-
ty among patients’ disease severity and needs for medical care.  
Health care expenditures per patient for each scenario were 
estimated with official rates for consultations, hospitalisations, 
diagnostics and drugs from the Swiss medical tariff system 
(TARMED), the tariff list for diagnostics (“Analysenliste”), the 
list of pharmaceutical specialties (“Spezialitätenliste”) and the 
diagnosis-related group-based hospital reimbursement system. 
Expenditures for model C were validated using real invoices 
from campylobacteriosis patients of the Swiss TPH travel clin-
ic. Patient numbers for each of the models and scenarios were 
extrapolated based on surveillance data from the NNSID, offi-
cial hospital statistics and estimates from previous studies. 
Total direct health care costs for Switzerland were then calcu-
lated as the sum of estimated patient numbers per scenario 
multiplied by health care expenditures per patient in each sce-
nario.  
A detailed description of the methods applied for this research 
component can be found in Chapter 9 i.e. Schmutz et al. 
(2017b). 
3.3. Ethical considerations 
All research was following the Essentials of Good Epidemio-
logical Practice (Altpeter et al. 2005) and complies with the 
ethical principles stipulated in the Declaration of Helsinki. Eth-
ical approval for projects was obtained from The Ethics 
Committee northwest/central Switzerland (EKNZ) if indicated 
by the Swiss Federal Act on Research involving Human Be-
ings. 
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The EKNZ approved the projects “Time trends of positivity 
rates from Campylobacter and Salmonella testing over a dec-
ade in Switzerland” (Chapter 4) and “Estimating health care 
costs of acute gastroenteritis and human campylobacteriosis in 
Switzerland” (Chapter 9) (Ref-No.: EKNZ:2014-164 and 
EKNZ:2014-159). The two studies “A tradition and an epidem-
ic: Determinants of the campylobacteriosis winter peak in 
Switzerland” (Chapter 4) and “Acute Gastroenteritis and Cam-
pylobacteriosis in Swiss Primary Care: The Viewpoint of 
General Practitioners” (Chapter 7) were commissioned by the 
FOPH and executed under the Swiss Epidemics Act (SR 
818.101 EpG) and, hence, did not require additional ethical 
approval from the EKNZ. Access to European and Swiss sur-
veillance data for the project “The recurrent 
campylobacteriosis epidemic over Christmas and New Year in 
Europe” (Chapter 5) was granted by TESSy, ECDC, Stock-
holm, Sweden and the FOPH, Bern, Switzerland according to 
the institutions’ data sharing policies following formal re-
quests. The study “Acute gastroenteritis in primary care: a 
longitudinal study in the Swiss Sentinel Surveillance Network, 
Sentinella” (Chapter 8) was conducted under the Swiss Epi-
demics Act (SR 818.101) and the ordinance on disease 
notification of humans (SR 818.141.1) not requiring ethical 
approval from an ethical committee. 
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4.1. Abstract 
Campylobacteriosis is the most frequently reported food-borne 
infection in Switzerland. We investigated determinants of in-
fections and illness experience in wintertime. A case-control 
study was conducted in Switzerland between December 2012 
and February 2013. Cases were recruited among laboratory-
confirmed campylobacteriosis patients. Population-based con-
trols were matched according to age group, sex and canton of 
residence. We determined risk factors associated with campyl-
obacteriosis, and help seeking behaviour and illness perception. 
The multivariable analysis identified two factors associated 
with an increased risk for campylobacteriosis: consumption of 
meat fondue (matched Odds Ratio [mOR], 4.0, 95% confi-
dence interval [CI] 2.3-7.1) and travelling abroad (mOR, 2.7, 
95%-CI, 1.1-6.4). Univariable analysis among meat fondue 
consumers revealed chicken as the type of meat with the high-
est risk of disease (mOR, 3.8, 95%-CI, 1.1-13.5). Most 
frequently reported signs and symptoms among patients were 
diarrhoea (98%), abdominal pain (81%), fever (66%), nausea 
(44%) and vomiting (34%). The median perceived disease se-
verity was 8 on a 1-to-10 rating scale. Patients reported a 
median duration of illness of 7 days and 14% were hospital-
ised. Meat fondues, mostly “Fondue chinoise”, traditionally 
consumed during the festive season in Switzerland, are the ma-
jor driver of the epidemic campylobacteriosis peak in 
wintertime. At these meals, individual handling and consump-
tion of chicken meat may play an important role in disease 
transmission. Laboratory-confirmed patients are severely ill 
and hospitalisation rate is considerable. Public health measures 
such as decontamination of chicken meat and improved food 
handling behaviour at the individual level are urgently needed. 
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4.2. Keywords 
Campylobacter, notification system, case-control study, Swit-
zerland, gastroenteritis, foodborne diseases 
4.3. Introduction 
In recent years, campylobacteriosis emerged as the most com-
monly reported zoonosis in Europe, including Switzerland [1, 
2]. In 2012, the notification rate was 106 cases per 100,000 
population corresponding to 8567 laboratory confirmed cases 
[3], the highest rate since campylobacteriosis became a notifia-
ble disease in 1988 [1]. By registering only laboratory-
confirmed cases, substantial underreporting is very likely. 
Human Campylobacter infections generally lead to self-
limiting, acute gastroenteritis with diarrhoea, abdominal pain, 
fever, vomiting and bloody stool as commonly reported symp-
toms [4]. Patients suffering of a severe infection and pregnant 
or immunocompromised patients require antibiotic treatment 
[5]. Rare but serious sequels of Campylobacter infections in-
clude reactive arthritis, febrile convulsions and Guillain-Barré 
syndrome [4] and contribute considerably to morbidity and 
economic costs of campylobacteriosis [6, 7]. Varying case-
definitions, targeted age-groups and co-morbidities, methodol-
ogies, and follow-up periods result in a broad range of reported 
case-fatality rates. Risk factors for sporadic and outbreak-
related Campylobacter infections have been extensively stud-
ied [8, 9]. Some 50-80% of sporadic human Campylobacter 
infections are attributable to chicken as a reservoir either 
through transmission via handling and consumption of poultry, 
eating undercooked poultry or via contact with live poultry 
[10-14]. Recent case-control studies identified chicken con-
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sumption as source of infection for 24-29% of all cases [14]. 
Similarly, consuming chicken is an attributable risk exposure 
for 27% of campylobacteriosis cases in Switzerland [15]. Indi-
rect evidence for an association between chicken consumption 
and human campylobacteriosis is provided by: i.) a significant 
reduction of campylobacteriosis case notifications after large-
scale market-withdrawals of chicken due to dioxin-
contaminated feed components [16] or an avian influenza out-
break [17] and ii.) congruent seasonality patterns of the 
incidence of campylobacteriosis in humans and Campylobacter 
colonisation of broiler flocks [18]. Other reported exposure 
risks originate from drinking unsafe water, consuming raw 
milk and unpasteurised dairy products, eating barbecued meat, 
travelling abroad and from contact with farm animals and pets 
[2, 8, 9]. Campylobacteriosis outbreaks in Europe are rare, ac-
counting for about 2% of campylobacteriosis cases only [14, 
19]. They are mostly associated with consumption of contami-
nated drinking water, raw milk and chicken products [9, 19, 
20]. 
In temperate regions, seasonal patterns of human campylobac-
teriosis exist with an increased incidence during summer 
months [21, 22]. In Switzerland and Germany, seasonal pat-
terns exhibit two distinct peaks: one in summer and one in 
winter [1, 23]. Reasons for this remain speculative: in Switzer-
land, suspected causes for both peaks include handling of raw 
and consumption of undercooked meat from barbecuing and 
from preparing a traditional meat fondue, a festive Christmas 
and New Year’s dish, which implicates the handling of raw 
meat by the consumer at the table [1]. The objectives for this 
study were to investigate determinants of the campylobacterio-
sis winter peak in Switzerland and to elucidate illness 
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perception, symptomatology, and help seeking patterns of 
campylobacteriosis patients. 
4.4. Methods 
A case-control study recruiting prospectively laboratory-
confirmed campylobacteriosis cases and population-based con-
trols was conducted between December 2012 and February 
2013.  
The National Notification System for Infectious Diseases 
(NNSID) of the Swiss Federal Office of Public Health 
(SFOPH) covers entire Switzerland. Campylobacter infections 
must be mandatorily reported by diagnostic laboratories. Four 
private laboratories, covering entire Switzerland and diagnos-
ing about one third of all notified cases, participated in case 
recruitment from 21
st
 December 2012 until 24
th
 January 2013. 
Considering the seasonal nature of Campylobacter infections, 
the study commenced after the SFOPH enacted that the manda-
tory notifications of participating laboratories had to include 
person-identifiable data as stipulated by the Swiss Epidemics 
Act.  
4.4.1. Cases 
All cases reported by the four laboratories to the NNSID were 
screened for eligibility. Eligibility criteria for cases were age 
≥5 years and Swiss residency. Cases were excluded if they re-
ported antibiotic treatment four weeks prior to disease onset or 
were not speaking German, French or Italian. 
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4.4.2. Controls 
Controls were selected from a random sample of the Swiss 
population obtained from the Federal Statistical Office. They 
were matched for sex, age group and canton of residence. Con-
trols were excluded if they reported a diarrhoeal illness four 
weeks prior to the corresponding case’s disease onset. In addi-
tion, the same exclusion criteria as for cases were applied. 
4.4.3. Sample size 
The study was designed to detect an effect size (odds ratio 
(OR)) of 2.5, with a power of 80% and a two-sided signifi-
cance level of 0.05 assuming a case-to-control ratio of 1:1. 
Rejection rates were estimated at 50% for cases and 75% for 
controls. To achieve a sample size of 100 cases and 100 con-
trols and to account for refusals and for exclusions after 
enrolment, sampling foresaw contacting 300 cases and 600 
controls. All eligible controls were included, resulting in a 
case-to-control ratio ranging from 1:1 to 1:4. 
4.4.4. Recruitment process 
Within 24 hours upon receiving a positive laboratory report we 
sent an information letter together with a photo-illustrated 
questionnaire to the case by priority mail. The same package 
was mailed to four matched controls within 24 hours after 
completion of the case interview. Following the written notice 
cases and controls were contacted by telephone and, after giv-
ing verbal consent to participate, either interviewed 
immediately or a suitable appointment for the interview was 
fixed. If controls refused participation, additional controls were 
selected until at least one per case could be interviewed. Cases 
and controls were excluded after 15 unsuccessful call attempts 
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or if no telephone number was available in the telephone direc-
tory or upon request via postal mail. For participants <15 years, 
letters were sent to their parents and either parent was inter-
viewed as surrogate. 
4.4.5. Questionnaire 
The questionnaire comprised a section on food- and non-food 
exposures and, for cases, a part on illness experience. It con-
tained questions regarding food consumption, origin of meat, 
eating and hygiene behaviour, contacts to animals and humans, 
knowledge about food-borne pathogens, recent travel history, 
occupational exposure and co-morbidity. For both, cases and 
matched controls, exposure information was collected for the 
seven days preceding the onset of the case’s disease, except for 
travel history (preceding two weeks). For case interviews, the 
questionnaire addressed morbidity, health seeking behaviour 
and treatment. Computer-assisted telephone interviews using 
LimeSurvey software were performed. In parallel, participants 
were encouraged to follow the interview questions in the pho-
to-illustrated questionnaire.  
4.4.6. Statistical analyses 
Collected data were exported to Stata 10.1 (Stata Corporation). 
Pair-matched analyses were performed where applicable and 
matched odds ratios (mOR) are presented. Univariable condi-
tional logistic regressions were performed. Variables with cells 
containing zero values in contingency tables were analysed 
using exact logistic regression.  
For the multivariable conditional logistic regression we consid-
ered variables with p≤0.2 in the univariable analysis. In case of 
correlated predictor variables only the one which was biologi-
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cally more plausible was kept in the model. In addition, we 
performed a subgroup analysis investigating risk factors among 
persons who reported fondue consumption. 
The population attributable fraction (PAF) was calculated for 
each statistically significant risk factor of the multivariable 
model as difference of nationwide observed cases and expected 
cases in absence of the risk factor. Expected cases were calcu-
lated using the multivariable mOR, frequency of exposure 
among cases and controls and the sex-, age- and canton-
specific prevalence of Campylobacter notifications during the 
study period. 
Subsequent exploratory data analysis including additional sub-
group and stratified analyses was conducted in order to assist in 
the interpretation and to generate new hypotheses. When con-
ditional analysis was not possible the results are presented 
descriptively. 
4.5. Results 
4.5.1. Response rate and basic characteristics of study par-
ticipants 
A total of 303 campylobacteriosis case notifications were re-
ceived by the study team. After exclusion of cases <5 years and 
non-Swiss residency, 289 cases and 898 controls were invited 
to participate in the study (Figure 4.1). We enrolled 180 (62%) 
cases and 324 (36%) controls of which 159 (55%) cases and 
280 (31%) controls were included in the analysis. Case-to-
control matching ratios were 1:1 for 72, 1:2 for 57, 1:3 for 26 
and 1:4 for 4 cases, respectively. Participating cases represent-
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ed 15% of all registered laboratory-confirmed campylobacteri-
osis cases during the study period. 
The median number of call attempts was 2 for cases and 3 for 
controls. The median time period for cases between disease 
onset and interview was 15 days (range 5-63 days). Median age 
of participants was 38 years and the sex ratio was close to uni-
ty. Both study groups were consistent with regard to most 
socio-demographic characteristics (Table 4.1). An imbalance 
was observed in nationality as only 8 (5.0%) cases compared to 
40 (14.3%) controls were not Swiss nationals.  
4.5.2. Risk factors for campylobacteriosis during the festive 
season 
4.5.2.1. Univariable conditional logistic regression analysis 
Among foods consumed during the week prior to disease onset, 
meat consumption was identified as significant risk factor 
(mOR, 5.2, 95% confidence interval [CI], 1.2-23.3), but the 
only type of meat significantly associated with an increased 
risk was chicken (mOR, 2.5, 95%-CI, 1.5-4.1) (Figure 4.2). 
Eating raw or undercooked meat was associated with increased 
risk of disease (mOR, 1.6, 95%-CI, 1.0-2.6); however the ef-
fect was not statistically significant. Conversely, the 
consumption of raw vegetables was significantly associated 
with a decreased risk (mOR, 0.4, 95%-CI, 0.2-0.7). In addition, 
the consumption of dried and smoked meat (mOR, 0.6, 95%-
CI, 0.4-0.9) and the consumption of ham (mOR, 0.6, 95%-CI, 
0.4-1.0) were associated with a decreased risk.  
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Figure 4.1: Study profile of cases and controls enrolled and recruit-
ed in the case-control study on Campylobacter 
infections in Switzerland, December 2012 – February 
2013 
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Table 4.1: Demographic characteristics of 159 cases and 280 con-
trols who participated in the case-control study on 
campylobacteriosis in Switzerland, December 2012 – 
February 2013 
Characteristic Cases, n (%) Controls, n (%) 
Sex   
Male 82 (51.6) 143 (51.1) 
Female 77 (48.4) 137 (48.9) 
Age groups (years)   
5-9 10 (6.3) 20 (7.1) 
10-14 6 (3.8) 8 (2.9) 
15-19 11 (6.9) 18 (6.4) 
20-24 18 (11.3) 39 (13.9) 
25-29 15 (9.4) 24 (8.6) 
30-44 39 (24.5) 65 (23.2) 
45-59 36 (22.6) 61 (21.8) 
60-74 16 (10.1) 31 (11.1) 
75+ 8 (5.0) 14 (5.0) 
Nationality   
Swiss 151 (95.0) 240 (85.7) 
Foreign 8 (5.0) 40 (14.3) 
Education
a
   
Low education 109 (68.6) 173 (61.8) 
High education 50 (31.4) 107 (38.2) 
a
Low education implies none, compulsory and vocational education. High 
education implies high school degree, university degree or other higher 
education 
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Figure 4.2: Univariable conditional logistic regression analysis of 
selected risk factors for campylobacteriosis in winter 
times (December 2012 – February 2013) in Switzerland 
a 
matched odds ratio 
b 
confidence interval 
c 
participants aged ≤15 or ≥65 years were excluded 
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The consumption of meat fondue was identified as a strong risk 
factor for disease (mOR, 3.9, 95%-CI, 2.4-6.4). The most fre-
quently consumed meat fondue variant, the so-called “Fondue 
chinoise”, was also strongly associated (mOR, 2.9, 95%-CI, 
1.8-4.7).  
The univariable analysis showed no significant association of 
travelling abroad (mOR, 1.7, 95%-CI, 0.8-3.4) and campylo-
bacteriosis. Having contact with children <5 was significantly 
associated with a decreased risk of illness (mOR, 0.5, 95%-CI, 
0.3-0.8). No significant association of the disease with occupa-
tional contacts involving ill persons, animals and children, raw 
and cooked foods was found. The same observation was made 
for non-occupational contacts to animals. Swiss nationality was 
associated with a significantly increased risk for disease (mOR, 
3.1, 95%-CI, 1.4-6.7). People with high education were less 
likely to suffer from disease (mOR, 0.7, 95%-CI, 0.4-1.1). 
Among the fondue consumers, chicken showed again the 
strongest effect (mOR, 3.8, 95%-CI, 1.1-13.5) of all meat types 
(Figure 4.3). There was no noteworthy difference between fon-
due meals consumed at home, or outside home at friends or at 
restaurants. Five out of six participants who reported fondue 
consumption at other locations (e.g. at holiday or alpine huts) 
were cases. The consumption of previously frozen meat at a 
meat fondue was significantly associated with a decreased risk 
of disease (mOR, 0.1, 95%-CI, 0.0-0.6). The type of plate used 
for raw and cooked meat at a meat fondue was significantly 
associated with campylobacteriosis: both, using one plate with 
compartments and using two separate plates were associated 
with a decreased risk of disease (plate with compartments: 
mOR, 0.4, 95%-CI, 0.1-1.1; two plates: mOR, 0.2, 95%-CI, 
0.1-0.6). 
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4.5.2.2. Multivariable conditional logistic regression analysis 
While the mOR for meat fondue remained unchanged, the ef-
fect was lower for chicken consumption in general (mOR 1.4 
vs. 2.5) and for Swiss nationality (mOR 2.1 vs. 3.1) (Figure 
4.4). In contrast, the observed association with travelling 
abroad was stronger (mOR 2.7 vs. 1.7). The estimated PAFs for 
the significant risk factors of the multivariable model were 
51.9% (95%-CI, 31.4-68.5%) for meat fondue and 13.5% 
(95%-CI, 1.1-33.5%) for travelling abroad. 
4.5.2.3. Exploratory subgroup and stratified analyses 
The stratified analysis by sex revealed a significant difference 
in odds for the consumption of chicken meat between females 
(crude OR [cOR], 4.9, 95%-CI, 2.0-13.6) and males (cOR, 1.4, 
95%-CI, 0.7-2.9). Likewise, the consumption of meat fondue 
increased the odds for disease among females (cOR, 5.6, 
95%CI, 2.9-10.8) significantly more compared to males (cOR, 
1.8, 95%-CI, 1.0-3.3). Out of 26 cases who did not eat chicken 
six reported the consumption of raw or undercooked meat 
(23% in cases vs. 18% in controls), six reported meat fondue 
consumption with other meat types (23% vs. 15%) but only a 
single person (case vs. 10 controls) reported travels abroad. 
4.5.3. Campylobacteriosis case characterisation 
Most frequently reported disease onset dates were December 
27
th
/28
th
 and January 2
nd
/3
rd 
(Figure 4.5). Median duration of 
illness was seven days (range 2.5 - 33). Only half of all patients 
(48%) reported full recovery.  
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Most commonly reported symptoms were diarrhoea, abdominal 
pain, fever, nausea, vomiting and headache (Table 4.2). Other 
reported symptoms included limb pain, shivering, fatigue, loss 
of appetite and vertigo. Irrespective of their sex, more than half 
of the patients rated the severity of their illness as ‘severe’ de-
noted by a median severity score of eight on a one-to-ten scale. 
4.5.3.1. First health care seeking 
Pharmacies and medical hotlines were consulted by 20% and 
5% of the patients before seeing a physician, respectively. One 
third (33%) of all patients had approached a physician directly.  
More than half (54%) visited a physician within three days 
after symptoms onset. Most patients (63%) visited a general 
practitioner (Figure 4.5, Table 4.2). Emergency facilities were 
visited by 26% of patients.  
4.5.3.2. Hospitalisation 
The hospitalisation rate was 14% and did not differ between 
sexes, and was increased among patients ≥60 years (33%). Half 
of the hospitalisations lasted at least 3 nights.  
4.5.3.3. Pharmacotherapy 
With one exception, all patients reported drug treatment; about 
two third received antibiotics. Other medications were applied 
for symptomatic treatment. Among the 24% of all patients who 
received an infusion for rehydration or intravenous drug appli-
cation, 42% were in outpatient treatment. 
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Table 4.2: Campylobacteriosis in Switzerland: Reported duration of 
illness, signs and symptoms, perceived severity, medical 
treatment and medication, December 2012-February 
2013 
 n (%) or Median 
(Range) 
(N=159) 
Campylobacter-associated morbidity  
Duration of illness [days]
a 
7 (2.5 – 33) 
No recovery by the time of the interview 43 (27.0) 
Perceived severity of illness
b 
8 (2 – 10) 
Symptoms
c
  
Diarrhoea 156 (98.1) 
Abdominal pain 128 (80.5) 
Fever 105 (66.0) 
Nausea 70 (44.0) 
Vomiting 54 (34.0) 
Headache 20 (12.6) 
Help seeking behaviour  
Health care seeking before consulting a 
physician
c
 
 
None: Immediate consultation of a 
physician 52 (32.7)  
Pharmacy 31 (19.5) 
Medical hotline 8 (5.0)  
Friends & family 68 (42.8) 
Internet 23 (14.5) 
Health guide 8 (5.0) 
Other 10 (6.3)  
Medical care seeking  
General practitioner (GP) 100 (62.9) 
Emergency department 23 (14.5) 
Emergency practice 19 (11.9) 
Paediatrician 6 (3.8) 
Medical specialist  4 (2.5) 
Other  7 (4.4) 
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Table 4.2 continued 
 n (%) or Median 
(Range) 
(N=159) 
Reasons for medical care seeking
c
  
Severe symptoms 105 (66.0) 
No amelioration 70 (44.0) 
Need of a medical certificate 6 (3.8) 
Other  44 (27.7) 
Hospitalisation  
Total 23 (14.5) 
Males
d
 13 (15.9) 
Females
e
 10 (13.0) 
Number of nights in hospital 3 (1 – 13) 
Medication  
Consumed drugs 158 (99.4) 
Drug classes
c
  
Antibiotic (Fluoroquinolones, Macro-
lides) 98 (61.6) 
Antidiarrhoeal (Loperamide, Charcoal) 84 (52.8) 
Probiotic (enterococci, saccharomyces) 73 (45.9) 
Analgesic (Acetaminophen, Dipyrone, 
NSAIDs) 66 (41.5) 
Antiemetic (Domperidone, Metoclo-
pramide, Meclozine) 17 (10.7) 
Spasmolytics (Butylscopolamine) 17 (10.7) 
Acid blockers (Proton pump inhibitors) 5 (3.1) 
Parenteral rehydration and/or drug appli-
cation  
38 (23.9) 
a 
only those recovered at time of interview included (n = 116) 
b 
N=158 
c 
multiple answers possible 
d 
N=82 
e 
N=77  
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Figure 4.5: a) Daily numbers of reported disease onsets of 
campylobacteriosis patients and b) dates of con-
sultations with a physician at an emergency 
facility or a general practice 
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4.6. Discussion 
We assessed determinants for Campylobacter infections in 
wintertime in Switzerland with a case-control study design 
among laboratory-confirmed campylobacteriosis patients. A 
traditional meal (meat fondue), typically consumed at festive 
occasions in wintertime, was identified as the most important 
risk factor, especially if chicken meat was served. Furthermore, 
our findings suggest that the campylobacteriosis cases regis-
tered in the national disease registry are severely ill. The last 
investigation of determinants of campylobacteriosis in Switzer-
land dates back more than two decades and did not include the 
winter festive season [24]. 
4.6.1. Factors associated with increased risk of Campylobac-
ter infections 
Meat fondues, predominantly “Fondue chinoise”, are con-
sumed traditionally in Switzerland during dinners around 
Christmas and New Year. In our study, disease onset dates 
peaked 2-3 days after those events. This is in line with the in-
cubation period of 2-5 days [4]. More than 50% of 
Campylobacter-related gastroenteritis can be attributed to the 
consumption of meat fondue during the study period. The 
“Fondue chinoise” comprises sliced raw meat being individu-
ally handled and boiled in a family-shared broth hotpot. In 
contrast to chicken none of the other meat types consumed dur-
ing fondue dishes were associated with Campylobacter 
infections. This is coherent with other studies identifying 
chicken as a risk exposure [11, 24-30]. This includes two out-
breaks of Campylobacter infections in which meat fondue 
including chicken meat were the suspected source of infection 
[31]. Since Germans consume meat fondue with increased 
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popularity on New Year’s Eve rather than at Christmas [32-34] 
Campylobacter-contaminated chicken could also be the cause 
for the peak of infections observed by Schielke et al. [23] in 
early January. 
Further we observed that meat fondue eaters who put their raw 
and cooked meat on the same plate were more likely to suffer 
from campylobacteriosis. Conversely, the use of a compart-
mented plate or using two separate plates appeared to be 
protective in our study and has been previously recommended 
[35]. Campylobacter spp. are quickly inactivated after dipping 
the sliced chicken meat into the boiling broth. Therefore, on-
the-plate cross-contamination of boiled meat from raw chicken 
meat juice is the most probable transmission route especially 
considering the low infectious dose of Campylobacter spp. 
[36]. We found women to have significantly higher odds than 
men for acquiring a Campylobacter infection after consump-
tion of chicken meat or meat fondue. Among our study 
participants women consumed more often chicken at meat fon-
dues than men which, however, does not explain the elevated 
risk.  
The consumption of undercooked meat as a risk factor for 
campylobacteriosis is well known [11, 13, 27, 28, 37]. In our 
study the consumption of raw or undercooked meat was asso-
ciated with campylobacteriosis especially in people not 
consuming meat fondue. We hypothesise that the strong effect 
of meat fondue consumption outweighs the known effect of 
raw or undercooked meat consumption and, therefore, is only 
statistically significant in the subgroup of people not consum-
ing meat fondue. Travelling abroad was the only behavioural 
factor in the multivariable analysis significantly associated 
with increased odds for Campylobacter infections. This risk 
PUBLISHED ARTICLE 
85 
factor has been described previously for Switzerland [24] and 
other countries [11, 25, 26, 28, 30]. Further, almost all acute 
gastroenteritis patients with travel history are tested for gastro-
intestinal pathogens and are more likely to be diagnosed 
(personal communication). 
One can argue that meat fondue represents an intermediate 
variable on the pathway from chicken consumption to 
Campylobacter spp. infection. Intermediate variables, if 
included in the multivariable analysis, might bias the estimates 
- usually towards the null. Therefore, we re-ran the regression 
models omitting meat fondue-consumption: as expected, 
chicken consumption showed a higher odds ratio (2.3) 
compared to the full model. The point estimates for all other 
variables remained similar, with the exception of travelling 
abroad which was associated with a smaller effect. 
4.6.2. Factors associated with reduced risk of Campylobacter 
infections 
The finding that a reduced risk of disease is associated with 
having contact to children <5 years is difficult to interpret; es-
pecially because a high incidence is noticed for this age-class 
in the NNSID [1]. Persons having contact with young children 
may differ in general and food hygiene and dietary habits [38]. 
High education was associated with a reduced risk of disease. 
The association with gastrointestinal diseases in high-income 
countries is discussed controversially [38-41]. Another factor 
associated with a decreased risk was the consumption of raw 
vegetables. Similar findings are described from several Euro-
pean countries and elsewhere [13, 25, 27, 28, 42] linking the 
protective effects of the consumption of raw vegetables to high 
amounts of antioxidants and carotenoids which act as bacterial 
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growth inhibitors and generally increase immunity to infection. 
Several reports underscore that people who eat raw vegetables 
differ from others concerning cooking and eating preferences 
and behaviour [13, 25, 27, 28, 42]. The consumption of raw 
vegetables, especially during winter time, may reflect a gener-
ally healthy lifestyle [25, 27, 28, 42]. 
An exploratory subgroup analysis among meat fondue con-
sumers indicates that consuming previously frozen meat is 
associated with a decreased risk of campylobacteriosis. Similar 
experiences were made in Iceland where the number of cam-
pylobacteriosis cases declined after freezing of meat 
originating from Campylobacter-infected broiler flocks [43]. In 
Switzerland, Baumgartner et al. [44] showed that chicken 
products were less contaminated with Campylobacter spp. after 
freezing, - a finding which is corroborated by the studies in 
Iceland [45] and Norway [46]. 
In summary, risk and preventive factors in this study point at 
contamination risks upstream at food production- and down-
stream at retail- and consumer sides. Consequently, potential 
preventive risk reduction measures could be applied upstream 
and downstream: upstream -, through decontamination at 
slaughter using peracetic acid [47] resulting in a decreased bac-
terial load at retail level or freezing of chicken meat before 
reaching retail [43, 45, 46]. Downstream risk prevention 
measures could include improving consumer awareness in 
handling raw chicken meat additionally to the current hygiene 
notice on Swiss chicken meat packages. 
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4.6.3. Illness perception and treatment of acute campylobac-
teriosis 
Patients suffering from Campylobacter infection reported typi-
cal symptoms of an acute gastroenteritis and a high perceived 
severity of illness. Comparable studies for Switzerland are 
lacking; however, the pattern is coherent with experiences from 
other countries [13, 48-51]. The reported severity of illness 
appears to be slightly higher compared to others [48]. Com-
pared to other countries the proportion of hospitalised patients 
(14%) was higher [13, 48] or slightly lower [52]. This variabil-
ity could be due to differences in health systems, including 
differing notification criteria, case definitions and health care 
provider structure. 
Although antibiotics are not generally recommended for treat-
ment of campylobacteriosis more than 60% of our study 
patients received antibiotic treatment. In absence of infor-
mation on the individual patient’s medical history we cannot 
judge whether antibiotic use was medically indicated. 
Generally, case-fatality rates in high-income countries range 
from 0.04-0.6% [2, 52-54]. We observed no death during our 
study. However, due to the similarity of epidemiological pat-
terns in Europe Campylobacter-attributable mortality is likely 
to occur also in Switzerland [2, 54]. 
4.6.4. Strengths and limitations 
We recruited all our cases from laboratory-confirmed campyl-
obacteriosis patients registered in the NNSID. Patients with a 
mild course of disease are less likely to consult a physician or 
to be tested for campylobacteriosis and, hence, less likely to be 
notified. Participating laboratories were from the private sector 
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only; therefore, the hospitalisation rate and the proportion of 
patients approaching emergency departments and policlinics 
directly may be underestimated. Similarly, recruiting cases 
from private laboratories, serving mainly general practitioners, 
could explain the imbalance in nationalities. Swiss nationals 
more often consult their general practitioners while non-Swiss 
are more likely to approach emergency departments. As ex-
pected, patients volunteered more often to participate in the 
study and contacted back the study team after initial contacting 
failed. Cases may remember their exposures more accurately 
than controls, since they might have been reflecting about what 
caused their illness. Nevertheless, “don’t know” was answered 
equally often by cases and controls. In addressing potential 
biases from recalling exposure risks we applied photo-
illustrated questionnaires. 
4.7. Conclusion 
The study provides strong evidence that the consumption of a 
national festive dish (“Fondue chinoise”) is a risk factor for 
human campylobacteriosis in Switzerland. The main risks as-
sociated with this dish are probably twofold: firstly, chicken 
meat is frequently contaminated with Campylobacter spp. [44]. 
Secondly, the possibilities of and occasions for cross-
contamination and ingestion of bacteria are manifold and the 
infection risk is exacerbated through individual food-handling 
at the table. Our findings, therefore, highlight the importance of 
food hygiene for chicken preparation and consumption at meat 
fondues. The steadily increasing number of notified campylo-
bacteriosis cases, the high population attributable fraction for 
meat fondue and the previously unknown severity of illness 
and hospitalisation rate underline the relative importance for 
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Swiss public health over the festive season and point toward 
the necessity for public health interventions. Prevention 
measures could include decontamination of chicken meat at 
slaughter resulting in a decreased bacterial load at retail level, 
freezing of chicken meat before reaching retail and improving 
consumer awareness in handling raw chicken meat. 
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5.1. Abstract 
Objective: Campylobacteriosis is the most frequently reported 
foodborne disease in Europe with a notification rate of 71 per 
100,000 population in the European Union in 2014. Surveil-
lance data show a clear seasonality whereby case numbers peak 
during summer months in entire Europe and at the turn of the 
year, especially in Germany and Switzerland. A detailed de-
scription of European surveillance data by country at the turn 
of the year was missing so far. The objectives of the presented 
work were to describe national surveillance data of The Euro-
pean Surveillance System for 14 countries during winter times 
and to generate hypotheses for the observed seasonality of 
campylobacteriosis cases. 
Results: The analysis included 317,986 cases notified between 
calendar weeks 45 and 8 of winter seasons 2006/2007 to 
2013/2014. Winter peaks in weekly case notifications and noti-
fication rates were observed for Austria, Belgium, Finland, 
Germany, Luxembourg, The Netherlands, Switzerland and 
Sweden while for Denmark, France, Ireland, Italy, Norway and 
the United Kingdom no unusual increase was observed. Gener-
ally, weekly notification rates peaked in calendar week 1 or 2 
after a strong decline in the last week of December and reached 
values of a multiple of the observed notification rates in the 
weeks before or after the peak e.g. up to 6.5 notifications per 
100,000 population per week in Luxembourg. Disease onset of 
cases notified during winter peaks occurred predominantly in 
calendar weeks 52 and 1 and point towards risk exposures 
around Christmas and New Year. The consumption of meat 
fondue or table top grilling poses such a risk and is popular in 
many countries with an observed winter peak. Additionally, 
increased travel activities over the festive season could foster 
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campylobacteriosis transmission. Surveillance artefacts (e.g. 
reporting delays due to public holidays) should be excluded as 
causes for country-specific winter peaks before investigating 
risk exposures. 
5.2. Keywords 
Campylobacter, infectious disease surveillance, Europe, sea-
sonality, The European Surveillance System (TESSy) 
5.3. Introduction 
Since 2005, human campylobacteriosis has been the most fre-
quently reported foodborne bacterial gastrointestinal disease in 
Europe. Case numbers are increasing [1]. In 2014, around 
237,000 cases were reported by 26 European Union (EU) 
member states corresponding to a notification rate of 71 per 
100,000 population [1]. European campylobacteriosis surveil-
lance data show a clear seasonal trend [2]. The number of 
notified cases starts to increase drastically in April and peaks 
during summer, between June and August [2]. The lowest 
numbers of cases are notified in February and March [2]. In the 
campylobacteriosis surveillance data of the EU, in particular of 
Germany, and of Switzerland, an additional seasonal peak be-
tween late December and early January, the so-called winter 
peak, has been described [1, 3, 4]. The monthly incidence in 
Germany peaks in January [3] and case numbers in Switzerland 
increase during the last week of December and the first week 
of January [4].  
Our investigation of the winter peak in Switzerland identified 
the consumption of meat fondue as main risk factor, especially 
if served with chicken [5]. Meat fondue is traditionally con-
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sumed on Christmas day and on New Year’s Eve in Switzer-
land and is also a popular dish at New Year’s Eve in Germany 
and Luxembourg [5, 6]. A detailed description of European 
Campylobacter surveillance data at the turn of the year is miss-
ing so far and hence, it is unknown in which other European 
countries winter peaks in notification data occur. This study 
analyses European country-specific surveillance data at the 
turn of the year from 2006 to 2014, to determine if winter 
peaks as observed in Switzerland and Germany also occur in 
other European countries and to generate hypotheses for the 
seasonal patterns. 
5.4. Main text 
5.4.1. Analysis of Campylobacter surveillance data 
This study considered Switzerland, Germany and neighbouring 
countries (Austria, Belgium, France, Italy, Luxembourg, The 
Netherlands), countries of the British Isles (Ireland, United 
Kingdom) and Nordic countries (Denmark, Finland, Norway, 
Sweden). For EU member states, case-based notification data 
on laboratory-confirmed Campylobacter infections from 2006 
to 2014 originated from The European Surveillance System 
(TESSy) - an indicator-based surveillance database for com-
municable diseases hosted by the European Centre for Disease 
Prevention and Control (ECDC) [7]. Surveillance data from the 
National Notification System for Infectious Diseases on labora-
tory-confirmed campylobacteriosis cases notified between 
2006 and 2014 were used for Switzerland. Our previous analy-
sis of Swiss notification data on Campylobacter showed that 
the winter peak is rather a short-term phenomenon and better 
observable in weekly than monthly notification data [4]. There-
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fore, we performed a descriptive analysis of country-specific 
weekly notification data focusing on the period of calendar 
weeks 45 to 8. 
A total of 1,530,564 campylobacteriosis case notifications were 
received from TESSy. For 147 case notifications or 0.03% of 
all United Kingdom notifications no information on the week 
of notification was available. Hence, they were excluded from 
further analyses. In 2006 and 2007 German notification data 
were reported on a monthly basis leading to the exclusion of 
118,142 case notifications. We additionally excluded 848 case 
notifications with a notification date in 2006 or 2014 but be-
longing to calendar week 52 of 2005 or calendar week 1 of 
2015. For Italy no notification data from 2006 until mid-2008 
were available. A total of 317,986 cases notified between cal-
endar weeks 45 and 8 of the winter seasons 2006/2007 to 
2013/2014 were analysed including 16,237 campylobacteriosis 
cases from Switzerland. 
Weekly notification rates were calculated using annual coun-
try-specific population numbers as per 1
st
 of January for each 
corresponding winter season from the Eurostat database [8]. 
The Dutch and French sentinel surveillance systems do not 
cover the whole population. We used the estimated population 
coverage for Campylobacter surveillance of 52% (The Nether-
lands) and 20% (France) [2] to calculate population numbers 
for the calculation of weekly notification rates. The population 
coverage of Campylobacter sentinel surveillance in Belgium 
and Italy is unknown and, hence, only case numbers were used. 
The sum of case numbers and the median of notification rates 
over all winter seasons are presented for each calendar week by 
country. Additionally, dates of disease onset or diagnosis were 
analysed to assess possible reporting delays.  
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Table 5.1: Winter peaks of campylobacteriosis case notifications as 
median notification rate and sum of case notifications 
over all winter seasons, 2006/2007-2013/2014 
Country 
Calendar 
week of peak
 
Median notifica-
tion rate
a 
Sum of case 
notifications 
Austria 2 1.3 887 
Belgium 2 n/a
b 
1302 
Finland 2 1.7 719 
Germany 2 1.5 8807 
Luxembourg 2 2.9 116 
The Netherlands 1 1.1 733 
Sweden 3 1.6 1250 
Switzerland 1 3.2 1964 
a
Rate per 100,000 population 
b
not applicable 
In the Additional file 1 of Bless et al. (2017a) case numbers 
and notification rates per calendar week for each winter season 
and country are presented. 
Figure 5.1: Number of case notifications and weekly notification 
rates per 100,000 population for campylobacteriosis in 
selected European countries, winter seasons 
2006/2007–2013/2014. 
a
Sum of weekly notifications from winter seasons 2006/2007–2013/2014 
(Germany and Italy: 2008/2009–2013/2014) 
b
Weekly notifications per 100,000 population = median of weekly notifica-
tion rates from winter seasons 2006/2007–2013/2014 (Germany 
2008/2009–2013/2014) 
c
Sum of weekly notifications only as coverage of surveillance system un-
known 
Note: Scales of y-axes differ between countries 
The recurrent campylobacteriosis epidemic 
106 
5.4.2. Seasonal patterns of campylobacteriosis 
The sum of case notifications and the median of notification 
rates by calendar week over all years increased at the end of 
December or beginning of January for Austria, Belgium (case 
notifications only), Finland, Germany, Luxembourg, The Neth-
erlands, Sweden and Switzerland and decreased towards the 
end of January (Figure 5.1). Winter peaks in terms of median 
notification rates were most pronounced in Luxembourg and 
Switzerland with peak rates of 2.9 and at 3.2 per 100,000 popu-
lation, respectively (Table 5.1). Less pronounced winter peaks 
were observed in The Netherlands and Austria with peak rates 
of 1.1 and 1.3 per 100,000 population, respectively.  
The sum of weekly case notifications in Belgium peaked in 
week 2. For the other countries (Denmark, France, Ireland, 
Italy, Norway and the United Kingdom) no unusual increase 
during the winter season was observed (Figure 5.1). A common 
characteristic of most countries was that the sum of case num-
bers and median notification rates were lowest at the end of 
December in week 52. 
The weekly case numbers and notification rates of winter peaks 
varied in each country by year (Additional file 1 of Bless et al. 
(2017a)). The most distinct winter peak with a weekly notifica-
tion rate of 6.5 per 100,000 population was observed in 
Luxembourg during the winter season 2013/2014 (Table 5.2). 
Peak rates in other countries ranged from 1.8 in Germany and 
The Netherlands to 4.5 notifications per 100,000 population in 
Switzerland. From the beginning of the observation period in 
2006/2007 to 2013/2014 peak case numbers and notification 
rates increased for Belgium, Germany, Luxembourg, The 
Netherlands, Sweden and Switzerland (Table 5.2). A more than 
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threefold increase was observed for Luxembourg and a twofold 
increase for Switzerland. For Austria and The Netherlands win-
ter peaks in 2006/2007 had higher peak rates compared to the 
subsequent years but afterwards peak rates started to increase 
discontinuously. In Austria peak rates increased by 45% from 
1.1 to 1.6 notifications per 100,000 population between 2011 
and 2014. The highest rate of the winter peak 2007/2008 in The 
Netherlands was 0.7 per 100,000 population and increased to 
twice this rate in 2013/2014. 
The Nordic countries Denmark and Norway exhibited no spe-
cific dynamics in the annual notification data on a regular basis 
(Additional file 1 of Bless et al. (2017a)). However, Danish 
weekly case numbers and notification rates showed irregular 
increases resembling a winter peak during some winter sea-
sons. In Norway case numbers and notification rates generally 
decreased around calendar weeks 51 and 52 and were some-
times slightly increased in calendar weeks 1, 2, or 3. 
Possible reporting delays were assessed for countries with ob-
servable winter peaks and for which dates of disease onset or 
dates of diagnosis were available (Austria, Belgium, Germany 
and Norway). Numbers of disease onset or diagnosis were 
summed up over all years per day and are depicted in Figure 
5.2. In Austria, Germany and Norway the daily numbers of 
disease onset peaked in the first week of January and to a 
smaller extent already in the last week of December. Peaks of 
disease onset dates occurred a few days to one week before 
winter peaks observed in actual notification data. The number 
of diagnoses in Belgium started to increase at the end of De-
cember and decreased after the second week of January. 
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Our analysis of notification data shows that seasonal transmis-
sion of Campylobacter infection occurs prominently and 
distinctively during winter time in many European countries. 
Weekly notification rates can increase up to a multiple of the 
observed notification rates in the weeks before or after the win-
ter peaks. In Switzerland and The Netherlands the notification 
rates already peaked in the first week of January whereas rates 
for the remaining countries peaked rather in week 2. So far this 
short-term phenomenon was described in the literature for 
Germany [3], Switzerland [4, 5] and Luxembourg [6]. For the 
EU the observation of a winter peak in January was reported 
for the first time for the years 2012 to 2014 [1]. 
Median notification rates over all winter seasons generally in-
crease suddenly in the first week of January after a strong 
decline in the last week of December and do peak in January. 
The strong decline at the end of December, also observable in 
countries without a winter peak, could be due to limited access 
to health care services and reporting delays during public holi-
days at the end of the year. A study on campylobacteriosis 
notification data of England and Wales showed that the report-
ing rate is lower during weeks with a public holiday sometimes 
resulting in additional reporting in the following week [9]. An-
nual weekly notification rates of winter peaks showed an 
increasing trend over the recent years in most affected coun-
tries which could be related to the general increase of 
campylobacteriosis case notifications in Europe since 2005 [1, 
2]. The analysis of Austrian, Belgian, German and Norwegian 
dates of disease onset and of diagnosis revealed that most noti-
fied cases show symptoms of campylobacteriosis in the last 
week of December and the first week of January. This observa-
tion was recently described for Germany [3].  
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Hence, winter peaks seen in surveillance data are likely de-
layed by a few days to one week compared to actual peaks of 
campylobacteriosis in the population when considering the 
“date used for statistics” of TESSy. These delays are likely 
caused by time needed for health care seeking, laboratory diag-
nostics and reporting. When taking into account an average 
incubation period for campylobacteriosis of 2-5 days, exposure 
to Campylobacter occurs likely around Christmas or New Year 
for notifications reported in the first two weeks of January [3, 
5]. 
5.4.3. Possible reasons for the seasonal patterns 
The sudden increases of weekly notification rates point towards 
a rapid change in exposure patterns or levels of exposures for 
campylobacteriosis in winter. Of particular interest appear 
food- and travel-related exposures around Christmas and New 
Year. In Finland and Sweden high proportions of travel-related 
cases (≥50%) are observed in annual surveillance data [1, 2]. 
Their winter peaks may be partially due to increased travel 
activities to foreign countries during Christmas and New Year 
holidays. In Switzerland, travelling abroad during the festive 
season was associated with almost three-time higher odds for 
contracting campylobacteriosis [5]. 
Figure 5.2: Sum of case notifications between 1st December and 
31st January. 
a
Austria by daily disease onset, winter seasons 2008/2009–2013/2014 
b
Germany by daily disease onset, winter seasons 2008/2009–2013/2014 
c
Norway by daily disease onset, winter seasons 2006/2007–2013/2014. 
d
Belgium by daily diagnoses, winter seasons 2011/2012–2012/2013 
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A recent study in Luxembourg identified the consumption of 
chicken in winter as risk factor for contracting campylobacteri-
osis and the authors hypothesised that it could be related to the 
traditional consumption of meat fondue during this time [6]. 
The consumption of meat fondue or table top grilling during 
the festive season is popular in Austria, Belgium, Germany, 
Luxembourg and The Netherlands. In Switzerland, the cam-
pylobacteriosis winter peak is associated with the frequent 
consumption of meat fondue at Christmas and New Year which 
increased the odds for contracting campylobacteriosis four-fold 
[5]. At these occasions, possibilities for Campylobacter trans-
mission include cross-contamination of cooked meat and/or 
side dishes by raw poultry meat and individual meat prepara-
tion at the table [5, 10]. Hence, individuals are likely to 
contract campylobacteriosis around Christmas and New Year 
as a consequence of increased exposure levels to foodborne 
and travel-related risk factors. 
5.5. Limitations 
The “date used for statistics” provided by TESSy can vary be-
tween reporting countries and could mean the dates of disease 
onset, of diagnosis, of notification or any other date. The use of 
a non-standardised reporting date and differences in the nation-
al surveillance systems make it difficult to exactly compare the 
temporal trends of winter peaks among countries. Reporting 
delays and other surveillance artefacts affecting notification 
rates of observed winter peaks could not be excluded. Conse-
quently, it should be evaluated whether these peaks represent a 
true epidemiological trend before investigating possible risk 
exposures. To our knowledge, there is no scientific evidence on 
the extent and significance of the consumption of meat fondue 
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or table top grilling for the investigated countries except for 
Switzerland [5].  
5.6. Abbreviations 
ECDC: European Centre for Disease Prevention and Control; 
EU: European Union; TESSy: The European Surveillance Sys-
tem. 
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6.1. Summary 
Background: Campylobacteriosis and salmonellosis are im-
portant foodborne diseases in Europe, including in Switzerland. 
In 2014, notification rates for Switzerland were 92.9 per 
100,000 population for campylobacteriosis and 15.2 per 
100,000 population for salmonellosis. These notification rates 
originate from laboratory-based surveillance whereby positive 
test results are reported to the National Notification System for 
Infectious Diseases. Consequently, notification rates do not 
directly correspond to the disease burden among the population 
as the number of positive tests depends on patients’ 
healthcare-seeking behaviour, stool sampling rates and other 
factors. 
Methods: We assessed laboratory positivity rates (proportion 
of positive tests among all tests performed) of diagnostic tests 
for Campylobacter and Salmonella from five private laborato-
ries in Switzerland between 2003 and 2012. We analysed 
demographic characteristics, temporal and spatial distribution 
of test numbers and positivity rates. Predictors for a positive 
test and disease seasonality were assessed with logistic regres-
sion analyses. 
Results: A total of 135 122 (13 095 positive) Campylobacter 
tests and 136 997 (2832 positive) Salmonella tests were ob-
tained with positive tests corresponding to 20.4% and 17.2% of 
notified campylobacteriosis and salmonellosis cases, respec-
tively. The number of tests conducted annually increased for 
both pathogens by 51% from 2003 to 2012. Annual positivity 
rates of Campylobacter increased from 7.6 to 11.1% and rates 
of Salmonella decreased from 2.7 to 1.5%. The largest increas-
es in annual Campylobacter positivity rates were observed for 
patients older than 85 years (+193.7%), followed by children 
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aged 5–9 years (+131.9%). Positivity rates and test numbers for 
both diseases by month or calendar week showed a distinct 
seasonality, with peak rates for Salmonella occurring in au-
tumn and for Campylobacter in summer and at the turn of the 
year. These findings were independent of patients’ age and 
sex. 
Conclusions: Both positivity rates and notification rates 
showed increasing trends for Campylobacter and decreasing 
trends for Salmonella, suggesting that these trends reflect 
changes in disease epidemiology at population level. The con-
tinuous assessment of positivity rates remains important to 
appropriately interpret changes observed in the notification 
system especially considering the increasing use of multiplex 
polymerase chain reaction test panels where multiple patho-
gens are tested simultaneously. 
6.2. Keywords 
Campylobacter, Salmonella, disease surveillance, denominator 
data, Switzerland, foodborne disease, seasonality, positivity, 
epidemiological trends, notification rate 
6.3. Introduction 
Human campylobacteriosis and salmonellosis are the most fre-
quently reported foodborne bacterial infections in Europe. In 
2014, notification rates in the European Union (EU) were 71.0 
cases per 100,000 population (corresponding to approximately 
236 900 cases) for campylobacteriosis and 23.4 cases per 
100,000 population (approximately 88 700 cases) for salmonel-
losis [1]. In the same year, in Switzerland, the notification rate 
for Campylobacter infections was 92.9 cases per 100,000 
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population (approximately 7600 cases) and 15.2 cases per 
100,000 population (approximately 1200 cases) for Salmonella 
infections [1]. During the mid-1990s, the annual number of 
notified human Campylobacter infections surpassed that of 
Salmonella infections in Switzerland [2]. This was owing to a 
reduction of human salmonellosis following the introduction of 
control measures in the egg and poultry industry, such as man-
datory screening of layer hens, in the early 1990s [2]. So far, 
similar control measures for Campylobacter are lacking and 
campylobacteriosis is currently the most frequently notified 
foodborne disease in Switzerland [2]. 
In Switzerland, notifiable diseases are monitored by the 
Federal Office of Public Health (FOPH) through the National 
Notification System for Infectious Diseases (NNSID) [3, 4]. 
Laboratory-based surveillance of Campylobacter and 
Salmonella infections, as defined by the Epidemics Act of 1970 
and its related ordinances, captured only those cases that tested 
positive [5–7]. Since the implementation of the new Epidemics 
Act at the beginning of 2016, the total number of tests 
conducted for these two pathogens, including the number of 
positive results, must be reported annually as aggregated 
numbers, stratified by month and test method [4, 8]. Hence, 
denominator data to help draw inferences from surveillance 
data about the epidemiological situation in the community have 
not been collected so far. The number of stool tests performed 
depends on the healthcare-seeking behaviour of patients with 
diarrhoea and the stool sampling rate of treating physicians [9–
11]. As not all individuals affected by acute gastroenteritis seek 
medical care or have a stool sample examined for enteric 
pathogens, there are likely to be many undetected (at 
community level) and unreported (at healthcare level) 
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campylobacteriosis and salmonellosis cases [12, 13]. Hence, 
changes in notification rates do not necessarily reflect an 
epidemiological trend, but could be attributable to changes in 
healthcare-seeking behaviour or stool sampling rates. A more 
informed interpretation of surveillance data is made possible by 
calculating positivity rates (proportion of positive tests among 
all tests performed). Because positivity rate calculations also 
consider denominator data, they adjust for the number of tests 
[14, 15]. We analysed laboratory data for stool tests performed 
for Campylobacter spp. and Salmonella spp. by Swiss 
diagnostic laboratories over a 10-year period to better interpret 
the trends of campylobacteriosis and salmonellosis case 
notifications seen in the NNSID. 
6.4. Materials and methods 
6.4.1. Selection of diagnostic laboratories 
The study aimed to include private diagnostic laboratories from 
all geographical and linguistic regions of Switzerland to reach 
an optimal representation of the campylobacteriosis cases re-
ported to the NNSID between 2003 and 2012. Eleven private 
diagnostic laboratories, each reporting more than 1000 cam-
pylobacteriosis cases during that decade, were contacted and 
invited to provide data for the study. The case-based laboratory 
data requested comprised patients’ demographic characteristics 
(sex, age, canton of residence, personal identification code as-
signed by laboratory) and test characteristics (pathogen tested, 
test result, date of test, test method) on all Campylobacter and 
Salmonella tests performed between 2003 and 2012. 
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6.4.2. Analysis of positivity rates 
Datasets from individual laboratories were transformed uni-
formly, merged and analysed with STATA™ Version 13.1 
(Stata Corporation; College Station, TX, USA). Firstly, double 
entries, repeated tests and tests for patients without Swiss resi-
dency were excluded. The following rules – based on disease 
durations and durations of organism excretion [16] – were ap-
plied to identify and exclude repeated tests: (i) control or 
follow-up tests, irrespective of result, following a positive re-
sult within 42 days for both, Campylobacter and Salmonella; 
(ii) negative tests following a negative result within 10 days 
(Campylobacter) or 21 days (Salmonella); and (iii) negative 
tests followed by a positive result within 10 days (Campylo-
bacter) or 21 days (Salmonella). The patient population was 
characterised by sex, age, diagnostic laboratory, test year and 
residence by greater region (corresponding to the Nomencla-
ture of Units for Territorial Statistics (NUTS) 2 level [17]). 
Age groups for statistical analyses were predefined. Residence 
by greater region was based on the patients’ canton of resi-
dence (NUTS 3 level). Descriptive analysis of positivity rates - 
defined as positive tests divided by total tests performed - and 
exploratory logistic regression analyses of predictors for and 
seasonality of positive tests were performed. Characteristics of 
laboratory-confirmed cases of campylobacteriosis and salmo-
nellosis were additionally compared with national surveillance 
data. Time trends of annual positivity rates were investigated 
using stratification and direct standardisation for age groups 
and sex. Thus, the population of individuals tested from 2003 
to 2012 was used as the reference population. The seasonality 
of monthly and weekly positivity rates was assessed by calcu-
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lating positivity rates from laboratory data from the whole ob-
servation period pooled by month or calendar week. 
6.4.3. Univariable and multivariable regression models 
In a first step, univariable logistic regression analyses were 
performed to estimate the effect of sex, age group, laboratory, 
residence by greater region, test week, test month and test year 
on the test result. Afterwards, a multivariable logistic regres-
sion model estimated the unconfounded effects of sex, age 
groups, laboratories, residence by greater region and test year 
on the test result. The effect of seasonal within-year variations 
on test outcome were investigated with a second multivariable 
logistic regression model including test month and adjustments 
for sex, age groups, laboratories, residence by greater region 
and test year. For this model, the test month with a positivity 
rate closest to the mean positivity rate of all test months was 
used as a baseline and test year was introduced as a random 
effect. The significance of variables in the multivariable mod-
els was assessed by likelihood ratio tests and the category of 
each variable with the most observations (except for test 
month) was used as a baseline to make the model more robust. 
Patients with missing information on the canton of residence 
were assigned the greater region of their corresponding labora-
tory. 
6.4.4. Ethical statement 
The study was approved by the local ethical committee 
“Ethikkommission Nordwest- und Zentralschweiz” [Ethical 
committee of Northwestern and Central Switzerland] (No.: 
EKNZ:2014-164). 
Time trends of positivity rates 
124 
6.5. Results 
6.5.1. Exclusion of test results and representativeness 
Eight laboratories agreed to participate in the study and five of 
them provided complete data for Campylobacter and 
Salmonella tests performed as requested. The eight laboratories 
conducted a total of 196 307 Campylobacter tests (17 694 
positive) and 199 062 Salmonella tests (4163 positive) between 
2003 and 2012. Excluding data from the three laboratories with 
incomplete data led to the exclusion of 43 530 (3345 positive) 
Campylobacter tests and 45 114 (640 positive) Salmonella 
tests. Among the remaining laboratories (A to E), removal of 
double entries, repeated tests and tests of non-Swiss residents 
led to the exclusion of a further 17 211 (1245 positive) 
Campylobacter tests and 16 499 (689 positive) Salmonella 
tests. Additionally, we excluded 444 (9 positive) 
Campylobacter tests and 452 (2 positive) Salmonella tests 
because of missing information on sex and/or age. In the 
detailed analysis, 135 122 (13 095 positive) Campylobacter 
tests and 136 997 (2832 positive) Salmonella tests were 
included. Culture-based test methods accounted for 98.7% of 
all Campylobacter and Salmonella tests conducted, and 
polymerase chain reaction (PCR) tests accounted for 1.3%. 
Positive tests included in the analysis corresponded to 20.4% 
and 17.2% of campylobacteriosis and salmonellosis cases, 
respectively, registered in the NNSID between 2003 and 2012 
(Table 6.1 and Table 6.2). 
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Figure 6.1: Number of stool tests for Campylobacter (a) and Sal-
monella (b) by sex in five diagnostic laboratories, 
Switzerland, 2003-2012. 
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6.5.2. Characteristics of the patient population and overview 
of tests performed 
The annual number of tests performed increased by 51.1% 
from 2003 to 2012 (11 674 to 17 641 tests) for Campylobacter 
and by 50.7% (11 842 to 17 842 tests) for Salmonella (Figure 
6.1). For both diseases, annual test numbers decreased by at 
least 6% for the age groups <5 years and 5–9 years, and 
increased by at least 31% in the older age groups. The median 
age of patients tested for Campylobacter was 42 years (range 
<1–108 years) and 41 years (range: <1–108 years) for 
Salmonella. Patients’ age differed significantly between 
laboratories and test years for both pathogens (Kruskal-Wallis 
test: p <0.01 for all four tests). Slightly more tests were 
conducted among females than among males for 
Campylobacter (54.8%) and for Salmonella (54.3%). The sex 
ratio differed between laboratories and test years for both 
pathogens (chi-square test: p<0.01 for all four tests). The 
patients’ residence by greater region was associated with the 
geographical location of the laboratory that performed the test. 
6.5.3. Annual positivity rates overall and by laboratory 
Annual Campylobacter positivity rates standardised for age 
and sex increased by 46.1% from 2003 (7.6%) to 2012 (11.1%) 
(Figure 6.2). Annual standardised Salmonella positivity rates 
showed an inverse trend and decreased by 44.4% from 2003 
(2.7%) to 2012 (1.5%). Campylobacter positivity rates strati-
fied by laboratory (and standardised for age and sex) showed 
similar annual trends (supplementary Figure S1 of Bless et al. 
(2017b)). The annual positivity rates of laboratory C were re-
markably lower throughout the investigated period compared 
with other laboratories.  
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Laboratory-specific Campylobacter positivity rates ranged 
from 3.8 to 9.4% in 2003 and continuously increased to 7.0–
13.2% in 2012. For Salmonella, annual positivity rates by la-
boratory differed only slightly between laboratories; the 
highest rates were observed for laboratory C, with two distinct 
peaks in 2007 and 2011. Overall, a decreasing trend was ob-
served; positivity rates dropped from 2.1–3.8% in 2003 to 1.2–
2.7% in 2012.  
6.5.4. Annual positivity rates by sex and age groups 
The annual Campylobacter positivity rates for males and 
females increased by 43.6% (from 9.4 to 13.5%) and by 45.2% 
(from 6.2 to 9.0%), respectively, from 2003 to 2012. In the 
same decade, annual Campylobacter positivity rates by age 
group increased for all age groups. The largest increase was 
observed for the age group ≥85 years (193.7%) followed by the 
5–9-year-olds (131.9%). Compared with 2003, annual 
Campylobacter positivity rates of sex-specific age groups were 
higher in 2012, except for females in the age group 10–14 
years (Figure 6.3a). Annual Campylobacter positivity rates 
were generally higher for males than for females over the entire 
observation period. For males and females in the age groups <5 
years, 5–9 years and ≥85 years, similar annual Campylobacter 
positivity rates were observed at the beginning of the decade 
but rates were later slightly higher for males in the age group ≥
85 years and for females in the age groups <5 years and 5–9 
years. 
Annual Salmonella positivity rates decreased from 3.3% to 
1.6% (−51.5%) for males and from 2.5% to 1.2% (−52.0%) for 
females between 2003 and 2012. Annual positivity rates de-
creased for all age groups between 2003 and 2012 except for   
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the age group 20–24 years, for which the rate remained rather 
stable. The largest relative decrease of positivity rates was ob-
served for the age groups 10–14 years and ≥85 years, where 
rates decreased from 10.5 to 3.7% (−64.8%) and from 0.8 to 
0.2% (−75.0%), respectively. Sex-specific Salmonella positivi-
ty rates were similar or slightly higher for males compared to 
females in all age groups although for some age groups, posi-
tivity rates varied strongly between years (Figure 6.3b). 
6.5.5. Seasonal trends in stool sampling and positivity rates 
The number of tests performed for Campylobacter and 
Salmonella started to increase in spring (Figure 6.4 panels a 
and c, Figure 6.5 panels a and c). Test numbers peaked in late 
August (calendar week 34) after a brief and strong temporary 
decline at the beginning of the month (calendar week 31). 
Afterwards, the number of tests decreased until the end of the 
year. Monthly test numbers were lowest in February for 
Campylobacter and Salmonella, even though calendar week 1 
was the week with the fewest tests performed. 
After a continuous increase during spring, monthly 
Campylobacter positivity rates peaked during summer months, 
with the highest monthly rate occurring in July (13.8%) (Figure 
6.4 panels b and d). Likewise, monthly Salmonella positivity 
rates started increasing during the spring.   
Figure 6.2: NNSID notification rates and positivity rates (standard-
ised for age and sex) of Campylobacter and Salmonella, 
Switzerland, 2003-2012. 
NNSID data provided by the Federal Office of Public Health, Bern, Swit-
zerland 
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They peaked twice, first in late summer (August) and then in 
the autumn, with the highest rate occurring in October (3.1%) 
(Figure 6.5 panels b and d).The highest weekly positivity rate 
for Campylobacter (17.3%) was in calendar week 1 (January), 
whereas the peak of weekly Salmonella positivity rates (3.5%) 
was in calendar week 43 (October). The lowest monthly posi-
tivity rates for Campylobacter and Salmonella were in 
February (5.3%) and March (1.1%), respectively. The seasonal 
trends of Campylobacter and Salmonella positivity rates were 
also observable for sex- and age-specific positivity rates alt-
hough less pronounced in certain groups. 
6.5.6. Regression analyses 
In the univariable regression analyses, sex, age, laboratory, 
residence by greater region, test week, test month and test year 
all had a significant effect on the test result for both diseases. 
The multivariable regression analysis of predictors for a posi-
tive Campylobacter test showed higher odds of a positive test 
for males than for females (odds ratio [OR] 1.53, 95% confi-
dence interval [CI] 1.47–1.59) (supplementary Table S1 of 
Bless et al. (2017b)). Patients in the age groups 15–19 years 
and 20–24 years had higher odds for a positive test outcome 
compared with the age group 25–44 years, whereas patients of 
other age groups had reduced odds. The patients’ place of 
residence by greater region had similar odds for a positive test, 
except for patients from the Ticino region (OR 0.44, 95% CI 
0.38–0.52). From 2003 to 2008, the odds increased continuous-
Figure 6.3: Annual positivity rates of Campylobacter (a) and 
Salmonella (b) by age group and sex, Switzerland, 
2003-2012. 
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ly and decreased slightly between 2009 and 2011 compared 
with 2012. 
The regression model for seasonal within-year variations 
showed that the odds for a positive Campylobacter test was 
highest in July (OR 1.52, 95% CI 1.40–1.65) and lowest in 
February (OR 0.55, 95% CI 0.49–0.61) compared with May, 
which had a positivity rate closest to the monthly average (sup-
plementary Table S2 of Bless et al. (2017b)). Significantly 
higher odds were also observed for June (OR 1.38, 95% CI 
1.26–1.50) and August (OR 1.24, 95% CI 1.14–1.35) compared 
with May. 
In the multivariable regression model for Salmonella, males 
had higher odds (OR 1.30, 95% CI 1.21–1.40) of a positive test 
than females (supplementary Table S3 of Bless et al. (2017b)). 
The odds of a positive test outcome increased threefold for the 
age groups <5 years, 5–9 years and 10–14 years compared with 
the age group 25–44 years. Greater region was no longer sig-
nificantly associated with the outcome in the multivariable 
regression model. The odds of a positive test outcome steadily 
decreased during the study period compared with 2012. In the 
second multivariable model for seasonality, the highest odds of 
a positive Salmonella test were observed in October (OR 1.61, 
95% CI 1.36–1.90) and August (OR 1.44, 95% CI 1.23–1.70) 
compared with November (supplementary Table S4 of Bless et 
al. (2017b)). The lowest odds (compared with November) were 
observed in March (OR 0.55, 95% C: 0.44–0.68) and February 
(OR 0.57, 95% CI 0.46–0.72). 
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Figure 6.4: Seasonality of Campylobacter tests and positivity rates 
(pooled over study period) per month and calendar week, 
Switzerland, 2003-2012. 
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Figure 6.5: Seasonality of Salmonella tests and positivity rates 
(pooled over study period) per month and calendar week, 
Switzerland, 2003-2012. 
PUBLISHED ARTICLE 
137 
6.6. Discussion 
Annual Campylobacter positivity rates standardised for age 
and sex increased from 2003 to 2012, whereas standardised 
Salmonella positivity rates decreased. During the same time 
period, campylobacteriosis notification rates increased from 
72.7 to 105.5 notifications per 100,000 population, whereas 
salmonellosis notification rates decreased from 29.8 to 15.4 per 
100,000 population. Campylobacter positivity rates were gen-
erally higher for males than females in all age groups. Monthly 
and weekly Campylobacter positivity rates showed a distinct 
seasonality, with a peak during the summer months and again 
at the beginning of the year, which was independent of sex and 
age group. Salmonella positivity rates showed a similar sea-
sonality, but peaked in autumn. Annual Salmonella positivity 
rates were similar or slightly higher for males than for females, 
with the highest rates observed in the younger age groups, <5, 
5–9 and 10–14 years. The observed seasonality and annual 
trends of positivity rates for both pathogens are congruent with 
reports from other countries [14, 18]. 
6.6.1. Annual positivity rates in relation to NNSID notifica-
tion rates 
Annual positivity rates of Campylobacter and Salmonella 
standardised for age and sex and annual NNSID notification 
rates showed similar trends. Multiple testing, data duplication 
or simultaneous testing of several pathogens could potentially 
affect both numerator and denominator data in different ways. 
However, similar trends were observed for the standardised 
annual positivity rates presented here and for the crude, non-
standardised positivity rates calculated from raw data from all 
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eight laboratories included in the study (supplementary Figure 
S2 of Bless et al. (2017b)). 
The stool test data analysed for this study originated mainly 
from culture-based test methods, which used to be the standard 
diagnostic method for detecting Campylobacter and 
Salmonella. Campylobacter, Salmonella and Shigella are often 
tested simultaneously [19]. In terms of relative frequency, more 
positive Salmonella tests (18.9%) than positive Campylobacter 
tests (8.4%) were excluded, whereas the proportion of excluded 
duplicate and repeated tests was similar for negative 
Campylobacter and Salmonella tests (11.2 vs 10.2%). The 
proportion of negative Salmonella tests excluded dropped only 
slightly from 10.2 to 9.4% when the same time span used for 
excluding negative Campylobacter tests was applied. Hence, 
only laboratory-confirmed campylobacteriosis and 
salmonellosis patients differ with regard to repeated testing. In 
summary, reducing the number of tests per patient and disease 
episode to one test result is crucial for an accurate calculation 
of positivity rates whereas the temporal trend of positivity rates 
is not considerably affected. 
The relative increase in standardised annual Campylobacter 
positivity rates (+46.1%) and the relative decrease in 
standardised annual Salmonella positivity rates between 2003 
and 2012 (−44.4%) are close to the increase in notification 
rates of Campylobacter (+45.0%) and the decrease in 
notification rates of Salmonella (−48.4%). During the same 
time period, the number of tests performed for Campylobacter 
and Salmonella increased by around 51%. The proportion of 
cases diagnosed by participating laboratories among NNSID 
case notifications increased by 37.7% for campylobacteriosis 
and by 26.9% for salmonellosis over the study period. 
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The observed increase of test numbers in our study was 
partially due to a single laboratory (laboratory A), where the 
number of tests increased 3.5 times for Campylobacter and 3.8 
times for Salmonella between 2003 and 2012. This laboratory 
was founded a few years before the study period. For the 
remaining laboratories (B, C, D, E), a smaller increase of 
32.0% for Campylobacter tests and of 29.0% for Salmonella 
tests was observed. An increase in testing frequency has also 
been observed in other European countries [14, 20], except in 
the Netherlands, where testing frequency remained rather 
stable [21]. Testing frequencies are largely influenced by 
physicians’ stool sampling behaviour and patients’ healthcare-
seeking behaviour [14, 22–25]. It is also possible that 
laboratories in the study increased their market shares. 
The increase of Campylobacter notification rates is probably 
due to a combination of increasing test numbers and an upward 
epidemiological trend in the population, as suggested by the 
increase in positivity rates. The decrease of Salmonella notifi-
cation rates presumably reflects an epidemiological trend in the 
population, as the notification rate decreased at the same time 
that testing frequency increased. The increase of campylobac-
teriosis cases in the population, together with the co-testing of 
Salmonella and Campylobacter, is probably responsible for the 
increase of Salmonella test numbers. 
In summary, notification rates are influenced by both epidemi-
ological trends in the population and test numbers. More 
infections in the population will lead to higher notification 
rates and fewer infections will lead to lower notification rates. 
On the other hand, increasing test numbers can lead to the de-
tection of more cases in the population, i.e., higher notification 
rates without necessarily reflecting an increase in disease fre-
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quency. Consequently, an observed increase in notification 
rates does not necessarily represent an actual increase of dis-
ease frequency in the population. A change in test numbers can 
be due to a number of factors such as changes in the prevalence 
of risk factors leading to testing, altered healthcare-seeking 
behaviour, and changes in physicians’ testing practices, hu-
man susceptibility, and pathogenicity. Assessing the interplay 
of notification rates and test numbers by positivity rates pro-
vides more insights into the epidemiological situation in the 
population than one of these measures alone. Nevertheless, 
understanding underlying reasons for changes in one of these 
measures requires further investigation. 
6.6.2. Positivity rates in relation to age and sex 
A remarkable increase in Campylobacter positivity rates was 
observed for the age groups 5–9 years and ≥85 years (+131.9% 
and +193.7%). Test numbers for the age group 5–9 years 
decreased during the observation period (−6.1%), and they 
more than doubled for the age group ≥85 years (+131.5%). 
During the same time period, notification rates for the ≥85 
years age group increased by 94.9% (47.2–92.0 per 100,000 
population) and for the 5–9 years age group by 30.7% (55.3–
72.3 per 100,000 population) [2]. It was found that adults and 
the elderly suffered increasingly more frequently from 
campylobacteriosis; this could be related to the frequent use of 
proton pump inhibitors and comorbidities in these age groups 
[2, 26, 27]. Others have also observed increasing test numbers 
among the elderly and related it to changes (increases) in 
healthcare-seeking and physicians’ testing behaviour [14, 18, 
24]. Additionally, the Swiss population aged ≥85 years 
increased by 29% from 2003 to 2012, which probably also 
contributed to the observed increase in test numbers [28]. 
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Salmonella notification rates and annual sex-specific positivity 
rates showed similar decreasing trends. The strongest decreases 
in age-specific annual Salmonella positivity rates were ob-
served for the age groups 10–14 years and ≥85 years (−64.8% 
and −75.0%, respectively). At the same time, notification rates 
dropped by 55.4% (39.2–17.5 per 100,000 population) for the 
10–14 year age group and by 55.6% (23.9–10.6 per 100,000 
population) for the ≥85 years group. It appears, therefore, that 
these decreases are true epidemiological trends. Age-specific 
Salmonella positivity rates tended to be slightly higher for 
males but did not remarkably differ between sexes. Similar 
observations have been made for corresponding NNSID data 
[2]. 
The increasing trend in Campylobacter positivity rates was 
similar for males and females. Also, male and female notifica-
tion rates to the NNSID likewise increased during this time [2]. 
Both positivity rates and notification rates for Campylobacter 
were higher among males than among females in nearly all age 
groups. Higher positivity rates for males have also been ob-
served by others [18]. Higher stool sampling rates have been 
reported for male patients in Canada [18] and for female pa-
tients in Wales [14]. Sex-specific differences in healthcare 
seeking or in risk exposures could account for this observation. 
6.6.3. Seasonality of positivity rates and notification rates 
Monthly and weekly Campylobacter and Salmonella positivity 
rates showed seasonal trends corresponding to the NNSID noti-
fication rates, which peaked during the summer months and, 
for Campylobacter, also at the beginning of the year [2]. Sum-
mer peaks of Campylobacter and Salmonella positivity rates 
have also been described previously [18]. Monthly and weekly 
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test numbers also peak in summer. The seasonal variation of 
test numbers could indicate seasonality of acute gastroenteritis, 
a temporal variation in the medical care-seeking behaviour of 
affected individuals and in the proportion of patients being 
tested. For instance, returning travellers are more likely to un-
dergo stool diagnostics [24, 25, 29], leading to increased test 
numbers during the public school holiday season in the sum-
mer. The combination of high test numbers and high positivity 
rates in summer and autumn generates the observed peak in 
case numbers in the NNSID [2]. 
Peaks of Campylobacter and Salmonella notification rates 
during summer months are observed in most European 
countries [1, 2, 27, 30, 31]. The prevalence of Campylobacter 
in broiler flocks and the contamination of chicken meat with 
Campylobacter at retail are higher during summer months than 
during the rest of the year [31–34]. This probably explains the 
observed seasonality as poultry meat from broilers is the main 
source of Campylobacter infections in Switzerland [35–37]. 
However, it seems that the summer peak is not caused by a 
single common source of infection and is more likely driven by 
multiple sources of animal and environmental exposures and 
climatic conditions [27, 31, 38, 39]. An additional reason for 
the summer peak in Switzerland and parts of the EU could be 
related to the culture of barbequing during summer, which 
provides multiple occasions for disease transmission through 
undercooking of and cross-contamination by poultry and red 
meat [40–43]. Travel abroad is a known risk factor for 
contracting campylobacteriosis [42–45] – also in Switzerland 
[46, 47] – and a large proportion of notified Salmonella 
infections in Switzerland is travel-related [48]. Hence, 
travelling probably contributes to the observed seasonality of 
PUBLISHED ARTICLE 
143 
campylobacteriosis and salmonellosis test numbers and case 
notifications in Switzerland. 
The highest weekly positivity rate for Campylobacter was 
found in calendar week 1 when test numbers were lowest. 
Notification rates of campylobacteriosis in Switzerland show a 
strong annual increase over Christmas and New Year (“winter 
peak”). A similar peak in notification data at the beginning of 
January has also been observed in Germany [30] and in the 
Campylobacter surveillance data of The European Surveillance 
System [1]. In Switzerland, the major driver for the winter peak 
is frequent consumption of meat fondue at festive occasions 
around this time, especially if it includes chicken meat [47]. 
The low test numbers over the festive season in December and 
January are probably related to a different healthcare-seeking 
behaviour and restricted access to healthcare services during 
the holiday period. Therefore, the winter peak in 
Campylobacter notification rates is probably attenuated and 
does not reveal the full magnitude of the problem. 
6.6.4. Strengths and limitations  
In Switzerland, private diagnostic laboratories operate on a 
regional or national level and predominantly serve the practices 
of general practitioners and medical specialists. The study did 
not consider hospital-based laboratories as their patient profile 
generally differs from the patient profile in private practices at 
the primary care level. Hospitalised patients are likely to be 
more severely affected by acute gastroenteritis and to undergo 
more extensive diagnostic testing. Hence, their pre-test proba-
bility for a positive Campylobacter or Salmonella test result is 
different from that of patients consulting at primary care prac-
tices [18]. The catchment population of the participating 
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laboratories is not known. Therefore, it was not possible to 
describe the catchment population, adjust for potential changes 
therein or to estimate any population-based indicators like stool 
sampling rates. Similarly, we could not assess how well the 
data of the five participating laboratories represent the whole 
tested population in Switzerland, given the latter is not known. 
We could only assess the representativeness of the patient pop-
ulation by comparing “our” positively tested patients with 
all notified cases (and hence, supposedly, all positively tested 
patients in Switzerland; Table 6.1 and Table 6.2). From this 
comparison we conclude that estimated positivity rates are like-
ly to represent accurately the epidemiological trends and 
situation in Switzerland as median age and the sex-ratio of cas-
es identified in participating laboratories and in cases from the 
NNSID were comparable. 
6.7. Conclusions 
The study results support the assertion that the increase in noti-
fication rates of campylobacteriosis and the decrease in 
notification rates of salmonellosis are epidemiological trends in 
the population. These trends cannot be solely explained by 
changing test numbers. Still, we believe it is important to con-
tinuously assess test numbers or positivity rates to note changes 
in stool testing frequency that could lead to changes in case 
numbers seen in the notification system. This becomes espe-
cially important in the light of the increasing use of multiplex 
PCR panels where multiple pathogens are tested simultaneous-
ly and, hence, test numbers can change substantially [49]. The 
annual collection of test numbers of selected notifiable diseases 
as stipulated under the newly enforced Swiss Epidemics Act 
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will allow for continuous assessment of positivity rates in the 
future. 
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7.1. Abstract 
Acute gastroenteritis (AG) is frequently caused by infectious 
intestinal diseases (IID) including food- and waterborne patho-
gens of public health importance. Among these pathogens, 
Campylobacter spp. plays a major role. Many European coun-
tries monitor selected IIDs within disease surveillance systems. 
In Switzerland, the information on IIDs is restricted to limited 
surveillance data, while no data is available for AG. We con-
ducted a qualitative study among Swiss general practitioners 
(GPs) to investigate the case management of AG and campylo-
bacteriosis patients, the associated disease burden and the 
determinants leading to registration in the National Notification 
System for Infectious Diseases (NNSID). Interviews were con-
ducted with a semi-structured questionnaire and underwent 
inductive content analysis based on Grounded Theory. The 
questionnaire was repeatedly adapted to capture emerging 
themes until the point of theoretical saturation. GPs perceived 
AG and campylobacteriosis of little relevance to their daily 
work and public health in general. According to GP self-
estimates each consults about two cases of AG per week and 
diagnoses a median of five campylobacteriosis cases per year. 
A large proportion of AG cases receives telephone consulta-
tions only and gets medical advice from the practice nurse. 
Antibiotic therapy is considered useful and stool diagnostics 
are performed for about a fifth of consulting AG patients. Stool 
diagnostics (“test”) and antibiotic therapy (“treat”) are interre-
lated and follow four strategies: “Wait & See”, “Treat & See”, 
“Treat & Test”, and “Test & See”. AG case management is 
diverse and includes different triage steps. A small proportion 
of AG patients have stool diagnostics performed and only posi-
tive tested patients are reported to the NNSID. As a result 
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severe cases and cases with a history of travel abroad are 
overrepresented in the NNSID. The use of multiplex PCR pan-
els in routine diagnostics likely leads to improved case 
management and higher case numbers in surveillance systems. 
7.2. Keywords 
campylobacteriosis, acute gastroenteritis, primary care, general 
practitioner, Switzerland 
7.3. Introduction 
Acute gastroenteritis (AG) is characterised by diarrhoea 
(watery, bloody), vomiting, fever, abdominal pain and cramps, 
nausea, and dehydration that occur in different combinations 
and with varying degrees of severity [1-3]. Those suffering 
from AG are frequently affected by infectious intestinal 
diseases (IID) caused by a wide range of gastrointestinal 
pathogens like viruses, bacteria and other parasites [1, 4, 5]. 
Food- and waterborne pathogens such as Campylobacter spp. 
and Salmonella spp., for example, are of particular public 
health concern as they can lead to disease outbreaks in addition 
to causing sporadic cases [6-8]. For this reason, many IID 
causing pathogens are monitored in most European Union (EU) 
countries and in Switzerland [9, 10]. The Swiss National 
Notification System for Infectious Diseases (NNSID) monitors 
a range of food- and waterborne pathogens including 
Campylobacter spp., Salmonella spp., Shigella spp. and 
enterohaemorrhagic Escherichia coli [9]. Among these, the 
most frequently notified IID in Switzerland is 
campylobacteriosis. Since 2006, a dramatic increase in case 
notifications has been observed, with an all-time high of almost 
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8500 notified cases in 2012 [11]. Increasing trends in case 
notifications were also observed in the European Union (EU) 
[10] e.g. England and Wales [12] or Germany [13] and in the 
United States of America (US) [14]. The NNSID is the only 
source of routine information on IIDs among the Swiss 
population, but it does not cover syndromic surveillance of 
AG, nor does any other surveillance system. 
The overall aim of the NNSID is to allow for the early detec-
tion of disease outbreaks and health threats from infectious 
diseases to initiate timely interventions for disease control. 
Additionally, the system supports a continuous assessment of 
existing preventive measures. Only laboratory-confirmed cases 
of notifiable IIDs are reported to the NNSID. Reported case 
data include the patient’s personal data (name or initials, ad-
dress or place of residence, sex, age), the applied diagnostics, 
the diagnosing laboratory and the physician in charge [9]. 
However, except for enterohaemorrhagic E. coli, the NNSID 
does not collect associated clinical information such as onset of 
disease, signs and symptoms, progression of disease, case 
management, hospitalisations, risk exposures or risk factors for 
IIDs [9]. In addition to insufficient knowledge on the clinical 
presentation of IIDs, the actual burden of IIDs and AG at the 
primary care level and the population level are unknown. To 
assess the disease burden from laboratory-based surveillance 
data at both levels, it is crucial to know the patients’ health care 
seeking behaviour and the physicians’ case management in-
cluding diagnostic practices. The lack of such information 
considerably impedes ability of the NNSID to capture minor 
epidemiological trends and interpretation of its data. The aims 
of this qualitative study among Swiss general practitioners 
(GPs), were to investigate the case management of AG and 
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campylobacteriosis patients, to assess the influence of patient’s 
health care seeking behaviour and of GPs’ clinical decision 
making on surveillance data and to collect estimates on the 
incidence of AG and campylobacteriosis at the primary care 
level. 
7.4. Materials & Methods 
7.4.1. Questionnaire development 
We developed a semi-structured questionnaire for face-to-face 
interviews that was informed by the study objectives, expert 
opinions and relevant literature. The questionnaire was divided 
into two parts. The first part covered GPs’ perception of AG 
and campylobacteriosis; that is, the perceived magnitude of the 
burden of AG and campylobacteriosis, incl. semi-quantitative 
estimates, relevance to public health, the clinical presentation 
(signs and symptoms) in daily practice, patients’ health care 
seeking behaviour (motives and processes), and the patients’ 
profile as it relates to risk behaviours and risk groups. The sec-
ond part, Case management, focused on the case management 
of AG and campylobacteriosis by evaluating diagnostic prac-
tices and treatment approaches (incl. influencing factors and 
logic behind the action) and reasons for related decisions, like 
referral to a specialist or hospitalisation. 
7.4.2. Interviewer training and pilot testing of questionnaire 
Pilot and study interviews were conducted by three female so-
cial scientists (SF, MZ and SH) and one male epidemiologist 
(PJB), between May and August 2013. The interviewers re-
ceived multiple trainings in qualitative interviewing techniques 
from a senior medical anthropologist (JMR). Pilot testing of the 
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questionnaire consisted of a preliminary interview with a key 
informant (senior GP), followed by five test interviews in 
German (four) and French (one). After the pilot, the question-
naire was re-structured accommodating the common procedure 
during the medical consultation with a patient with AG. The 
pilot indicated that the variety of determinants and approaches 
for symptomatic treatment are rather limited. Therefore, the 
questionnaire rather focused on examining the complex deter-
minants and approaches for antibiotic therapy. 
7.4.3. Recruitment of GPs and interview procedure 
GPs who had managed campylobacteriosis patients in a previ-
ous case-control study [15] but were otherwise not actively 
engaged, were invited for an interview for the purpose of the 
current study. In addition to those 146 German-speaking and 
29 French-speaking GPs of the case-control study [15] we pur-
posely recruited six French-speaking GPs for the study to 
better represent the French-speaking area of Switzerland. GPs 
were invited with an information letter sent by postal mail. 
After the anticipated receipt of the information letter, GPs were 
contacted by telephone and the study and study objectives were 
described. Verbal informed consent was obtained and an ap-
pointment for the interview arranged. The interview was 
conducted at a place of the GP’s choice, which was usually in 
his or her own practice. Interviews generally lasted for 20-40 
minutes and were tape recorded and transcribed. 
7.4.4. Data analysis 
Data analysis followed the principles of inductive content anal-
ysis as required by Grounded Theory and was performed with 
Weft-QDA software (http://pressure.to/qda/). Upon comple-
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tion, interviews were immediately transcribed and iteratively 
analysed, while data collection was ongoing. This approach 
allowed us (i) to capture emerging themes that could be includ-
ed in subsequent interviews, (ii) to refine the question guide 
and (iii) to evaluate the saturation process. Codes for data anal-
ysis were continuously developed and assigned to GPs’ 
narratives. All interviews were coded by a senior medical an-
thropologist (JMR). Theoretical saturation of themes and 
factors was eventually reached and study results were dis-
cussed at length by the research team. Semi-quantitative 
estimates of the perceived magnitude of AG and campylobac-
teriosis and the rates for requesting faecal specimens are given 
as the reported median and range. 
7.4.5. Ethics statement 
The work presented in this article and the previous case-control 
study [15] formed a project mandated by the Swiss Federal 
Government studying the epidemic increase of human 
Campylobacter spp. infections in Switzerland. Over the last 
decade notification rates for campylobacteriosis had not only 
steadily increased between 2005 and 2012 but also weekly 
notification rates peaked annually at the turn of the year. In 
2011/2012 weekly notifications increased extraordinarily 
twofold compared to the previous and following weeks [11]. In 
concert with the general epidemiological trend this situation 
was categorised as an epidemic threat by the Federal 
Government. In response the Federal Office of Public Health 
(FOPH) commissioned the project for the winter 2012/2013 
enforcing the Swiss Epidemics Act (SR 818.101 EpG). Projects 
conducted under the Epidemics Act do not require ethical 
approval. Hence, we did not seek approval from an ethical 
committee for the study but conducted the study in line with 
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the Declaration of Helsinki. Participating GPs provided verbal 
informed consent. They received an information letter of the 
FOPH and were subsequently contacted by telephone. During 
the telephone conversation interviewers explained again the 
purpose of the study and repeated the content of the 
information letter. GP’s were subsequently formally asked to 
participate and their response check marked on the consent 
form. We did not obtain written informed consent as the 
interviews focused solely on GPs’ professional views about the 
subject matter and not on any personal aspects or data of 
individual patients. The GPs’ personal data were anonymised 
and they did not receive any financial compensation for their 
participation. 
7.5. Results 
7.5.1. Characteristics of participating GPs 
In total, 69 GPs participated in the study (51 German-speaking 
and 18 French-speaking). The participation rate among GPs 
from the previous case-control study was 36.0% (63/175). Of 
the study participants, 13 (18.8%) were female and 56 (81.2%) 
were male. The majority (62) of interviewed GPs had special-
ised in general internal medicine, while five specialised in 
paediatrics, one in anaesthesia and one in urology. The latter 
two also provided primary health care. The median profession-
al experience of GPs was 23 years (range: 3-39 years) and the 
median number of patients consulted per GP per week (as es-
timated by the GPs) was 138 (range: 32-300). Slightly more 
than half of the interviewed GPs (38/69) worked at a practice 
located in a semi-urban community, and practices located in 
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urban and rural communities accounted for 30.4% (21/69) and 
14.5% (10/69) of the sample. 
7.5.2. Perception of acute gastroenteritis and campylobac-
teriosis 
Nearly all interviewed GPs considered AG in Switzerland to be 
of little relevance for the patient, uncommon in daily practice 
and of minor public health importance in Switzerland (Table 
7.1). In contrast, GPs highlighted that AG plays an important 
role in travel medicine and patients with a travel history. 
Interviewed GPs estimated observing a median of 2 cases of 
AG per week (range: 0-10 cases per week) and a median of 5 
(range: 0-52) laboratory-confirmed cases of campylobacteriosis 
each year. GPs highlighted that the real number of 
campylobacteriosis cases is higher than that indicated by 
laboratory-confirmed cases due to patients’ health care seeking 
behaviour (not all AG patients contact a GP) and GPs’ testing 
behaviour (not all AG cases are tested). The general perception 
was that, Campylobacter spp. has surpassed Salmonella spp. as 
the primary cause of bacterial diarrhoea in Switzerland, 
compared to the 1990s. Campylobacteriosis cases occur in 
waves or phases throughout the year and usually peak during 
the summer months and between December and January. GPs 
explicitly linked the summer peak to barbequing and the winter 
peak to traditional consumption of meat fondue (Table 7.1). 
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Table 7.1: Perception and burden of acute gastroenteritis and cam-
pylobacteriosis in Swiss primary care. 
Participant Quotes 
SFY12 “I have the impression that they [campylobacteriosis and 
AG] are not such a public health problem. Because I do, 
if I have them, if I discover them...I treat them. I don’t 
have the impression that they…in any case for me…they 
are not a problem for me.” 
MZ20 “(…) Diarrheal diseases only become problematic when 
there is an electrolyte and fluid imbalance. Most at risk 
are children. (…) But all in all, it is not a problem. Diar-
rheal diseases are generally self-limiting.” 
MZ20 “So, first of all, I do not diagnose every campylobacter 
case or every bacterial diarrhoeal case. I only conduct 
targeted testing. I do not do routine testing in the case of 
diarrhoea. This means that I certainly miss some of the 
cases.” 
SF02 “Indeed. Before, the main problem was Salmonella. I 
have rarely seen Shigella. Very rarely. Nowadays, cam-
pylobacter is more common.” 
SF01 “In summer, it can be [observed] during the barbeque 
season, it [barbeque] is a fostering element.” 
MZ01 “One can see this after every festivity day. So after 
Christmas, people show up with campylobacter infections. 
This is due to the poultry. Fondue chinoise [meat fondue] 
is stretched out with poultry.” 
“After the fondue chinoise season there are increasing 
campylobacter infections, yes.” 
PJB16 “Mostly it is fondue chinoise or barbeques. That is the 
classic. Nowadays it is rarely eggs or sauces compared to 
earlier times, but fondue chinoise is really classic. 
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GPs agreed on the basic signs of bacterial AG, particularly for 
campylobacteriosis: symptoms like abdominal pains and 
cramps or fever appear abruptly and the patient feels and pre-
sents as very ill (Table 7.2). Nausea and vomiting were also 
mentioned but occur less frequently. Some GPs also mentioned 
pain in the limbs and headache. Campylobacteriosis was seen 
as a self-limiting disease, easy to treat, and generally not dan-
gerous for peoples’ health (Table 7.1). However it can lead to a 
severe, painful and disturbing health condition that prevents 
people from working (Table 7.2). GPs recognised the im-
portance of AG and campylobacteriosis for vulnerable patients 
such as infants, the elderly, or individuals suffering from co-
morbidities. Campylobacteriosis can affect anyone, inde-
pendently of age, sex or socio-economic status. However, 
young adults and middle-aged people appear to be affected 
more frequently than the rest of the population, and especially 
more frequently than vulnerable groups. The perceived risk 
factors for contracting campylobacteriosis mentioned were: 
handling and eating raw or undercooked poultry, travelling and 
eating “unsafe” food, eating out in canteens or restaurants, bar-
becuing, consuming meat fondue with poultry or ready-to-eat 
salads and working in the food sector. Campylobacteriosis pa-
tients are generally unable to work for several days to more 
than one week (Table 7.2). The patient’s general condition is 
the main criterion for sickness certification and duration of sick 
leave. Other medical factors linked to occupation (physical or 
nonphysical activities; activities that can put others at risk) or 
social factors (like pressure by the employer or the patients 
themselves) also play a role. 
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7.5.3. Health care seeking behaviour and medical encounters 
at the primary care level 
GPs reported on patients’ individual health care seeking behav-
iour. Individuals affected by AG consult their GP within 
several hours to days after the onset of symptoms. Factors ac-
counting for prompt or delayed patient consultation included 
perceived severity, pain and distress, past experiences, attitude 
towards coping with disease, health insurance deductible or the 
need for a medical certificate. Up to 60% of all AG-related 
enquiries lead to telephone consultations only, without a face-
to-face consultation at the practice.  
Table 7.2: Clinical presentation and risk groups for campylobacteri-
osis. 
Participant Quotes 
PJB17 “It’s [symptoms of campylobacteriosis] for sure relatively 
fast appearing diarrhoea, watery diarrhoea, nausea, 
frequently fever. So they are really doing badly for a few 
days.” 
MZ13 “They [campylobacteriosis cases] mostly have fever. But 
it is mostly not very high. Whereby this also occurs for 
viral infections....The patients have also a bad general 
condition. Blood [in stool] I don't see so often. (…) The 
patients simply feel bad. When one only has a gastro-
intestinal flu, one doesn't feel fit. One also has to run to 
the toilet all the time. But somehow, people with campylo-
bacter really look very bad. (…)They are very pale and 
almost collapse.” 
MZ01 “Campylobacteriosis goes across all the social strata, all 
generations, across everything.” 
PJB21 “No, it [the risk group] is less children, mostly age 
groups from 20-25 to 60-65 years, this middle group. Less 
so children and older people.” 
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Table 7.2 continued 
Thus, practice nurses play a key role in evaluating the severity 
of disease, filtering patients for consultations at the practice 
and providing appropriate medical advice on the telephone. 
Several physical (e.g. severity), psychosocial (e.g. anxiety, 
mutual trust), and situational (e.g. GPs’ workloads) factors can 
favour either telephone or face-to-face consultations. After the 
first consultation and with appropriate measures taken, most 
GPs either schedule a follow-up appointment (usually by phone 
but sometimes at the medical practice) or ask patients to call if 
the symptoms do not improve. The follow-up serves as a 
means for evaluating the course of disease and for establishing 
further actions if needed. GPs’ workloads can be an obstacle to 
routine follow-up. Medical treatment is either concluded pas-
Participant Quotes 
PJB16 “Until they [the patients] start to improve a little after 
three to four days, until they are healthier again it goes 
approximately one week. Then they return to work, except 
if they have a physical work, then, it might need a little bit 
longer. But people working in the office or students can 
go back to work after a week – still a little impaired, not 
completely normal yet. Then it gradually improves.” 
PJB14 “Independent of the stool test, the patient is anyway ill for 
three to five days and can’t go for work. For patients 
working in the food sector, maybe even ten to fourteen 
days. The employers don’t really like it because it is a 
long time.” 
PJB05 “Another reason [for treating with antibiotics] is the 
importance of the working position of the patient. Some 
really need to go to work, others do not. Some ask for it 
[antibiotics].” 
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sively, i.e. patients do not contact the GP again, or actively at a 
follow-up consultation.  
7.5.4. Diagnostic and treatment approaches 
Routine consultation of an AG patient starts with history 
taking, including assessment of potential risk exposures 
followed by a clinical examination and point-of-care 
diagnostics (e.g. C-reactive protein (CRP) level). Faecal 
specimens for diagnostic purposes (mainly stool-cultures for 
Campylobacter spp., Salmonella spp. and Shigella spp.) are 
requested for a median of 18% (5-60%) of AG patients 
depending on the general condition, fever, blood in faeces, 
elevated CRP level e.g. >100 mg/l, prolonged disease duration, 
relevant co-morbidities, patient’s occupation and a positive 
history of ingesting risky food or of travel (Table 7.3). 
Table 7.3: Diagnostic approaches for AG cases among Swiss GPs. 
Participant Quotes 
MZ23 “For each patient, I first make an anamnesis. I ask him 
since when has he had it. When did it start? Have you 
eaten something special? Have you done something spe-
cial? Have you been abroad? Just the anamnesis. After 
this, the first impression of the patient. When there is 
massive diarrhoea, you can see that the patient is suffer-
ing. An important symptom is fever. Febrile diarrhoea has 
to be looked at differently. (…) Then I usually take CRP 
and blood status. Harmless diarrhoea has mostly a CRP 
of 20 to 40. But campylobacter have often 100, 120. 
Sometimes, they also have a leucocytosis. And when I 
have a suspicion, I request a stool examination.” 
MZ19 “Fever, bad general condition and when the patient him-
self says that he feels bad. Then I do a blood test, so  
PUBLISHED ARTICLE 
169 
Table 7.3 continued 
Symptomatic treatment of AG, including antimotility drugs and 
oral rehydration therapy for simple cases or intravenous rehy-
dration therapy for severe cases, is very common (Table 7.4). 
Antibiotic therapy plays only a secondary role due to the self-
limiting nature of most AG cases. Nevertheless, antibiotic ther-
apy is considered useful but prescribed cautiously. Its 
indication depends on disease severity, general condition, fe-
ver, inflammation parameters, occupation and partially on stool 
diagnostic results (Table 7.5). GPs mostly prescribe ciproflox-
acin and to a lesser extent erythromycin or specific classes of 
antibiotics, depending on the stool diagnostic result. Most GPs 
were concerned about potential antibiotic resistance of gastro-
intestinal bacteria. However, only some remembered 
Participant Quotes 
 CRP and leucocytes. I only check stool bacteriology when 
the values are clearly increased.” 
PJB06 “An anamnesis revealing a risk situation. I say it like this, 
did he have a risk situation, did he eat eggs, or poultry 
products or mozzarella or such products somewhere, so 
farmer products (…) or does he have fever?”  
MZ16 “In fact, there are two reasons for which one generally 
makes a stool examination: If the patient really feels ill 
and miserable. (…) As a general rule, I then give Imodi-
um. When the patient has taken it correctly, and it doesn't 
work, then I might do a stool test. Then there is a second 
group: Patients who were abroad. For these patients, it is 
possible that I primarily do a stool test. (…) Then there is 
a third group, where I primarily do a stool examination. 
When the patients come from an old people's home and 
one knows that there are already several people who fell 
ill.” 
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experiencing this problem in their medical practice (Table 7.5). 
GPs were aware that frequent prescription of antibiotics is 
positively associated with the occurrence of antibiotic re-
sistance. However, many also consider antibiotic therapies as 
very helpful for individual treatment, even if not medically 
indicated, to shorten disease duration or to ameliorate symp-
toms, for example. 
Table 7.4: Symptomatic treatment approaches for AG cases among 
Swiss GPs. 
Participant Quotes 
MZ11 “So primarily, I administer probiotics. At first, I focus on 
nutritional establishment and [recommend] the intake of 
fluids with light meals and without any dairy products for 
two, three days. Like this, one manages the patient slowly. 
This is standard for me.” 
PJB18 “There is the “solution of thirds”. (…) one third orange 
juice, one third black tea and one third mineral water, 
heavily sugared. (…) It contains everything, potassium in 
the orange juice, bicarbonate in the mineral water and 
you have fluid and sugar. (…) [it] is a cheap electrolyte 
solution.” 
PJB02 “And then only if…someone has 12 stools per day, I also 
give antidiarrhoeals. This is something that relieves the 
symptoms. But otherwise, in the first 3 days, cleaning of 
the intestine belongs to the body’s self-healing processes." 
PJB06 “So what I mean, what I sometimes do, I give someone an 
infusion. When somebody is prone to collapsing and has 
low blood pressure with nothing risky otherwise. Then we 
do an infusion here or at home. This I indeed like to do, I 
like to offer this.” 
PJB21 “They do essentially get better and the fever decreases 
faster if one gives an infusion and puts the fluid balance a 
little back in order.” 
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Table 7.5: Prescription of antibiotic therapy for AG cases and the 
perception of antibiotic resistance. 
Participant Quotes 
MZ23 “If somebody feels really sick and has a high fever, I may 
give him antibiotics quicker than recommended. (…) But 
on the other hand...if somebody has a fever of 39 degrees 
for two days and diarrhoea, you don't leave him to wait 
for another two, three days. With these cases, I am rela-
tively easy in giving antibiotics.” 
PJB17 “The indication of antibiotics is generally not due to the 
test result campylobacter, but rather due to the sympto-
matology” 
MZ18 Interviewer: “When do you give antibiotics?” 
“If there is extremely high fever and there are extremely 
high inflammation values, a CRP of 100 or higher.” 
PJB14 “If I don’t know the pathogen yet, I empirically give 
ciprofloxacin.” 
Interviewer: “And after you get the test result?” 
“If it is Campylobacter jejuni, I change to a macrolide” 
MZ15 “In fact, I almost always treat with ciprofloxacin. I at-
tended a tropical course. There I have heard that 
resistances are building slowly and that erythromycin 
products would be better. But up to now, I have always 
had good experiences with ciprofloxacin.” 
PJB02 “The resistance problem is known. Often there is a quino-
lone-resistance and then macrolides have to be used. It is 
only a matter of time until resistances also appear there.” 
PJB18 “Yes I had one single case that did not react to it [ciprof-
loxacin]…with campylobacter. There, I had to do a 
second culture with an antibiotic resistance profile. Then 
it worked, indeed with azithromycin and not with ciprof-
loxacin.” 
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7.5.5. The interplay of stool diagnostics and antibiotic 
therapy 
Initiating stool diagnostics (“Test”) is interrelated with antibi-
otic therapy (“Treat”) and follows four distinct approaches to 
acting and reacting in specific medical, social and physical 
situations (Table 7.6). GPs can lean towards “Treat & See”, 
“Treat & Test” or “Test & See”, and some can “Wait & See” 
longer than others. Few respondents openly refused an individ-
ual approach or adhered to one of these approaches only. The 
approaches “Wait & See” and “Treat & Test” appeared to be 
preferred. 
Table 7.6: Diagnostic and antibiotic therapy approaches among 
Swiss GPs. 
Approach Quotes 
Wait & See PJB08: “Waiting doesn’t mean omitting. Watchful waiting 
as it is called. It is a pleasant fact that, in general, a lot of 
problems that we are confronted with in general medicine 
are self-limiting. For this reason, I do not have to make a 
big effort concerning diagnostics. One decides based on 
the evidence (observing the course of the disease) and 
says: ‘Come again in two days’. Mostly they have to come 
again for a medical certificate. Or I tell the patient to 
report within a certain period if it doesn’t improve.” 
 MZ18: “Basically, one goes ahead step by step. First, one 
observes. One waits. One leaves it open. One only does a 
stool culture when diarrhoea persists. Not for every pa-
tient.” 
 Interviewer: “So the self-healing tendency plays a role?” 
 MZ18: “Exactly. One waits, often for one week or so. But 
when the pains are extreme or it takes longer, then we 
take a stool culture.” 
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Table 7.6 continued 
Approach Quotes 
Treat & See MZ17: “I am convinced that for 99% of the cases, we 
don't know the disease agent. We treat with a broad spec-
trum antibiotic. I cannot make a throat smear for every 
patient with sore throat (…). I think this is not the objec-
tive of a general practitioner.” 
 Interviewer: “So in the end you treat blindly. So, inde-
pendent of a test result.” 
 MZ18: “Yes, exactly. This is in our science not unusual. 
One applies a broad spectrum antibiotic. (…) For a lung 
infection, for example, you of course do not know whether 
a patient has this or that bacterium. This is of no interest 
to me in the general practice. And in general, it does not 
help the patient either. If you make a culture then you 
have the result maybe next Wednesday or Thursday. When 
you must send the sample you have to consider that the 
patient has pains and inflammation values for the next 
four, five days. What is the examination good for? It costs 
the patient money. In the deductible-system the patient 
pays, without any use.” 
Treat & Test MZ03: “And then there is such a thing ... there is such a 
cookbook rule, if there is bloody diarrhoea, or febrile 
diarrhoea. After doing stool bacteriology I give mostly 
ciprofloxacin. I say: “You go home first, then you fill the 
container, and then you swallow these tablets”. And this 
has shown quite good results. (…) And I say he should 
not take the tablets beforehand, otherwise we do not 
know what it is and we have no diagnosis, if it does 
not get better. (…) And I know it [test result] within 
four days. “Usually you [the patient] get better. But 
if you do not feel better, we know which bug it is." 
 MZ15: “Mostly, one also does a CRP, in order to 
determine whether it is a bacterium or a virus. (…)  
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Table 7.6 continued 
Approach Quotes 
 Depending on the result of the blood examination, I give 
him [the patient] a tube to take home. I always say then 
that it costs a lot of money. If you feel better, we don't 
need to send it. One has to treat anyway before one has 
the result. (…) it is practically always blind treatment. It 
is rare that the laboratory calls and we have not yet treat-
ed. It is then rather a confirmation that something is 
there. I, in fact, almost always treat with ciprofloxacin. 
(…) When I have the impression that the patient does not 
necessarily want to know it, I take the stool sample and I 
start treatment. When he gets better, we don't send it.” 
 MZ19: “When a patient comes with this psycho-social 
pressure, for example he has to work, then you do give 
him antibiotics. Then I don't wait until I receive the re-
sults. I treat immediately.” 
Test & See PJB03: “When the patient says he hasn’t improved at all, 
the test result is there, maybe against expectation…of 
campylobacter, and he  says: ‘I don’t get better at all’, he 
has still stomach cramps, diarrhoea and so on, then I 
treat him” 
 Interviewer: “So it might take some time until you get the 
test result. What is the influence of this in your treat-
ment?” 
PJB23: “Generally none. In the first phase, the treatment 
is independent of the stool sample.” 
Interviewer: “In the first phase. What do you do then with 
a positive result?” 
PJB23: “Let’s say it is salmonella or campylobacter posi-
tive, it doesn’t mean that they get ciprofloxacin. It simply 
means that one keeps an eye on them. I look how fast they 
recover and follow-up after a week, checking inflamma-
tion indicators.” 
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Table 7.6 continued 
Wait & See: This approach seems to be the standard starting 
point for most AG episodes. It is based on the principle that 
symptoms of AG including campylobacteriosis disappear after 
two to five days. It is mostly applied when the episode is recent 
and mild, or if the patient is in good general condition. Practice 
nurses evaluate the patient by telephone and decide if there is a 
need for a consultation or if the patient should wait out the dis-
ease’s progression. Diet, rehydration and symptomatic 
treatment recommendations are provided at this stage. 
Treat & See: Few GPs reported treating AG with antibiotics 
without requesting a faecal specimen. The underlying logic is 
that there is no need to know the exact cause of AG for a suc-
cessful treatment, particularly if there is indication of a 
bacterial infection, such as an elevated CRP level. Other rea-
sons were: the costs of stool diagnostics, wish to reduce the 
duration of suffering and infeasibility of requesting a faecal 
specimen (if the patient has to travel or the episode occurs just 
before the weekend, for example). The approach is a pragmatic 
Approach Quotes 
 Interviewer: “So a positive test result doesn’t always 
indicate an antibiotic use or so?” 
PJB23: “No. (…)  A young healthy person can overcome 
these diseases without antibiotics, they are not necessary. 
Second, there is a risk that we will have more chronic 
carriers if we give antibiotics. For salmonella this is 
known, they recover faster but they remain longer carri-
ers, really for a long time and this is what I want to 
avoid.” 
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one, focused on patients’ wellbeing and against the perceived 
norm for cautious use of antibiotics. 
Treat & Test: Antibiotic therapy starts before knowing the 
stool diagnostic result but after faecal specimen collection. It 
can then be modified upon receiving diagnostic results. This 
approach implies that empirical treatment usually works and 
that stool diagnostics are helpful for the post-diagnostic adapta-
tion of antibiotic therapy. GPs’ responses indicate the need to 
start antibiotic therapy immediately due to social (e.g. the pa-
tient has to work) and medical considerations (e.g. bad general 
condition). Reasons for applying this approach include the pos-
sibility of redirecting treatment if indicated, and considering 
public health aspects (e.g. if the patient works in the food sec-
tor or in health care). 
Test & See: This approach implies that antibiotic therapy only 
starts if indicated and after knowing the stool diagnostic result. 
However, antibiotics are only indicated if bacterial pathogens 
are identified and symptoms persist or the patient’s general 
condition deteriorates. Then the approach transforms to “Test 
and Treat” and the patient receives the pathogen-specific anti-
biotic therapy. GP’s applying this approach seek to avoid 
unnecessary and empirical ‘best-guess’ antibiotic therapies. 
7.5.6. Referrals 
Generally, GPs manage AG patients themselves at their prac-
tices. Complex cases of AG are referred to a specialist 
(gastroenterologist, specialist for infectious diseases, specialist 
in tropical and travel medicine) or a hospital. Reasons for refer-
ring a patient to a specialist include the development of 
persistent or chronic gastroenteritis (e.g. diarrhoea persists sev-
eral weeks, prolonged blood in faeces) or no response to the 
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usual treatments. A specialist in travel medicine is specifically 
approached if gastrointestinal problems persist after travelling 
abroad. Hospitalisation of AG patients is rather uncommon. 
Hospital referrals occur in case of bad general condition, severe 
dehydration, fear of sepsis, suspicion of diverticulitis or appen-
dicitis or if vulnerable patients suffer from severe AG. They 
also occur in cases where patients cannot manage at home due 
to lack of social support (e.g. elderly people living alone) or 
travel (e.g. tourists staying in a hotel). 
7.6. Discussion 
A qualitative study among 69 GPs in Switzerland on the clini-
cal presentation and case management of acute gastroenteritis 
and campylobacteriosis showed that GPs see around two pa-
tients with AG per week and a median of 5 campylobacteriosis 
cases per year. However, AG patients can also treat themselves 
at home, sometimes with medical advice from the practice 
nurse. Campylobacteriosis and AG are perceived as having 
little relevance for general public health, daily clinical practice 
and the average patient. Case management in the form of anti-
biotic therapy and stool diagnostics follows four approaches: 
“Wait & See”, “Treat & See”, “Treat & Test” or “Test & See”. 
GPs request faecal specimens for stool diagnostics from 18% 
of AG patients and prefer empirical antibiotic therapy before 
stool diagnostic results are available over result-based antibi-
otic therapy.  
7.6.1. The burden of acute gastroenteritis and campylobac-
teriosis 
GPs generally observe that, among causes of IIDs, 
Campylobacter spp. has surpassed Salmonella spp. in the last 
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20 years. This is confirmed by the trends of campylobacteriosis 
and salmonellosis case numbers reported to the NNSID [11]. 
Similar trends in notification rates were observed in the EU 
[10] e.g. Wales [16] whereas in the US the incidence of 
Salmonella spp. remained higher than for Campylobacter spp. 
[14, 17]. NNSID data also support GPs’ impressions that 
young adults and middle-aged people are more frequently 
affected [11]. More prevalent exposure risks among these 
groups, such as traveling abroad, eating out and preparing food 
themselves, as stated by GPs, could be responsible for 
increased case numbers. However, data to support this 
assumption are not yet available for Switzerland. 
The described seasonality of campylobacteriosis cases is 
reflected in the NNSID data [11]. Two distinct peaks of 
campylobacteriosis, one during summer months and one 
shorter peak over the festive season in December and January, 
lead to more primary care attendance. The summer peak of 
campylobacteriosis case notifications is observable throughout 
Europe [10]. The winter peak has been described in detail for 
Switzerland and Germany and is also observable in European 
notification data [10, 11, 13]. GPs associated the frequent 
consumption of meat fondue over the festive season in winter 
with increased campylobacteriosis case numbers. Indeed, meat 
fondue consumption was found to be the major risk factor for 
the winter peak of campylobacteriosis in Switzerland, as it is 
tradition to consume it at Christmas and New Year times [15]. 
The association of the summer peak with the barbeque season 
is plausible as barbequing meat provides many occasions for 
undercooking and re- and cross-contamination [18]. Studies in 
Switzerland [19] and Germany [20] showed higher 
Campylobacter spp. contamination rates of chicken meat 
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during summer months. Additional drivers for infection could 
also be more frequent recreational water activities or travels in 
summer, both risk factors that have been previously described 
for campylobacteriosis [18, 21-23]. GPs also observed that 
consultations due to AG occur in a clustered manner, with 
alternating case-free weeks and then several cases occurring in 
a single week. This might be due to small, local epidemics of 
viral IIDs. Switzerland does not have routine syndromic 
surveillance of AG, which would allow investigations of 
temporal and seasonal AG trends. This would be desirable, as 
other European countries such as France have had positive 
experiences with routine syndromic surveillance of AG [24]. 
7.6.2. The influence of patients’ health care seeking behav-
iour on NNSID case numbers 
Many AG affected individuals do not contact a GP at all or 
only get advice by telephone, depending on their health care 
seeking behaviour. GPs are aware that this leads to an underes-
timation of the IID burden at the primary care level and has - 
together with case management approaches - an influence on 
NNSID case numbers. This has already been described for oth-
er disease surveillance systems [5, 25, 26]. However, patients 
suffering from a bacterial gastrointestinal infection appear to be 
more likely to consult a GP than patients with a viral gastroin-
testinal infection [5, 27]. In the Netherlands, national GP 
guidelines recommend telephone consultations by practice 
nurses to deal with simple AG cases to reduce the number of 
consultations and stool diagnostics [28]. In Switzerland, the 
active promotion of telephone consultations for patients with 
mild AG could help to reduce health care expenditures, which 
are among the highest in the world [29]. According to study 
GPs, severely affected patients often directly consult the emer-
The viewpoint of general practitioners 
180 
gency department of a hospital, whereas the average AG case 
is dealt with at the practice and is rarely referred to a specialist 
or hospital. This is comparable with other findings reporting 
8.5% of GPs hospitalising an AG patient during the seven days 
preceding the interview [30]. However, hospitalised AG pa-
tients suffering from an IID are likely to undergo intensive 
diagnostics and, hence, will not be missed by the NNSID if 
diagnosed with a notifiable disease.  
7.6.3. The influence of diagnostic approaches on NNSID case 
numbers 
The GPs’ self-estimated proportion of requesting faecal speci-
mens for 18% of patients is comparable to other studies where 
rates vary between 4.3% and 50% [25, 28, 31-33]. Individual 
rates differed strongly among the GPs interviewed. The ob-
served heterogeneity seems to be rather common and has also 
been observed among English GPs [31]. It is likely related to 
GPs’ individually perceived usefulness of stool diagnostic re-
sults for case management and the patient populations they 
serve. This highlights the need to systematically estimate the 
faecal specimen testing rate to assess the disease burden of 
notifiable IIDs at the primary care level from NNSID case 
numbers. 
The determinants for requesting a faecal specimen, as found by 
this study, are similar to those found in other studies [28, 30-
32, 34-36] and are consistent with published recommendations 
on the clinical management of AG cases [4, 37]. Additionally, 
our study showed that factors related to the health system (e.g. 
health insurance deductible or duration of stool diagnostics) 
also influence the decision to perform stool diagnostics. An 
important determinant for performing stool diagnostics was the 
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patient’s CRP level. An elevated CRP level is considered in-
dicative of a bacterial infection, making distinct stool 
diagnostics more likely. Arguments for this criterion were the 
limited treatment possibilities for viral causes of AG and the 
need to know the bacterial cause for targeted antibiotic therapy. 
Requesting a faecal specimen based on a positive travel histo-
ry, as observed in our study, may not always be appropriate as 
stool diagnostics are not recommended for watery or traveller’s 
diarrhoea due to the low yield of recognising pathogenic bacte-
ria (e.g. enterotoxigenic E. coli) in the sample [37]. In 
accordance with others [32, 34], we observed that mainly se-
verely affected patients or patients with a history of travelling 
abroad undergo stool diagnostics in Switzerland, likely leading 
to a high proportion of severe and imported cases in the 
NNSID. Imported and domestic cases cannot be distinguished 
in the NNSID for most IIDs as laboratory reports do not in-
clude any information on exposure. Hence, the possible 
overrepresentation of imported cases should be considered 
when interpreting NNSID data as they are of less relevance for 
assessing national disease transmission and interventions. To 
improve the interpretation of NNSID data it would be advisa-
ble to include patients’ recent travel history on case 
notifications to differentiate between imported and domestic 
cases, similarly to other European countries [10]. The prefer-
ence of severe cases for stool diagnostics also explains the 
perceived high severity of disease by notified cases (7 on a 
rating scale from 1 = not severe, to 10 = very severe) and the 
high antibiotic prescription rate (61.6%) found in our case-
control study on determinants of campylobacteriosis in Swit-
zerland [15]. 
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When the study was conducted, the first diagnostic laboratories 
had introduced multiplex polymerase chain reaction (PCR) 
panels for IIDs in routine diagnostics. Up until then, the routine 
stool diagnostics applied to AG patients were stool-cultures for 
Campylobacter spp., Salmonella spp. and Shigella spp. [38]. 
Only a few of the interviewed GPs had already deliberately 
ordered stool diagnostics with this new diagnostic tool. Multi-
plex PCR panels will likely affect case numbers in the NNSID 
if they are routinely deployed by Swiss GPs. They have a high-
er detection rate of IIDs in faecal specimens compared to 
conventional methods due to a higher sensitivity and the wide 
range of IIDs tested simultaneously [39-41]. Greater sensitivity 
will likely lead to increased case numbers of the routinely test-
ed and notifiable IIDs (Campylobacter spp., Salmonella spp. 
and Shigella spp.) within the NNSID. Similarly, stool diagnos-
tics for other specific notifiable IIDs, e.g. enterohaemorrhagic 
E. coli, were mainly requested for AG patients with a certain 
suspicion such as blood in faeces. More tests will be conducted 
for these IIDs because faecal specimens investigated by multi-
plex PCR panels are tested for the same range of IIDs 
independent of the suspected cause which could lead to the 
detection of more cases. 
7.6.4. “Treat & See” and “Treat & Test” for targeted antibi-
otic therapies 
The GPs in our study considered stool diagnostics and antibi-
otic therapy useful for managing AG cases. The “Wait & See” 
approach, including symptomatic treatment, is the approach 
applied most often to AG case management among Swiss GPs. 
This is in line with published case management guidelines for 
simple AG cases [1, 4, 37, 38]. From a public health perspec-
tive, the “Treat & See” and “Treat & Test” approaches are 
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questionable as both can lead to untargeted antibiotic therapies. 
Similar to the “Wait & See” approach, the “Treat & See” ap-
proach additionally contributes to the underreporting of IID 
cases in the NNSID.  
Studies showed that in a large proportion of faecal specimens 
from AG patients no or viral pathogens are identified and, 
hence, disease is likely not caused by bacteria [42-45]. The 
aforementioned approaches bear a high probability of incor-
rectly treating those patients with antibiotics. In the era of 
increasing antibiotic resistance among gastrointestinal bacterial 
pathogens, untargeted antibiotic therapy should be avoided. 
Additionally, antibiotic therapy needs to be carefully consid-
ered for its potentially counter-productive effects for bacterial 
infections such as Escherichia coli O157:H7, for example [46, 
47]. Timely antibiotic therapy is desirable to reduce disease 
duration and to increase the wellbeing of the patient in cases of 
severe AG (e.g. with febrile dysentery with an indication of a 
bacterial cause such as an elevated CRP level or based on food 
history) [4, 36, 37]. 
A major reason for applying the “Treat & See” and “Treat & 
Test” approaches is the perceived long duration until culture-
based stool diagnostic results are available. Therefore, fast mo-
lecular diagnostics for IIDs such as multiplex PCR panels 
would enable the physician to initiate timely and targeted anti-
biotic therapy and are desirable [36, 39]. When these are 
widely deployed, “Test & See” could become the preferred 
approach to AG case management over “Wait & See”. The fast 
availability of diagnostic results will also permit a shift to “Test 
and Treat”, including a specific and timely treatment approach 
based on stool diagnostic results. GPs in our study were prone 
to change their treatment approach based on the stool diagnos-
The viewpoint of general practitioners 
184 
tic results. However, immediate antibiotic therapy will remain 
the therapy of choice for severely affected patients to assure the 
wellbeing of the patient. 
Swiss surveillance data shows that Campylobacter spp. is the 
most frequent bacterial cause of IIDs [11]. But around 50% of 
tested Campylobacter spp. isolates from humans are resistant 
to fluoroquinolones according to Swiss study and surveillance 
data [48, 49]. Therefore, the prescription of ciprofloxacin 
(fluoroquinolone) for AG cases with a suspected bacterial 
cause, as mentioned by interviewed GPs, is questionable. 
Azithromycin (macrolide) would be the drug of choice for 
treating campylobacteriosis and is also appropriate for treating 
salmonellosis and shigellosis [4, 37]. A similar level of 
resistance of Campylobacter spp. to fluoroquinolones is 
observed in EU countries, but varies considerably between 
countries. As a result, the European Food Safety Authority and 
the European Centre for Disease Prevention and Control no 
longer consider fluoroquinolones appropriate for routine 
empirical treatment of human campylobacteriosis [50]. In 
summary, empirical antibiotic therapy for the treatment of AG 
patients should be avoided whenever possible and macrolides 
(e.g. azithromycin or erythromycin) are recommended for 
empirical treatment if it is indicated for the wellbeing of the 
patient. 
7.6.5. Discussion of research approach 
A wide range of GPs was accessible through the previously 
conducted case-control study [15] and provided an ideal and 
unique opportunity to assess the case management of AG and 
campylobacteriosis patients and the associated disease burden 
at the primary care level. A qualitative research approach was 
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chosen due to the lack of information on AG and campylobac-
teriosis at the primary care level in Switzerland and the 
unknown willingness of GPs to participate. This allowed re-
searchers to collect information on all aspects of interest nearly 
independent of the participation rate, but limited the possibili-
ties for quantifying some of the results. Semi-quantitative 
estimates on the disease burden by GPs allowed a first assess-
ment of the unknown disease burden at the primary care level. 
Such estimates of disease burden should be interpreted with 
caution as they are influenced by several factors. The progres-
sion of the interview, the time point of the interview in regard 
to disease seasonality or the GP’s importance alluded to the 
disease can lead to over- or underestimation. The large sample 
of 69 GPs from the German- and French-speaking parts of 
Switzerland increased the geographical and paradigmatic varia-
tion represented, leading to an improved saturation of 
investigated themes. Additionally, interviewers followed-up on 
various topics with different levels of detail during the inter-
views due to different backgrounds of interviewers, resulting in 
even wider variation and fast theoretical saturation. We lack 
interviews with GPs from the Italian-speaking part of Switzer-
land but we assume that – due to the minor differences between 
French- and German-speaking GPs – differences in case man-
agement and disease burden would only slightly differ from 
our study results. It might appear that the study generated only 
general knowledge, but it is the first and largest study to date 
providing a comprehensive overview of the applied case man-
agement, disease burden and determinants leading to disease 
notification in Switzerland. 
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7.7. Conclusions 
The health care seeking behaviour of AG patients leading to 
primary care attendance, and GPs’ varying case management 
approaches including triage steps and stool diagnostic frequen-
cy need to be taken into account when interpreting NNSID 
data. Patients severely affected by AG or who travelled abroad 
are more frequently seeking care and are hence, overrepresent-
ed among campylobacteriosis cases notified in the NNSID. As 
a result, the NNSID monitors the epidemiological situation of 
notifiable IIDs of more severe disease expressions rather than 
the entire spectrum of notifiable IID suffering in the Swiss 
population. The current transition from routine culture-based 
stool diagnostics to routine multiplex PCR panels in diagnostic 
laboratories will likely counter act such a skewed epidemiolog-
ical data situation. This expectation is mainly driven by the 
higher sensitivity of these molecular diagnostics and by a pos-
sible increase in the number of stool diagnostics conducted due 
to faster availability of diagnostic results. Therefore, the antici-
pated increase in case numbers will not necessarily reflect an 
epidemiological trend in the Swiss population and should be 
considered when communicating NNSID data to stakeholders. 
Knowledge on which diagnostic methods are available and 
actually applied is important for public health authorities to 
accurately interpret NNSID data, particularly during the transi-
tion period. Consequently, further research should be 
conducted on the impact of routine multiplex PCR panels on 
the composition and number of cases registered in the NNSID 
and possible changes in case management including antibiotic 
therapies. 
PUBLISHED ARTICLE 
187 
7.8. Acknowledgments 
The authors would like to thank the participants of the pilot 
study and the study participants. We kindly thank Sonia 
Ferroni Yameogo, Meike-Kathrin Zuske and Susanna 
Hausmann-Muela for their commitment in interviewing 
physicians, and Amena Briët, from the Swiss Tropical and 
Public Health Institute, for her critical language editing. The 
support of the Swiss Federal Office of Public Health, Division 
of Communicable Diseases for the study is gratefully 
acknowledged. 
7.9. References 
1. Thielman NM, Guerrant RL. Acute infectious diarrhea. N Engl 
J Med. 2004;350(1):38-47. doi: 10.1056/NEJMcp031534. 
pmid: 14702426 
2. Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, 
Slutsker L, Tauxe RV, et al. Practice guidelines for the man-
agement of infectious diarrhea. Clin Infect Dis. 
2001;32(3):331-51. doi: 10.1086/318514. pmid: 11170940 
3. Morgan DR, Chidi V, Owen RL. Gastroenteritis. In: Schloss-
berg D, editor. Clinical Infectious Disease. 2nd ed. Cambridge, 
United Kingdom: Cambridge University Press; 2015. pp. 334-
41. 
4. DuPont HL. Acute infectious diarrhea in immunocompetent 
adults. N Engl J Med. 2014;370(16):1532-40. doi: 
10.1056/NEJMra1301069. pmid: 24738670 
The viewpoint of general practitioners 
188 
5. Tam CC, Rodrigues LC, Viviani L, Dodds JP, Evans MR, 
Hunter PR, et al. Longitudinal study of infectious intestinal 
disease in the UK (IID2 study): incidence in the community 
and presenting to general practice. Gut. 2012;61(1):69-77. doi: 
10.1136/gut.2011.238386. pmid: 21708822 
6. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson 
MA, Roy SL, et al. Foodborne illness acquired in the United 
States--major pathogens. Emerg Infect Dis. 2011;17(1):7-15. 
doi: 10.3201/eid1701.091101p1. pmid: 21192848 
7. Painter JA, Hoekstra RM, Ayers T, Tauxe RV, Braden CR, 
Angulo FJ, et al. Attribution of foodborne illnesses, hospitali-
zations, and deaths to food commodities by using outbreak 
data, United States, 1998-2008. Emerg Infect Dis. 
2013;19(3):407-15. doi: 10.3201/eid1903.111866. pmid: 
23622497 
8. Schmid H, Baumgartner A. Foodborne outbreaks in Switzer-
land - current statistics, future developments, practical 
guidelines for the investigation of outbreaks and a historical 
review. Bern, Switzerland: The Federal Office of Public 
Health, Food Safety Division; 2012. 
9. [Ordinance of the FDHA on the notification of observations on 
human communicable diseases of 2015], SR 818.101.126, 
Federal Department of Home Affairs, Bern, Switzerland 
(March 5, 2016). German. 
10. European Food Safety Authority and European Centre for 
Disease Prevention and Control. The European Union sum-
mary report on trends and sources of zoonoses, zoonotic 
agents and food-borne outbreaks in 2014. EFSA Journal. 
2015;13(12):191pp. doi: 10.2903/j.efsa.2015.4329 
PUBLISHED ARTICLE 
189 
11. Schmutz C, Mausezahl D, Jost M, Baumgartner A, Mau-
sezahl-Feuz M. Inverse trends of Campylobacter and 
Salmonella in Swiss surveillance data, 1988-2013. Euro Sur-
veill. 2016;21(6). doi: 10.2807/1560-
7917.ES.2016.21.6.30130. pmid: 26898102 
12. Nichols GL, Richardson JF, Sheppard SK, Lane C, Sarran C. 
Campylobacter epidemiology: a descriptive study reviewing 1 
million cases in England and Wales between 1989 and 2011. 
BMJ Open. 2012;2(4). doi: 10.1136/bmjopen-2012-001179. 
pmid: 22798256 
13. Schielke A, Rosner BM, Stark K. Epidemiology of campylo-
bacteriosis in Germany - insights from 10 years of 
surveillance. BMC Infect Dis. 2014;14(1):30. doi: 
10.1186/1471-2334-14-30. pmid: 24422983 
14. Crim SM, Griffin PM, Tauxe R, Marder EP, Gilliss D, 
Cronquist AB, et al. Preliminary incidence and trends of infec-
tion with pathogens transmitted commonly through food - 
Foodborne Diseases Active Surveillance Network, 10 U.S. 
sites, 2006-2014. MMWR Morb Mortal Wkly Rep. 
2015;64(18):495-9. pmid: 25974634 
15. Bless PJ, Schmutz C, Suter K, Jost M, Hattendorf J, Mau-
sezahl-Feuz M, et al. A tradition and an epidemic: 
determinants of the campylobacteriosis winter peak in Swit-
zerland. Eur J Epidemiol. 2014;29(7):527-37. doi: 
10.1007/s10654-014-9917-0. pmid: 24990236 
16. Janiec J, Evans MR, Thomas DR, Davies GH, Lewis H. La-
boratory-based surveillance of Campylobacter and Salmonella 
infection and the importance of denominator data. Epidemiol 
Infect. 2012;140(11):2045-52. doi: 
10.1017/S0950268811002822. pmid: 22217369 
The viewpoint of general practitioners 
190 
17. Centers for Disease Control and Prevention (CDC). Vital 
signs: incidence and trends of infection with pathogens trans-
mitted commonly through food--foodborne diseases active 
surveillance network, 10 U.S. sites, 1996-2010. MMWR Morb 
Mortal Wkly Rep. 2011;60(22):749-55. pmid: 21659984 
18. Mughini Gras L, Smid JH, Wagenaar JA, de Boer AG, 
Havelaar AH, Friesema IHM, et al. Risk Factors for Campylo-
bacteriosis of Chicken, Ruminant, and Environmental Origin: 
A Combined Case-Control and Source Attribution Analysis. 
PLoS One. 2012;7(8):e42599. doi: 
10.1371/journal.pone.0042599 
19. Baumgartner A, Felleisen R. Market surveillance for contami-
nation with thermotolerant campylobacters on various 
categories of chicken meat in Switzerland. J Food Prot. 
2011;74(12):2048-54. doi: 10.4315/0362-028X.JFP-11-228. 
pmid: 22186044 
20. Scherer K, Bartelt E, Sommerfeld C, Hildebrandt G. Quantifi-
cation of Campylobacter on the surface and in the muscle of 
chicken legs at retail. J Food Prot. 2006;69(4):757-61. pmid: 
16629016 
21. Neimann J, Engberg J, Molbak K, Wegener HC. A case-
control study of risk factors for sporadic campylobacter infec-
tions in Denmark. Epidemiol Infect. 2003;130(3):353-66. 
pmid: 12825719 
22. Schorr D, Schmid H, Rieder HL, Baumgartner A, Vorkauf H, 
Burnens A. Risk factors for Campylobacter enteritis in Swit-
zerland. Zentralbl Hyg Umweltmed. 1994;196(4):327-37. 
pmid: 7748438 
PUBLISHED ARTICLE 
191 
23. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, 
Breukink BJ, Wagenaar JA, Van Pelt W. Risk factors for in-
digenous Campylobacter jejuni and Campylobacter coli 
infections in The Netherlands: a case-control study. Epidemiol 
Infect. 2010;138(10):1391-404. doi: 
10.1017/S095026881000052X. pmid: 20223048 
24. Flahault A, Blanchon T, Dorleans Y, Toubiana L, Vibert JF, 
Valleron AJ. Virtual surveillance of communicable diseases: a 
20-year experience in France. Stat Methods Med Res. 
2006;15(5):413-21. pmid: 17089946 
25. Van Cauteren D, Turbelin C, Fonteneau L, Hanslik T, De Valk 
H, Blanchon T. Physician practices in requesting stool samples 
for patients with acute gastroenteritis, France, August 2013-
July 2014. Epidemiol Infect. 2015;143(12):2532-8. doi: 
10.1017/S0950268814003884. pmid: 25592030 
26. van Pelt W, de Wit MA, Wannet WJ, Ligtvoet EJ, Widdowson 
MA, van Duynhoven YT. Laboratory surveillance of bacterial 
gastroenteric pathogens in The Netherlands, 1991-2001. Epi-
demiol Infect. 2003;130(3):431-41. pmid: 12825727 
27. de Wit MA, Kortbeek LM, Koopmans MP, de Jager CJ, Wan-
net WJ, Bartelds AI, et al. A comparison of gastroenteritis in a 
general practice-based study and a community-based study. 
Epidemiol Infect. 2001;127(3):389-97. pmid: 11811870 
28. van den Brandhof WE, Bartelds AI, Koopmans MP, van 
Duynhoven YT. General practitioner practices in requesting 
laboratory tests for patients with gastroenteritis in the Nether-
lands, 2001-2002. BMC Fam Pract. 2006;7:56. doi: 
10.1186/1471-2296-7-56. pmid: 17014713 
The viewpoint of general practitioners 
192 
29. Lorenzoni L, Belloni A, Sassi F. Health-care expenditure and 
health policy in the USA versus other high-spending OECD 
countries. Lancet. 2014;384(9937):83-92. doi: 10.1016/S0140-
6736(14)60571-7. pmid: 24993914 
30. Hennessy TW, Marcus R, Deneen V, Reddy S, Vugia D, 
Townes J, et al. Survey of physician diagnostic practices for 
patients with acute diarrhea: Clinical and public health impli-
cations. Clin Infect Dis. 2004;38:S203-S11. doi: 
10.1086/381588. pmid: WOS:000220734900013 
31. McNulty CA, Lasseter G, Verlander NQ, Yoxall H, Moore P, 
O'Brien SJ, et al. Management of suspected infectious diar-
rhoea by English GPs: are they right? Br J Gen Pract. 
2014;64(618):e24-30. doi: 10.3399/bjgp14X676429. pmid: 
24567579 
32. Scallan E, Jones TF, Cronquist A, Thomas S, Frenzen P, 
Hoefer D, et al. Factors associated with seeking medical care 
and submitting a stool sample in estimating the burden of 
foodborne illness. Foodborne Pathog Dis. 2006;3(4):432-8. 
doi: 10.1089/fpd.2006.3.432. pmid: 17199525 
33. Kubota K, Kasuga F, Iwasaki E, Inagaki S, Sakurai Y, Ko-
matsu M, et al. Estimating the burden of acute gastroenteritis 
and foodborne illness caused by Campylobacter, Salmonella, 
and Vibrio parahaemolyticus by using population-based tele-
phone survey data, Miyagi Prefecture, Japan, 2005 to 2006. J 
Food Prot. 2011;74(10):1592-8. doi: 10.4315/0362-028X.JFP-
10-387. pmid: 22004803 
PUBLISHED ARTICLE 
193 
34. Scallan E, Fitzgerald M, Cormican M, Smyth B, Devine M, 
Daly L, et al. The investigation of acute gastroenteritis in gen-
eral practice: a survey of general practitioners in Northern 
Ireland and Republic of Ireland. Eur J Gen Pract. 2005;11(3-
4):136-8. pmid: 16671321 
35. Ke BX, Ran L, Wu SY, Deng XL, Ke CW, Feng ZJ, et al. 
Survey of Physician Diagnostic and Treatment Practices for 
Patients with Acute Diarrhea in Guangdong Province, China. 
Foodborne Pathog Dis. 2012;9(1):47-53. doi: 
10.1089/fpd.2011.0964. pmid: WOS:000299031300008 
36. McNulty CA, Lasseter G, Newby K, Joshi P, Yoxall H, Kuma-
ran K, et al. Stool submission by general practitioners in SW 
England - when, why and how? A qualitative study. BMC 
Fam Pract. 2012;13:77. doi: 10.1186/1471-2296-13-77. pmid: 
22870944 
37. DuPont HL. Bacterial diarrhea. N Engl J Med. 
2009;361(16):1560-9. doi: 10.1056/NEJMcp0904162. pmid: 
19828533 
38. Schweiger A, Markwalder K, Vogt M. Infektiöse Diarrhoe: 
Epidemiologie, Klinik und Diagnostik. Schweiz Med Forum. 
2005;5:714-23. 
39. Wessels E, Rusman LG, van Bussel MJ, Claas EC. Added 
value of multiplex Luminex Gastrointestinal Pathogen Panel 
(xTAG(R) GPP) testing in the diagnosis of infectious gastro-
enteritis. Clin Microbiol Infect. 2014;20(3):O182-7. doi: 
10.1111/1469-0691.12364. pmid: 24131399 
The viewpoint of general practitioners 
194 
40. Spina A, Kerr KG, Cormican M, Barbut F, Eigentler A, Zerva 
L, et al. Spectrum of enteropathogens detected by the FilmAr-
ray GI Panel in a multicentre study of community-acquired 
gastroenteritis. Clin Microbiol Infect. 2015;21(8):719-28. doi: 
10.1016/j.cmi.2015.04.007. pmid: 25908431 
41. Binnicker MJ. Multiplex Molecular Panels for Diagnosis of 
Gastrointestinal Infection: Performance, Result Interpretation, 
and Cost-Effectiveness. J Clin Microbiol. 2015;53(12):3723-8. 
doi: 10.1128/JCM.02103-15. pmid: 26311866 
42. Tam CC, O'Brien SJ, Tompkins DS, Bolton FJ, Berry L, 
Dodds J, et al. Changes in causes of acute gastroenteritis in the 
United Kingdom over 15 years: microbiologic findings from 2 
prospective, population-based studies of infectious intestinal 
disease. Clin Infect Dis. 2012;54(9):1275-86. doi: 
10.1093/cid/cis028. pmid: 22412058 
43. Huhulescu S, Kiss R, Brettlecker M, Cerny RJ, Hess C, We-
walka G, et al. Etiology of acute gastroenteritis in three 
sentinel general practices, Austria 2007. Infection. 
2009;37(2):103-8. doi: 10.1007/s15010-008-8106-z. pmid: 
19148576 
44. Karsten C, Baumgarte S, Friedrich AW, von Eiff C, Becker K, 
Wosniok W, et al. Incidence and risk factors for community-
acquired acute gastroenteritis in north-west Germany in 2004. 
Eur J Clin Microbiol Infect Dis. 2009;28(8):935-43. doi: 
10.1007/s10096-009-0729-1. pmid: 19319582 
45. Friesema IH, De Boer RF, Duizer E, Kortbeek LM, Notermans 
DW, Smeulders A, et al. Aetiology of acute gastroenteritis in 
adults requiring hospitalization in The Netherlands. Epidemiol 
Infect. 2012;140(10):1780-6. doi: 
10.1017/S0950268811002652. pmid: 22152987 
PUBLISHED ARTICLE 
195 
46. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The 
risk of the hemolytic-uremic syndrome after antibiotic treat-
ment of Escherichia coli O157:H7 infections. N Engl J Med. 
2000;342(26):1930-6. doi: 10.1056/NEJM200006293422601. 
pmid: 10874060 
47. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic 
uremic syndrome after antibiotic treatment of Escherichia coli 
O157:H7 enteritis: a meta-analysis. JAMA. 2002;288(8):996-
1001. pmid: 12190370. 
48. Swiss Centre for Antibiotic Resistance. anresis.ch 2016 [cited 
29 April 2016]. Available: 
http://anresis.ch/index.php/indexen.html. 
49. Niederer L, Kuhnert P, Egger R, Buttner S, Hachler H, Kor-
czak BM. Genotypes and antibiotic resistances of 
Campylobacter jejuni and Campylobacter coli isolates from 
domestic and travel-associated human cases. Appl Environ 
Microbiol. 2012;78(1):288-91. doi: 10.1128/AEM.06194-11. 
pmid: 22020515 
50. European Food Safety Authority and European Centre for 
Disease Prevention and Control. EU Summary Report on an-
timicrobial resistance in zoonotic and indicator bacteria from 
humans, animals and food in 2013. EFSA Journal. 
2015;13(2):4036, 178pp. doi: 10.2903/j.efsa.2015.403 
 
 196 
 
 197 
8. ARTICLE 5: Acute gastroenteritis in primary 
care: a longitudinal study in the Swiss 
Sentinel Surveillance Network, Sentinella 
Claudia Schmutz
1,2
, Philipp J. Bless
1,2
, Marianne Jost
3
, Mirjam 
Mäusezahl-Feuz
3
, Daniel Mäusezahl
1,2
, Swiss Sentinel Surveil-
lance Network 
 
1
Swiss Tropical and Public Health Institute, Basel, Switzerland 
2
University of Basel, Basel, Switzerland 
3
Federal Office of Public Health, Schwarzenburgstrasse 157, 
3003 Bern, Switzerland 
 
Claudia Schmutz and Philipp J. Bless contributed equally to 
this paper. 
 
 
 
 
 
 
 
This article has been published in 
Infection 2017, 45(6):811-824 
Acute gastroenteritis in primary care 
198 
8.1. Abstract 
Purpose: Acute gastroenteritis (AG) leads to considerable bur-
den of disease, health care costs and socio-economic impact 
worldwide. We assessed the frequency of medical consulta-
tions and work absenteeism due to AG at primary care level, 
and physicians’ case management using the Swiss Sentinel 
Surveillance Network “Sentinella”. 
Methods: During the one-year, longitudinal study in 2014, 172 
physicians participating in “Sentinella” reported consultations 
due to AG including information on clinical presentation, stool 
diagnostics, treatment, and work absenteeism. 
Results: An incidence of 2146 first consultations due to AG at 
primary care level per 100,000 inhabitants in Switzerland was 
calculated for 2014 based on reported 3.9 thousand cases. Phy-
sicians classified patients’ general condition at first 
consultation with a median score of 7 (1=poor, 10=good). The 
majority (92%) of patients received dietary recommendations 
and/or medical prescriptions; antibiotics were prescribed in 
8.5%. Stool testing was initiated in 12.3% of cases; more fre-
quently in patients reporting recent travel. Among employees 
(15-64 years), 86.3% were on sick leave. Median duration of 
sick leave was four days.  
Conclusions: The burden of AG in primary care is high and 
comparable with that of influenza-like illness (ILI) in Switzer-
land. Work absenteeism is substantial, leading to considerable 
socio-economic impact. Mandatory infectious disease surveil-
lance underestimates the burden of AG considering that stool 
testing is not conducted routinely. While a national strategy to 
reduce the burden of ILI exists, similar comprehensive preven-
tion efforts should be considered for AG. 
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8.2. Keywords 
Acute gastroenteritis; sentinel surveillance; primary health 
care; Switzerland; antibiotics; infectious intestinal diseases 
8.3. Background 
Acute gastroenteritis (AG) is a common disease in humans 
worldwide. Case definition varies between studies and 
countries but mostly includes signs and symptoms of diarrhoea, 
vomiting, nausea, abdominal cramps or pain, fever, and blood 
or mucus in the stool [1-5]. AG can be caused by a wide 
variety of pathogens ranging from viruses and bacteria to 
protozoa and other parasites [5]. A study in Austria identified 
norovirus, Clostridium difficile and rotavirus as the most 
frequent aetiological agents in patients consulting general 
practitioners (GPs) due to AG [4]. Norovirus, rotavirus, 
sapovirus and Campylobacter spp. were the most common 
organisms among cases of infectious intestinal disease (IID) 
presenting to the GP in the United Kingdom [6].  
Bacterial pathogens causing AG which have to be reported to 
the National Notification System for Infectious Diseases 
(NNSID) include positive laboratory tests for 
Campylobacter spp., Salmonella spp., and Shigella spp. as well 
as clinical and laboratory reports of positively tested patients 
with Listeria monocytogenes and enterohaemorrhagic E. coli 
(EHEC). None of the above mentioned viral causes of AG are 
notifiable in Switzerland [7]. As a result, the NNSID 
underestimates the true burden of AG because of non-notifiable 
pathogens causing AG. Additionally, not every patient 
suffering from AG presents to a physician (under-
ascertainment) and, the physician does not always initiate stool 
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diagnosis to investigate the aetiology of the illness 
(underreporting) [8, 9]. Hence, what is seen in the Swiss 
mandatory notification system represents only an incomplete 
picture of the burden of disease due to AG. The determinants 
of under-ascertainment or underreporting have been described 
for several countries but not for Switzerland: In the UK, it is 
estimated that every case of IID reported to national 
surveillance represents 9.5 cases presenting to a GP or 147 
cases in the community [6]. In the Netherlands, 8% of patients 
with an IID visited a physician [10]. Van Cauteren et al. [11] 
estimated that of 115 community cases of campylobacteriosis 
and 20 community cases of salmonellosis one case is reported 
to the surveillance system in France. However, it has to be 
noted that the French surveillance systems are voluntary for 
these two pathogens.  
Swiss routine surveillance data suggest an increasing frequency 
of campylobacteriosis and a decreasing frequency of salmonel-
losis [12]. More than half of campylobacteriosis patients in a 
case-control study approached a physician within three days 
after onset of symptoms and 14.5% were hospitalised [13]. A 
subsequent qualitative survey among primary care physicians 
described case management approaches including treatment 
strategies and stool diagnostic testing behaviours from the phy-
sicians’ perspective for patients with AG [8]. Four main 
approaches were identified of which only two – the “test & 
wait” and the “test & treat” approaches – include stool speci-
men testing and, hence, would result in case registration in the 
mandatory disease surveillance system in case of a positive test 
outcome. Healthcare costs for AG in Switzerland were estimat-
ed at €29-45 million annually [14].  
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In Switzerland, we lack data on under-ascertainment and un-
der-reporting. Under-ascertainment refers to people not seeking 
healthcare and, hence, not being captured by the surveillance 
system as defined by Gibbons et al. [9]. Under-reporting is 
defined as people seeking healthcare but not being reported 
because of under-diagnosis – not diagnosing or misdiagnosing 
the infection or pathogen – or under-notification – failure to 
report positive diagnoses [9]. 
This study within the Swiss Sentinel Surveillance Network, 
Sentinella, aimed at understanding the lower levels of the bur-
den of illness pyramid and addressing the incidence of AG in a 
broader context. Specifically, the study aimed at understanding 
determinants of under-diagnosis by (i) estimating the incidence 
and burden of AG seen at the primary care level, (ii) describing 
the physicians’ case management (diagnostics, treatment) of 
AG patients and (iii) estimating the work loss due to AG of 
cases presenting to a physician. 
8.4. Methods 
A one-year, longitudinal study in Sentinella, during the year 
2014, was conducted asking physicians to report cases of AG 
on a weekly basis (later referred to as data from the “weekly 
questionnaire”). A questionnaire about disease characteristics, 
stool testing, and treating strategies was completed for a subset 
of cases (later referred to as “supplementary questionnaire”). 
8.4.1. Study setting 
Sentinella is a voluntary surveillance system and research net-
work of primary care physicians existing since 1986 which is 
operated and funded by the Federal Office of Public Health 
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(FOPH). Physicians are organised in six geographical regions, 
each having its representative within the Sentinella steering 
committee. The steering committee, consisting of physicians 
and researchers of academic primary care institutes, meets reg-
ularly to set the research priorities and to decide on submitted 
projects. Our study was accepted to run in 2014.  
During the Sentinella-year 2014, 172 physicians (47% general 
practitioners, 37% internists and 16% paediatricians; thereafter 
referred to as “Sentinella-physicians”) covering entire Switzer-
land were active in the network. In Switzerland, 6930 
physicians were practicing in the ambulatory sector with the 
main specialty “general internal medicine” (summarising gen-
eral practitioners and internists) or “paediatrics” in 2014 
according to the Swiss medical association FMH [15]. Among 
these, 86% were practicing in general internal medicine and 
14% in paediatrics. 
8.4.2. Case definition 
A case of AG was defined as (a) a patient consulting a Senti-
nella-physician for the first time during the illness episode and 
suffering from diarrhoea (at least 3 watery or pasty stools daily; 
for at least 24 hours but 14 days the longest) likely due to an 
infectious cause or (b) a patient consulting a Sentinella-
physician for the first time during the illness episode with vom-
iting and abdominal cramps without significant diarrhoea, 
likely due to an infectious cause. Patients were excluded if di-
arrhoea was due to a known gastrointestinal disease (e.g. 
Crohn’s disease, ulcerative colitis, coeliac disease), medication 
intake (e.g. antibiotics) or food intolerance. Also patients with 
persistent diarrhoea (>14 days) or if vomiting was due to preg-
nancy were excluded.  
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8.4.3. Data collection 
Sentinella-physicians reported basic data on patients suffering 
from AG on a weekly questionnaire, and more detailed data for 
a subsample of patients through a supplementary questionnaire 
which were available in German and French. German versions 
of the weekly (part on AG only) and supplementary question-
naires are available online (see electronic supplementary 
material 1 of Schmutz et al. (2017a)). The questionnaires were 
piloted with 10 general practitioners.  
The weekly questionnaire included information on sex, date of 
birth, stool testing and hospitalisation of all AG patients (see 
case definition) seen in the corresponding week. The supple-
mentary questionnaire contained additional questions on 
employment status, date(s) of symptom onset and consulta-
tion(s), signs and symptoms until first consultation, general 
condition, antibiotic and symptomatic treatment, stool testing, 
sick leave, hospitalisation, sequelae, and selected risk expo-
sures in the seven days preceding symptom onset. 
Weekly questionnaires were available on paper and electroni-
cally according to the Sentinella standard procedure (method 
chosen by physician). More than half of the Sentinella-
physicians reported electronically, all others reported on paper. 
Supplementary questionnaires were available on paper only. 
While weekly paper questionnaires were sent to the FOPH 
once a week by postal mail according to routine procedures, 
Sentinella-physicians were asked to send the supplementary 
questionnaire as soon as they considered the corresponding 
case as “completed”. Weekly electronic questionnaires were 
entered directly into the Sentinella-database by the Sentinella-
physician. 
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Information available on Sentinella-physicians included the 
physicians’ specialty and location of practice. Sentinella-
physicians additionally reported the total number of daily phy-
sician-patient contacts (PPCs) on the weekly questionnaire. A 
PPC is defined as each consultation independent of place (in 
practice or as domiciliary visit) and time (during or off consul-
tation-hour or on emergency service) and serves as 
denominator for calculating disease incidence rates. 
8.4.4. Subsample for supplementary questionnaire 
We expected that each Sentinella-physician would report 
around two AG cases per week based on the pilot testing and 
discussions with physicians. Assuming that 150 physicians 
report during 48 weeks, 14,400 cases were expected during the 
1-year-study period. In order to reduce the anticipated work 
load for Sentinella-physicians but still reaching an appropriate 
sample size allowing for estimates with acceptable precision 
we decided to apply the supplementary questionnaire to a sub-
sample of cases. The targeted subsample size was set at 4800 
cases (one third of all cases). A sampling scheme was defined 
whereby every Sentinella-physician had to complete supple-
mentary questionnaires during four consecutive weeks four 
times a year (=16 weeks per physician per year). We randomly 
assigned each Sentinella-physician a sampling pattern with 
sampling periods distributed equally over the year, hence not 
allowing for two consecutive sampling periods. 
Case numbers in the first half of the study period were lower 
than expected necessitating the sampling scheme to change to 
full sampling. Starting from week 25 (starting on 14.06.2014) 
supplementary questionnaires had to be completed for every 
AG patient until the end of the study. 
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8.4.5. Data entry and analysis 
Weekly questionnaires on paper forms and all supplementary 
questionnaires were entered into the electronic Sentinella-
database at the FOPH. Ten percent of supplementary question-
naires were randomly selected for double entry to assess data 
quality. Double entries of questionnaires were compared and 
discrepancies were eliminated by re-checking against the origi-
nal paper forms. 
Cases of Sentinella-physicians who reported PPC for less than 
75% of the weeks during the study period, i.e. <39 of 52 weeks 
were excluded from data analysis. This rule and cut-off value 
for regularly reporting physicians is standard for analyses of 
Sentinella data. Additionally, cases not fulfilling the case defi-
nition or cases where the Sentinella-physician spontaneously 
indicated a final diagnosis not in agreement with infectious AG 
were excluded from the analysis of supplementary question-
naire data. 
Data of weekly questionnaires were analysed descriptively. We 
calculated the average number of cases per Sentinella-
physician and week and the number of initial consultations due 
to AG per 1000 PPCs per week. Additionally, we estimated the 
incidence and total number of first consultations due to AG at 
the primary care level for 2014 in Switzerland by the standard 
extrapolation of the Sentinella system which is described else-
where [16]. 
Due to the mid-study change in the sampling scheme of 
supplementary questionnaires, analyses of the supplementary 
questionnaire data were weighted according to the sampling 
probability: information from the supplementary questionnaire 
of cases reported during the first half of the study period was 
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analysed using a sampling weight of 3.25 (as each physician 
was required to submit a supplementary questionnaire for each 
case seen during 16 of 52 weeks; 1/(16/52)=3.25) while 
information reported during the second half had a sampling 
weight of 1 (supplementary questionnaire required for every 
case). Point-estimates including 95% confidence intervals (CI) 
and interquartile ranges (IQR) for medians are reported for 
weighted analyses. Data from supplementary questionnaires 
were analysed descriptively and differences were assessed for 
significance by weighted, univariable logistic regression. For 
all analyses involving employment status, only patients aged 
15-64 years were considered. Data was analysed and 
represented graphically using Stata 13.1 (StataCorp.). Maps 
were created using ArcGIS 10.2.1 for desktop (Environmental 
Systems Research Institute, Inc., Esri). 
8.5. Results 
8.5.1. Physician and patient characteristics 
In total, 3867 cases of AG were reported on weekly question-
naires by 172 participating Sentinella-physicians. After 
exclusion of cases reported by not regularly reporting Sentinel-
la-physicians (130 cases) and for other reasons (3 cases), 3734 
cases were used for analyses of weekly questionnaires. 2200 
cases were retained for the analyses of supplementary ques-
tionnaires. The detailed inclusion process is described in Figure 
8.1. 
Out of 172 physicians registered in the Sentinella system in 
2014, 154 of the regularly reporting physicians reported at least 
one case of AG on the weekly questionnaire. Over the whole 
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study period, individual physicians reported up to 400 cases 
(median: 17, IQR: 7-29).  
A total of 144 physicians submitted at least one supplementary 
questionnaire of a case fulfilling the case definition (Figure 
8.1). The subsample of cases with supplementary question-
naires was comparable to cases reported on weekly forms in 
terms of basic patient characteristics (Table 8.1). 
Median age of AG cases was 21 years (IQR: 5-41 years). Chil-
dren, adolescents and young adults (age groups <1, 1-4, 5-9, 
10-14, 15-19 and 20-29 years) were overrepresented among 
AG cases consulting a physician compared to the frequency of 
those age groups in the general Swiss population for both gen-
ders (Figure 8.2). In the age group of 10-14 year olds, males 
were more frequent than females. In adults, female cases aged 
20-29 years were most frequently reported while in males the 
30-44 year age group predominated. 
8.5.2. Burden of AG at primary care level 
Each week, 15-139 cases (median: 69, IQR: 54-80) were re-
ported (Figure 8.3). Case numbers were highest during the first 
weeks of the year (maximum in week 4) and decreased thereaf-
ter. A median rate of 5.4 first consultations due to AG per 1000 
PPCs per week (IQR: 4.6-6.7) was observed. The notifications 
correspond to 2146 first consultations due to AG at primary 
care level per 100,000 inhabitants or 174,610 first consultations 
due to AG in Switzerland in 2014 using the standard extrapola-
tion method of the FOPH for Sentinella data. Incidence (of first 
consultations) by Sentinella-region is displayed in Figure 8.4. 
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Figure 8.1: Study profile of notified cases and reporting physicians. 
Acute gastroenteritis study, Swiss Sentinel Surveillance 
Network, 2014. 
AG acute gastroenteritis 
PPC physician–patient contact 
PUBLISHED ARTICLE 
209 
  
T
ab
le
 8
.1
: 
B
as
ic
 c
h
ar
ac
te
ri
st
ic
s 
o
f 
ac
u
te
 g
as
tr
o
en
te
ri
ti
s 
ca
se
s 
re
p
o
rt
ed
 o
n
 t
h
e 
w
ee
k
ly
 a
n
d
 s
u
p
p
le
m
e
n
-
ta
ry
 q
u
es
ti
o
n
n
ai
re
s 
b
y
 p
h
y
si
ci
an
s 
fr
o
m
 t
h
e 
S
w
is
s 
S
en
ti
n
el
 S
u
rv
ei
ll
an
ce
 N
et
w
o
rk
 i
n
 2
0
1
4
 
 
W
ee
k
ly
 f
o
r
m
 
S
u
p
p
le
m
en
ta
ry
 q
u
es
ti
o
n
n
a
ir
e
 
C
as
es
 i
n
cl
u
d
ed
 i
n
 a
n
a
ly
si
s 
(N
) 
3
7
3
4
 
2
2
0
0
 
 
P
ro
p
o
rt
io
n
 o
f 
m
a
le
 c
as
es
, 
%
 (
9
5
%
-C
I)
 
5
0
.2
 
5
0
.6
 (
4
8
.0
-5
3
.3
) 
M
ed
ia
n
 a
g
e,
 y
ea
rs
 (
IQ
R
) 
2
1
 (
5
-4
1
) 
2
2
 (
6
.0
 [
9
5
%
-C
I:
 2
.6
-9
.4
] 
–
 
4
3
.0
 [
9
5
%
-C
I:
 3
8
.1
-4
7
.9
])
 
P
h
y
si
ci
an
s’
 a
re
a 
o
f 
sp
ec
ia
li
sa
ti
o
n
 
 
  
G
en
er
al
 m
ed
ic
in
e,
 %
 (
9
5
%
-C
I)
 
3
5
.3
 
3
7
.5
 (
2
9
.9
-4
5
.8
) 
In
te
rn
al
 m
ed
ic
in
e,
 %
 (
9
5
%
-C
I)
 
2
6
.7
 
2
7
.6
 (
2
1
.1
-3
5
.4
) 
P
ae
d
ia
tr
ic
s,
 %
 (
9
5
%
-C
I)
 
3
8
.0
 
3
4
.9
 (
2
5
.7
-4
5
.3
) 
S
to
o
l 
te
st
in
g
 i
n
it
ia
te
d
, 
%
 (
9
5
%
-C
I)
 
1
0
.9
 
1
2
.3
 (
1
0
.1
-1
4
.8
) 
H
o
sp
it
al
is
ed
, 
%
 (
9
5
%
-C
I)
 
2
.0
 
2
.7
 (
1
.9
-3
.7
) 
 
Acute gastroenteritis in primary care 
210 
 
Figure 8.2: Age distribution by sex among acute gastroenteritis cases 
reported by Sentinella-physicians on weekly and/or sup-
plementary questionnaires, Swiss Sentinel Surveillance 
Network, 2014.  
Age distribution of Swiss population (official numbers, [17]) added for 
comparison 
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8.5.3. Health care seeking and clinical presentation 
The median time from symptom onset to first consultation was 
2 days (95%-CI: 2.0-2.0, IQR: 1.0 [95%-CI: 1.0-1.0] – 3.0 
[95%-CI: 2.4-3.6]). The majority of patients (87.9% [95%-CI: 
85.6-89.9]) suffered from diarrhoea (Table 8.2). Loss of appe-
tite was reported for 63.5% (95%-CI: 58.4-68.4), abdominal 
pain or cramps for 61.1% (95%-CI: 57.0-65.1), nausea for 
60.4% (95%-CI: 56.6-64.1) and vomiting for 57.5% (95%-CI: 
54.3-60.7) of patients. Less frequently reported signs and 
symptoms included flatulence, fever, dehydration and head-
ache. 
The majority of patients consulted the Sentinella-physician 
only once (79.6%, 95%-CI: 76.5-82.4) (Table 8.2). The median 
general condition of cases as reported by Sentinella-physicians 
at the time of first consultation was 7 (95%-CI: 6.5-7.5, IQR: 
5.0 [95%-CI: 4.5-5.5] – 9.0 [95%-CI: 8.5-9.5]) on a rating scale 
from 1 (poor) to 10 (good). Overall, 86.3% (95%-CI: 83.1-
89.0) of employed patients were unable to work. The odds for a 
good general condition (7 or above) was lower for employed 
patients compared to unemployed patients although not signifi-
cantly (Odds ratio [OR] 0.76, 95%-CI: 0.52-1.11, p=0.159).The 
median duration of sick leave was 4 days (95%-CI: 3.8-4.2, 
IQR: 3.0 [95%-CI: 3.0-3.0] – 5.0 [95%-CI: 4.5-5.5]). For all 
except 7 cases the duration of sick leave was below 15 days. 
The hospitalisation rate was 2.7% (95%-CI: 1.9-3.7). The high-
est hospitalisation rate was observed for the >74 year age group 
(11.5%, 95%-CI: 6.4-19.9) whereas for the remaining age 
groups the rates were below 4%. For 2.0% (95%-CI: 1.4-2.9) 
of patients Sentinella-physicians reported sequelae, like dehy-
dration, diverticulitis, or colitis. No deaths due to AG were 
reported.  
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8.5.4. Stool diagnostics and results 
Sentinella-physicians reported the initiation of stool specimen 
testing in 12.3% (95%-CI: 10.1-14.8); in 11.6% (95%-CI: 9.5-
14.1) of cases they indicated that the sample was actually sent 
off (Table 8.3). The odds for stool testing did not differ be-
tween sexes ([female vs. male]: OR=1.13, 95%-CI: 0.84-1.50, 
p=0.423) but differed by age group (p<0.001): The proportion 
of stool testing was generally higher among older age groups. 
Paediatricians initiated stool testing less frequently (OR=0.32, 
95%-CI: 0.18-0.55, p<0.001) than general practitioners. The 
odds of initiating stool testing did not differ significantly for 
internists compared to general practitioners (OR=1.13, 95%-
CI: 0.71-1.78, p=0.610). 
Even though the questionnaire explicitly asked for the main 
reason for initiating stool testing, multiple answers were given 
for 31.0% (95%-CI: 24.9-37.8) of cases. The three most fre-
quent reasons mentioned were protracted course of disease 
(29.4%, 95%-CI: 21.9-38.2), poor general condition (11.5%, 
95%-CI: 6.9-18.4) and due to a specific symptom (9.5%, 95%-
CI: 4.6-18.6) when excluding those with multiple answers. 
When considering also multiple answers, staying abroad before 
Figure 8.3: Acute gastroenteritis cases reported by physicians from 
the Swiss Sentinel Surveillance Network in 2014 
(28.12.2013 – 26.12.2014): weekly case numbers (bars) 
and number of initial AG consultations per 1000 physi-
cian–patient contacts (PPCs, “consultations”) per week 
(line) 
Vertical, dashed line: date of change of sampling scheme (from subsample 
of cases with supplementary questionnaires to supplementary questionnaire 
for every reported case) 
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symptom onset was the third most frequent reason (data not 
shown). 
Travelling within the seven days preceding symptom onset was 
reported for 9.0% (95%-CI: 7.4-10.8) of cases. Patients with 
recent travel history were significantly more likely to undergo 
stool testing than patients not reporting any recent travels 
(OR=3.60, 95%-CI: 2.47-5.33, p<0.001). Among patients with 
recent travel history, 30.0% (95%-CI: 22.7-38.6) were tested 
while for patients without travel to a foreign country in the 
seven days preceding the symptom onset this proportion was 
10.6% (95%-CI: 8.6-13.0). “Staying abroad” was indicated as 
the main reason for testing for 40.8% (95%-CI: 24.4-59.6) of 
patients with a travel history. Protracted course of disease was 
the second most often mentioned reason for stool testing 
among patients with travel history abroad (17.4%, 95%-CI: 
7.2-36.2). 
A positive test result was reported for more than one third 
(35.9%, 95%-CI: 29.2-43.2) of tested patients while for the 
remaining 64.1% (95%-CI: 56.8-70.8) of patients test results 
were negative or not specified. The most frequently identified 
pathogen was Campylobacter spp. (50.8%, 95%-CI: 39.2-62.3) 
followed by norovirus (10.9%, 95%-CI: 5.0-21.9), and 
Blastocystis spp. (9.6%, 95%-CI: 4.0-21.1) (Table 8.3). Other 
pathogens identified included rotavirus, Clostridium spp., 
Entamoeba spp., pathogenic E. coli, Candida spp., 
Salmonella spp., Giardia spp., microsporidia, adenovirus, 
Aeromonas spp. and hepatitis E virus. Two pathogens were 
identified in 11.5% (95%-CI: 5.4-22.9) of the 98 cases with a 
positive stool test result.  
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Figure 8.4: Calculated incidence of first consultations due to acute 
gastroenteritis at primary care level in Switzerland by 
Sentinella-region, based on standard extrapolation. 
Swiss Sentinel Surveillance Network, 2014 
Note: an outlier (one physician reporting 400 cases) was excluded from this 
extrapolation by region 
Source of map shapefile: Swiss Federal Office of Topography 
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Table 8.2: Characteristics of cases with acute gastroenteritis at first 
consultation and number of consultations as reported by 
primary care physicians from the Swiss Sentinel Surveil-
lance Network, 2014. 
 
  
 
Number of 
cases [n] 
Percent [%] 
(95% 
confidence 
interval) 
Signs and symptoms until 
first consultation
a
 
(N=2200) 
 
 
 Diarrhoea 1940 87.9 (85.6-89.9) 
Diarrhoea with blood and/or 
mucus 
249 10.8 (8.5-13.7) 
Loss of appetite 1345 63.5 (58.4-68.4) 
Abdominal pain/cramps 1329 61.1 (57.0-65.1) 
Nausea 1296 60.4 (56.6-64.1) 
Vomiting 1227 57.5 (54.3-60.7) 
Flatulence 896 40.6 (35.6-45.7) 
Fever 530 25.0 (22.3-27.9) 
Dehydration 183 8.5 (6.6-11.0) 
Headache 68 3.2 (2.1-4.8) 
General condition at first 
consultation (according to 
physicians’ impression) 
(N=2115) 
   
Poor – 1 1 0.09 (0.01-0.6) 
2 28 1.1 (0.7-1.9) 
3 95 4.6 (3.3-6.4) 
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Table 8.2 continued 
a
 multiple answers possible 
  
 
Number of 
cases [n] 
Percent [%] 
(95% 
confidence 
interval) 
General condition at first 
consultation (according to 
physicians’ impression) 
(N=2115) 
   
4 177 8.4 (6.2-11.4) 
5 237 10.7 (7.9-14.4) 
6 228 10.1 (8.3-12.3) 
7 318 15.8 (13.6-18.2) 
8 476 23.9 (20.6-27.5) 
9 356 16.5 (13.5-20.1) 
Good – 10 199 8.7 (6.3-12.0) 
Number of consultations 
(N=2200) 
   
1 1742 79.6 (76.5-82.4) 
2 365 16.4 (14.0-19.2) 
3 75 3.2 (2.4-4.2) 
4 18 0.8 (0.4-1.5) 
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Table 8.3: Frequency of and reasons for prescription of stool diag-
nostics among acute gastroenteritis patients consulting 
primary care physicians from the Swiss Sentinel Surveil-
lance Network, 2014. 
  
 
Number of 
cases [n] 
Percent 
[%] 
(95% 
confidence 
interval) 
Stool test initiated (N=2176) 286 12.3 (10.1-14.8) 
Stool test performed (N=2176) 272 11.6 (9.5-14.1) 
Main reason for stool testing 
(N=197) 
   
Protracted course of disease 62 29.4 21.9-38.2 
Poor general condition 23 11.5 6.9-18.4 
Specific symptom 19 9.5 4.6-18.6 
Stay abroad before symptom onset 18 7.8 4.5-13.1 
Comorbidity 10 5.3 2.5-10.7 
Outbreak investigation 8 5.3 1.6-16.4 
Occupation 10 3.8 1.8-8.1 
Resident/patient institution 2 2.0 0.5-8.0 
Age 2 1.3 0.3-6.2 
Contact to animals 1 1.0 0.1-6.8 
Contact to ill persons 1 0.3 0.04-2.3 
Other reasons (e.g. elevated CRP 
level, leucocytosis, recent antibiotic 
therapy) 
20 10.5 6.5-16.6 
Reason not specified 21 12.2 6.4-22.2 
Pathogens identified
a
 (N=98)    
Campylobacter spp. 57 50.8 (39.2-62.3) 
Norovirus 8 10.9 (5.0-21.9) 
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Table 8.3 continued 
a
Two pathogens were identified in 11.5% (95%-CI: 5.4-22.9) of the 98 
cases with a positive stool test result 
8.5.5. Approaches for symptomatic and antibiotic therapy 
In 92.0% (95%-CI: 89.8-93.8) of cases, Sentinella-physicians 
gave dietary recommendations, or prescribed symptomatic 
and/or antibiotic treatment. Most commonly, patients were 
advised to care for fluid replacement by the intake of sufficient 
tea, broth etc. (58.3%, 95%-CI: 53.0-63.3) (Table 8.4). Distinct 
rehydration therapies such as electrolyte solution (11.4%, 95%-
CI: 7.8-16.4) and infusion therapies (1.7%, 95%-CI: 1.1-2.6) 
were less frequently prescribed. Symptomatic treatment in-
cluded probiotics (45.9%, 95%-CI: 39.1-52.8), antiemetics 
(45.4%, 95%-CI: 40.5-50.4), antidiarrhoeals (28.8%, 95%-CI: 
23.6-34.6), analgesics (16.3%, 95%-CI: 12.8-20.5), and spas-
 
Number of 
cases [n] 
Percent [%] 
(95% 
confidence 
interval) 
Pathogens identified
a
 (N=98)    
Blastocystis spp. 6 9.6 (4.0-21.1) 
Rotavirus 5 8.9 (2.9-24.2) 
Clostridium spp. 7 7.3 (2.9-17.2) 
Entamoeba spp. 4 5.4 (1.7-15.8) 
Pathogenic E. coli 6 5.3 (2.0-13.1) 
Candida spp. 3 4.8 (1.4-15.6) 
Salmonella spp. 6 3.8 (1.7-8.2) 
Other (Giardia spp., 
adenovirus, Aeromonas spp., 
hepatitis E) 
4 4.0 (1.2-12.5) 
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molytics (15.0%, 95%-CI: 11.5-19.2). Antibiotics were pre-
scribed in 8.5% (95%-CI: 6.5-11.0) of cases (Table 8.4).  
The Sentinella-physicians initiated stool testing and prescribed 
antibiotics at the first consultation in 33 cases (unweighted 
results, Table 8.5). Stool diagnostics revealed presence of a 
pathogen susceptible to antibiotics in 20 of these cases. No 
antibiotics were prescribed in 22 cases even though a pathogen 
which is theoretically susceptible to antibiotics was identified. 
The majority of patients receiving antibiotics was treated with 
quinolones (60.2%, 95%-CI: 48.5-70.9), followed by macro-
lides, metronidazole, aminopenicillin, trimethoprim/ 
sulfamethoxazole, cephalosporin and tetracycline (Table 8.4). 
Two or more antibiotic classes were reported to be used for 
8.5% (95%-CI: 4.6-15.2) of cases. No antibiotic class was re-
ported for 1.6% (95%-CI: 0.6-4.4) of cases treated with 
antibiotics. 
Main reasons for the prescription of antibiotic therapy included 
(suspicion of) bacterial gastroenteritis (41.1%, 95%-CI: 25.0-
59.5), duration of illness (9.0%, 95%-CI: 3.4-19.6), a specific 
symptom (7.2%, 95%-CI: 3.4-14.8) and others (Table 8.4). 
Sentinella-physicians mentioned several reasons for 23.9% 
(95%-CI: 16.6-32.2) of the patients despite being asked to indi-
cate only the main reason. When considering also multiple 
answers, “poor general condition” was the third most frequent-
ly mentioned reason for antibiotic therapy (data not shown). 
Similar to stool testing, antibiotic prescription was associated 
with age (p<0.001) and with the physicians’ specialty 
(p<0.001) but not with sex (p=0.511) (data not shown). Again, 
children and adolescents were less frequently treated with anti-
biotics compared to adults. Among the >74-year-old age group, 
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one fifth of cases received antibiotics (20.0%, 95%-CI: 12.8-
29.7). Nearly three-quarter of the antibiotic therapies were pre-
scribed at the first consultation (71.3%, 95%-CI: 60.5-80.1). 
These patients had a lower general condition according to phy-
sicians’ impression (median: 5.0, 95%-CI: 4.0-6.0, IQR: 4.0 
[95%-CI: 3.0-5.0] – 7.0 [95%-CI: 6.0-8.0]) than patients re-
ceiving antibiotics later on (median 7.0, 95%-CI: 6.0-8.0, IQR: 
5.0 [95%-CI: 4.0-6.0] – 8.0 [95%-CI: 7.0-9.0]) and also suf-
fered slightly more frequently from fever (44.7%, 95%-CI: 
34.5%-55.4 vs. 38.9%, 95%-CI: 24.0-56.2). However, both 
differences were not statistically significant. Patients with a 
recent history of travel had significant higher odds to undergo 
antibiotic therapy (OR=1.75, 95%-CI: 1.06-2.88, p=0.029). 
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Table 8.4: Frequency of prescription of antibiotic and symptomatic 
treatment, and reasons for prescription of antibiotic ther-
apy among acute gastroenteritis patients consulting 
primary care physicians from the Swiss Sentinel Surveil-
lance Network, 2014. 
  
 
Number of 
cases [n] 
Percent [%] 
(95% 
confidence 
interval) 
Antibiotic therapy prescribed 
(N=2089) 
195 8.5 (6.5-11.0) 
Antibiotic class prescribed
a
 
(N=195)    
Quinolone 123 60.2 (48.5-70.9) 
Macrolide 30 15.0 (9.3-23.3) 
Metronidazole 21 12.8 (7.7-20.5) 
Aminopenicillin 22 11.6 (6.3-20.5) 
Trimethoprim/sulfamethoxazole 7 4.5 (1.5-12.7) 
Cephalosporin 5 3.1 (1.1-8.6) 
Tetracycline 1 0.3 (0.0-2.4) 
Not specified 5 1.6 (0.6-4.4) 
Main reason for prescription 
of antibiotics (N=195)    
Bacterial gastroenteritis 64 41.1 25.0-59.5 
Duration of illness 12 9.0 3.4-19.6 
Specific symptom 10 7.2 3.4-14.8 
Expecting attitude of patient 6 4.5 1.7-11.6 
Poor general condition 6 3.6 1.3-9.2 
Immunosuppression 3 3.2 0.9-11.0 
High, prolonged fever 5 3.1 1.0-9.3 
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Table 8.4 continued 
a 
multiple answers possible 
  
 
Number of 
cases [n] 
Percent [%] 
(95% 
confidence 
interval) 
Main reason for prescription 
of antibiotics (N=195) 
   
Polymorbidity 4 2.7 0.8-8.5 
Preventively 3 2.3 0.6-8.5 
Other reasons (e.g. elevated 
CRP level, leucocytosis, co-
infection) 
22 13.3 7.9-21.6 
Reason not specified 14 9.9 5.2-18.2 
Recommended symptomatic 
treatment
a
 (N=1909)    
Fluid replacement with tea, 
broth 
1089 58.3 (53.0-63.3) 
Probiotics 875 45.9 (39.1-52.8) 
Antiemetics 851 45.4 (40.5-50.4) 
Antidiarrhoeals 584 28.8 (23.6-34.6) 
Analgesics 330 16.3 (12.8-20.5) 
Spasmolytics 287 15.0 (11.5-19.2) 
Rehydration solution 201 11.4 (7.8-16.4) 
Intravenous rehydration 36 1.7 (1.1-2.6) 
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Table 8.5: Time point of prescription of stool testing and antibiotic 
treatment among acute gastroenteritis patients consulting 
primary care physicians, Swiss Sentinel Surveillance 
Network, 2014. 
Note: unweighted results. Cases with missing information on (date of) anti-
biotic prescription and/or (date of) stool test were excluded. 
 
No 
antibiotics 
prescribed 
Antibiotic 
prescribed 
at first 
consultation 
Antibiotic 
prescribed 
at follow-up 
consultation 
No stool test initiated 1713 70 11 
Stool test initiated at first 
consultation 
68 33 7 
thereof with positive re-
sult for a pathogen 
susceptible to antibiotic 
therapy
1
 
12 20 5 
thereof with positive re-
sult for a pathogen not 
susceptible to antibiotic 
therapy
1
 
4 1  
Stool test initiated at fol-
low-up consultation 
56 3 22 
thereof with positive re-
sult for a pathogen 
susceptible to antibiotic 
therapy
1
 
10 2 11 
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Table 8.5 continued 
 
No 
antibiotics 
prescribed 
Antibiotic 
prescribed 
at first 
consultation 
Antibiotic 
prescribed 
at follow-up 
consultation 
Stool test initiated at fol-
low-up consultation 
56 3 22 
thereof with positive re-
sult for a pathogen not 
susceptible to antibiotic 
therapy
a
 
4  1 
a
 Not considering possible antibiotic resistances and treatment recommenda-
tions 
8.6. Discussion 
This study underscored that acute gastroenteritis is common in 
Swiss primary care: extrapolated annual consultation numbers 
(175,000 first consultations) are comparable to those of influ-
enza-like illness (ILI) during an influenza season (varying 
between 107,000 and 276,000 ILI cases in the last three sea-
sons [18-20]). The majority of patients is symptomatically 
treated and does not require multiple consultations. However, 
most episodes of AG lead to a sick leave of several days, 
though the physician-assessed general state of the patients is 
considered as “fairly good”. Stool specimen testing is not sys-
tematically conducted and antibiotic therapy is applied to less 
than 10% of patients. 
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8.6.1. Multiple factors influence physicians’ decision making 
Sentinella-physicians reported more than one reason for stool 
testing in a third of cases despite being explicitly asked for the 
main reason in the questionnaire. This suggests that a combina-
tion of factors plays a role in decision-making. The same holds 
true for the prescription of antibiotic treatment where in around 
a quarter of cases several reasons were mentioned albeit physi-
cians were asked to indicate the main reason. The reasons 
mentioned most frequently for stool testing – namely protract-
ed course of disease, poor general condition, due to a specific 
symptom and a history of recent travel – are in line with find-
ings from other studies: three of the aforementioned four 
factors (all except “specific symptom”) were also mentioned by 
GPs participating in a qualitative study in Switzerland [8] and 
in a study from Northern Ireland and the Republic of Ireland 
[21]. The Irish study further reported that stool testing is fre-
quently prescribed if the illness is associated with an outbreak 
or if the physicians suspect a link with a particular consumed 
food item or food premises (pub, restaurant, take away). Simi-
larly, a qualitative study among GPs in the UK found that long 
duration of illness, recent travel, blood in the stool, patient be-
ing unwell and exclusion of an infectious cause were the 
reasons mentioned most frequently for stool testing [22]. Fac-
tors most strongly associated with requesting a stool culture 
were bloody diarrhoea, diarrhoea lasting more than 3 days, and 
a diagnosis of AIDS in a postal survey among physicians in the 
United States [23]. 
Considering that protracted course of disease and poor general 
condition were mentioned most frequently as main reasons for 
stool testing in our study, the difference in reported general 
condition at the time of first consultation among tested and 
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untested patients seems rather small (median 7.0, 95%-CI: 6.5-
7.5, IQR: 5.0 [95%-CI: 4.5-5.5] – 8.0 [95%-CI: 7.5-8.5] vs. 
median 8.0, 95%-CI: 7.5-8.5, IQR: 6.0 [95%-CI: 5.5-6.5] – 9.0 
[95%-CI: 8.5-9.5]). One explanation for this is that a “protract-
ed course of disease” does not necessarily equate with a poor 
general condition but simply reflects the lack of improvement 
of symptoms with an average or fairly good general condition. 
Most of the aforementioned studies [8, 21, 22] acknowledge 
that decisions for testing are subjective and depend on the phy-
sicians’ experiences and attitudes. 
AG, whether of viral or bacterial origin, is usually self-limiting 
[5]. Antibiotics are mainly recommended for severely affected 
patients and are most effective if given early [5, 24, 25]. “Bac-
terial gastroenteritis” was most frequently mentioned as main 
reason for antibiotic therapy in our study. We cannot judge 
whether this reasoning was based on laboratory results or on 
physicians’ experience. However, only two cases with positive 
stool test results for pathogens not susceptible to antibiotics 
were prescribed antibiotics in our study. The second most 
common reasoning for antibiotic treatment, namely duration of 
illness, was also reported by Swiss GPs in an extensive qualita-
tive assessment [8]. A study from Poland concluded that 
factors associated with antibacterial drug administration in-
cluded the work environment of the physician (working in 
large practices and hospital wards favoured antibiotic prescrip-
tion compared to small practices), presence of fever, or mucus 
or blood in stool, age of the patient and (rural/urban) residence 
[26]. Presence of fever, or mucus or blood in stool could also 
be a factor leading to antibiotic therapy in our study as the third 
most frequent mentioned main reason for antibiotic prescrip-
tion was suffering from a specific symptom. 
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Some 62% of all cases with a laboratory-confirmed 
Campylobacter infection received antibiotic treatment in our 
study. This finding is important in the context of antibiotic 
resistance development. More than half of those patients 
received quinolones and one third was treated with macrolides 
– a finding confirming results from an earlier qualitative study 
among Swiss GPs [8]. Given antibiotic resistance levels for 
fluoroquinolones as high as 55.3% for human Campylobacter 
isolates in Switzerland in 2014 [27], these studies’ findings 
underscore the need for changes in prescription practise in 
Switzerland. A similar level of resistance (60.2%) was 
observed in Europe in 2014 [28]. Consequently, the European 
Food Safety Authority and the European Centre for Disease 
Prevention and Control do no longer recommend 
fluoroquinolones for the empirical treatment of human 
campylobacteriosis.  
8.6.2. Physicians’ case management impacts on the mandato-
ry surveillance system 
A stool test was performed only for 11.6% of patients consult-
ing a Sentinella-physician due to AG. Of these, 19.8% (95%-
CI: 15.1-25.6) had a positive result for a notifiable pathogen. 
Hence, a very small proportion of 2.3% (=11.6%*19.8%) of 
AG patients consulting a Sentinella-physician were actually 
reportable to the mandatory reporting system. This is in line 
with Swiss physicians’ typical treatment pattern for AG of 
“wait & see”, which can be followed by a “treat & see” ap-
proach or a desirable (from the perspective of the NNSID) “test 
& see” or “test & treat” approach based on illness progression 
[8]. Considering the (main) reasons mentioned for stool testing, 
patients with a prolonged duration of illness and patients re-
porting recent travel abroad are likely overrepresented among 
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notified cases. The proportion of patients with stool testing 
varies substantially between countries: it was found to be 4.3% 
or 9.1% in France [29], 6% in Italy [30], 7% in Ireland [31], 
12% in the Netherlands [32], 19% in the US [33] and 25% in 
Denmark [34]. 
The pathogen most often identified through stool testing in this 
study (Campylobacter spp.) is also the pathogen most frequent-
ly reported to Swiss national surveillance. Norovirus, which is 
not notifiable in Switzerland but in several countries of the 
European Union, was the second most common identified 
pathogen. 
8.6.3. Mild disease with high socio-economic burden 
Physicians rated the general condition of AG patients as rela-
tively good. Nevertheless, a high proportion of 86.3% of 
employed patients was not able to work due to the illness. Sick 
leave is considerable with a median of 4 days. The risk of 
transmission seems to play a subordinate role as a reason for 
inability to work. Similar findings were reported in a French 
study where 79% of working patients were on sick leave for a 
median duration of 3 days [35]. In a Danish study, only 35% of 
patients with AG reported having missed work or school as a 
result of illness [34]. However, this Danish study was a popula-
tion-based study in which only 13% of patients were seen by a 
physician and/or hospitalised. In our study, we did not observe 
a difference in time from symptom onset to consultation be-
tween employed and unemployed patients (data not shown). 
This indicates that the need of a medical certificate is unlikely 
to be a main reason for consultation.  
It is well known that some pathogens causing AG are easily 
transmitted from human-to-human, especially viruses, and con-
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tact with diarrhoea patients has been described as a risk factor 
for AG previously [35, 36]. In our study, 28.6% (95%-CI: 
24.9-32.6) of the patients had contact to other people suffering 
from similar signs and symptoms in the seven days preceding 
symptom onset. Thus, it is possible that these patients had a 
common source of infection or transmitted the disease among 
each other. 
In summary, our findings suggest that AG is a common, but 
generally mild disease which results, however, in a high social 
and economic burden. The overall financial burden due to AG 
(including losses in productivity) is likely a multiple of the 
healthcare costs estimated for Switzerland in the range of 
€29-45 million annually [14]. 
8.6.4. Sentinella is invaluable to investigate current public 
health issues 
All information for this study was derived from physicians in 
the Swiss Sentinel Surveillance Network. This study was spe-
cifically set up by the FOPH to clarify current epidemiological 
questions about gastroenteritis in Switzerland, using a national 
primary care sentinel surveillance platform. 
We consider it a strength of the study to have obtained infor-
mation on diagnosis and treatment directly from treating 
primary care physicians. However, the actual duration of sick 
leave might have been longer or shorter than reported or certi-
fied by the physician. Similarly, we could not record the 
overall duration of the illness as in this study we could not send 
out follow-up questionnaires at the end of an AG episode.  
A limitation of our study is the change in sampling scheme for 
supplementary questionnaires for the second half of the study 
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period, especially considering that AG is subject to seasonal 
variation. However, we believe that changing to full sampling 
and using weighted analyses to adjust for the change in sam-
pling scheme resulted in more reliable data than continuing 
without changing the sampling scheme and obtaining far less 
supplementary questionnaires. 
We expected to observe a seasonality of case reports consider-
ing the literature [4, 36], results of a previous study [8] and 
surveillance data [12], with a peak of AG in winter (December-
March) and during summer (June-September). Instead we 
found a decreasing number of initial consultations per 1000 
PPCs over the year which we assume is partially due to report-
ing fatigue of the Sentinella-physicians partaking in the study. 
This is supported by a survey conducted among Sentinella-
physicians in which they were asked about the time required 
for participating in the sentinel network – in total and for the 
different research topics. Physicians indicated that the study on 
AG was comparatively time-consuming although the majority 
indicated that the total amount of time required for notifying 
was acceptable [37].  
8.7. Conclusion 
Not to our complete surprise, this study has shown that acute 
gastroenteritis is a common disease in Switzerland with consul-
tation frequencies comparable to influenza-like illnesses. AG 
presented to physicians lead to substantial sick leave in the 
employed, resulting in considerable socio-economic costs due 
to productivity loss.  
Furthermore, as suspected, the study confirms that the National 
Notification System for Infectious Diseases captures – if at all 
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– only a fraction of the scope of the problem (see introduction 
for currently notifiable diarrhoea-causing pathogens). Hence, 
the Swiss Sentinel Surveillance Network, Sentinella, represents 
a very important complementary surveillance instrument to 
grasp principal dynamics of infectious disease epidemiology at 
the primary care level.  
The FOPH and the Federal Food Safety and Veterinary Office, 
being responsible to maintain population health and food safety 
in Switzerland, are currently lacking effective tools for pin-
pointing and a comprehensive national programme addressing 
the control of foodborne diseases and AG. While there are ef-
forts to increase food safety and consumer hygiene including 
campaigns to increase awareness for food and kitchen hygiene 
among consumers in Switzerland, prevention measures to re-
duce contamination at food production or retail level are 
incomplete. Overall, there is an imbalance in national disease 
prevention and control efforts for AG considering that national 
strategies to reduce the burden of seasonal influenza – an infec-
tion with a disease burden comparable to AG – exist since 
many years. 
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9.1. Abstract 
Rising numbers of campylobacteriosis case notifications in 
Switzerland resulted in an increased attention to acute 
gastroenteritis (AG) in general. Patients with a laboratory-
confirmed Campylobacter infection perceive their disease as 
severe and around 15% of these patients are hospitalized. This 
study aimed at estimating healthcare costs due to AG and 
campylobacteriosis in Switzerland. We used official health 
statistics, data from different studies and expert opinion for 
estimating individual treatment costs for patients with different 
illness severity and for extrapolating overall costs due to AG 
and campylobacteriosis. We estimated that total Swiss 
healthcare costs resulting from these diseases amount to €29–
45 million annually. Data suggest that patients with AG 
consulting a physician without a stool diagnostic test account 
for €9.0–24.2 million, patients with a negative stool test result 
for Campylobacter spp. for €12.3 million, patients testing 
positive for Campylobacter spp. for €1.8 million and 
hospitalized campylobacteriosis patients for €6.5 million/year. 
Healthcare costs of campylobacteriosis are high and most 
likely increasing in Switzerland considering that 
campylobacteriosis case notifications steadily increased in the 
past decade. Costs and potential cost savings for the healthcare 
system should be considered when designing sectorial and 
cross-sectorial interventions to reduce the burden of human 
campylobacteriosis in Switzerland. 
9.2. Keywords 
Acute gastroenteritis, campylobacteriosis, healthcare costs, 
Switzerland. 
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9.3. Introduction 
Since 1995 Campylobacter spp. has been the most frequently 
reported gastrointestinal bacterial pathogen in humans in Swit-
zerland [1] and since 2005 in the European Union (EU) [2]. An 
estimated 9.25 million cases of campylobacteriosis occurred in 
2009 in the 27 EU member states, of which around 2% were 
reported [3]. Havelaar et al. estimated the ‘true’ incidence rate 
of campylobacteriosis in these countries at 30–13,500/100,000 
population (350/100,000 in Switzerland). 
In Switzerland, positive test results for Campylobacter spp. 
have to be notified by diagnostic laboratories to the Federal 
Office of Public Health (FOPH) since 1988 [4]. In 2012, 8480 
campylobacteriosis cases were registered within the National 
Notification System for Infectious Diseases (NNSID), which is 
the highest number reported so far [1]. This corresponds to a 
notification rate of 105 cases/100,000 resident population in 
Switzerland. The extent to which campylobacteriosis contrib-
utes to the public health burden of acute gastrointestinal illness 
is unknown. In The Netherlands, about twice the population 
size of Switzerland, approximately 4.8 million cases of gastro-
enteritis occur annually, whereby 220,000 patients need 
medical consultation [5]. 
A study among 69 general practitioners (GPs) concluded a ris-
ing awareness of campylobacteriosis as a public health problem 
in Switzerland (Supplementary material of Schmutz et al. 
(2017b)). Despite its mostly self-limiting nature, the health 
burden of campylobacteriosis in the Swiss population may be 
significantly higher than figures from the NNSID indicate. Se-
vere cases and complications such as Guillain–Barré syndrome, 
reactive arthritis and post-infectious irritable bowel syndrome 
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amplify the burden of disease and in particular the economic 
burden [6–8]. 
The estimated economic burden (equating healthcare costs at 
large, including, e.g. loss of productivity and/or transportation 
and other direct and indirect non-healthcare costs) of gastroin-
testinal infections or foodborne illnesses in high-income 
countries varies between €14 (Australia [9]) and €1305 (United 
States [10]) per case in the community ([9–20] in Table 9.1). 
Thereby, healthcare costs account for €3–155/case in the com-
munity [9–20]. This wide range is partially due to 
heterogeneity in case definitions and definitions of economic 
burden. The yearly costs for gastroenteritis due to 14 food-
related pathogens and associated sequelae in The Netherlands 
were estimated at around €468 million [11]. 
For campylobacteriosis, the estimated economic burden per 
case varies, ranging from €117 (The Netherlands [17]) to 
€6141 (United States [12]) ([8, 10–12, 17, 20, 26] in Table 
9.2). Healthcare costs of campylobacteriosis cases were esti-
mated at €8/case in New Zealand, €82–280 in The Netherlands 
and €163–253 in the United States ([8, 10–12, 20] in Table 
9.2). These numbers are difficult to compare as case definitions 
and cost items included vary between studies. For example, 
sequelae due to campylobacteriosis were considered in some 
studies while in others they were not. Campylobacteriosis-
associated acute gastroenteritis (AG) accounts for approximate-
ly 108 000 cases/year in The Netherlands, causing annual 
societal costs of about €81.5 million (including sequelae) [11]. 
In the EU, campylobacteriosis cases account for expenditures 
of public health systems and for productivity losses of around 
€2.4 billion/year according to the European Food Safety Au-
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thority [28]. The economic burden highlights the importance of 
this widespread and common disease. 
A quantification of healthcare costs due to AG and/ or campyl-
obacteriosis in Switzerland is lacking so far. Due to the rising 
number of campylobacteriosis case notifications in recent 
years, we conducted several studies which aimed at generating 
a better understanding of the epidemiology of campylobacteri-
osis in Switzerland. We investigated epidemiological 
determinants [29], described time trends in notification data 
[1], the campylobacteriosis-associated illness experience from 
the patients’ perspective [29, 30], the case management strate-
gies of GPs  and laboratory positivity rates of 
Campylobacter spp. (Supplementary material of Schmutz et al. 
(2017b)). In concert, these studies indicate that campylobac-
teriosis is causing a considerable burden of disease which 
considerably impacts the health system in Switzerland and is 
likely associated with high costs. 
The aim of this study was to estimate the total annual costs for 
the medical treatment of campylobacteriosis in Switzerland. 
However, given that available data do not systematically dis-
tinguish campylobacteriosis from AG we focused this analysis 
on available data of both conditions. To the best of our 
knowledge, this is the first study estimating healthcare costs 
due to AG and campylobacteriosis in Switzerland. 
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Table 9.1: Overview of selected studies estimating the cost-of-
illness of gastrointestinal or foodborne illnesses 
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Table 9.1 continued 
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Table 9.2: Overview of selected studies estimating the cost-of-
illness of campylobacteriosis 
PUBLISHED ARTICLE 
249 
9.4. Methods 
We developed patient management models and estimated their 
frequency and associated costs from the perspective of the 
healthcare system. 
9.4.1. Typology of patients: patient management models 
Cost estimation was based on four different patient manage-
ment models for AG which were derived from a broad expert 
consultation across a purposive enquiry among practitioners in 
private general and specialized practices (four), clinics and 
university hospitals (four), authors opinions and data available 
to them: (i) patients consulting a physician without stool testing 
(patient management model A), (ii) patients consulting a phy-
sician with negative Campylobacter stool test results (patient 
management model B), (iii) patients consulting a physician and 
having a positive Campylobacter stool test result (patient man-
agement model C), and (iv) hospitalized campylobacteriosis 
cases (patient management model D). 
9.4.2. Population figures as basis for modelling: sources and 
approach 
The number of notified campylobacteriosis cases occurring 
each year in Switzerland was retrieved from the NNSID [1]. A 
study assessing the trend in Campylobacter positivity rates was 
conducted (thereafter referred to as the ‘Positivity study’). This 
study used data of eight Swiss diagnostic laboratories on 
Campylobacter tests performed between 2003 and 2012. 
Positivity rates, defined as the proportion of Campylobacter-
positive to total number of Campylobacter tests, were 
calculated. The number of Campylobacter tests performed in 
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Switzerland was estimated based on the preliminary positivity 
rate of 2012. 
In 2013, a qualitative study among 69 GPs was conducted in 
Switzerland (thereafter referred to as the ‘Swiss GP study’). 
Using a semi-structured questionnaire, physicians were inter-
viewed about their case management strategies for and general 
perception of AG and campylobacteriosis. From this study, 
GPs’ estimates on the proportion of AG patients with a stool 
test prescribed were available. 
In 2014, the Swiss Sentinel Surveillance Network decided to 
study AG for 12 months; 170 participating GPs reported all 
cases consulting due to AG. This study (thereafter referred to 
as the ‘Sentinella study’) also provides estimates on the propor-
tion of patients with a stool test. 
The results used for cost estimates from the ‘Positivity’, the 
‘Swiss GP’ and the ‘Sentinella study’ are preliminary. Short 
summaries of these studies including the preliminary results 
used for estimating healthcare costs can be found in the 
Supplementary material of Schmutz et al. (2017b). Final results 
of all these studies will be published separately. 
We used the number of hospitalizations due to the ICD-10 code 
‘A04.5 Campylobacter enteritis’ as reported in official hospital 
statistics published by the Federal Statistical Office [31]. We 
compared this number with estimates based on the hospitaliza-
tion rate found in our case-control study on determinants of 
campylobacteriosis [29] and the number of campylobacteriosis 
case notifications from the NNSID [1]. 
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9.4.2.1. Population-level estimates 
The number of campylobacteriosis cases registered at the 
FOPH was assumed to correspond to the number of patients in 
management models C and D in the whole of Switzerland. The 
number of hospitalizations in Switzerland (patient management 
model D) was extracted from official hospital statistics (hospi-
talizations due to Campylobacter enteritis, ICD-10 code A04.5) 
[31]. 
Patients in management model D  
= cases hospitalized due to ICD-10 code A04.5 
Patients in management model C  
= cases in NNSID − patients in management model D 
The proportion of positive to total number of campylobacterio-
sis tests was used to estimate the number of patients in 
management model B based on notified cases (hence, cases 
with a positive test result). 
Patients in management model B 
= 
cases in NNSID
positivity rate (= 
positive tests in x labs
all tests in x labs
)
 − cases in NNSID 
The proportion of patients with stool testing (as opposed to 
consultation without stool testing) was used to estimate case 
numbers for patient management model A. 
Patients in management model A 
= [
𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑖𝑛 𝑚𝑎𝑛𝑎𝑔𝑒𝑚𝑒𝑛𝑡 𝑚𝑜𝑑𝑒𝑙 𝐵 +  𝑐𝑎𝑠𝑒𝑠 𝑖𝑛 𝑁𝑁𝑆𝐼𝐷 (=  𝑎𝑙𝑙 𝑡𝑒𝑠𝑡𝑒𝑑)
𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑤𝑖𝑡ℎ 𝑠𝑡𝑜𝑜𝑙 𝑡𝑒𝑠𝑡
]  
− all tested 
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The data sources used for the extrapolation from individual to 
population-based costs are summarized in Figure 9.1a. 
9.4.3. Healthcare expenditures 
Healthcare costs for each of the patient management models 
were estimated by combining associated medical standard pro-
cedures with publicly available respective rates for accounting. 
We extrapolated these individual case management costs to 
estimate healthcare costs associated with AG and campylobac-
teriosis in Switzerland in 2012. 
9.4.3.1. Sources of cost data 
We used different sources in order to calculate healthcare ex-
penditure due to Campylobacter infections: from the Swiss GP 
study, based on expert opinions and using preliminary results 
of the Sentinella study, treatment schemes and standard ap-
proaches for case management (including number and duration 
of consultations, laboratory tests performed and medications 
prescribed) were identified. Consultation costs of GPs were 
calculated using the number of points from the publicly availa-
ble Swiss medical tariff system, TARMED (as of June 2012) 
[32] and a point value of €0.7138 which is used in the canton 
of Bern [33]. Similarly, points for laboratory diagnostics were 
extracted from the official tariff list (‘Analysenliste’; as of Jan-
uary 2012) using a point value of €0.83 applied throughout 
Switzerland [34]. Costs for medications were extracted from 
the list of pharmaceutical specialities (‘Spezialitätenliste’, ver-
sion of 1 January 2012) [35]. Calculation of hospitalization 
costs was based on the flat rates of the Swiss diagnosis-related 
group-based (DRG-based) hospital reimbursement system and 
a base rate which is applied by several regional hospitals in the 
canton of Bern, both for 2012 [36, 37]. Costs in Swiss francs 
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were converted to Euros using an exchange rate for the Euro of 
€0.83 per Swiss franc (average exchange rate January 2012–
December 2012) [23]. The cost estimation process for the pa-
tient management models is presented in Figure 9.1b. 
We obtained primary cost data from invoices for consultations 
of Campylobacter-positive patients, covering all patient con-
sultations between 2011 and 2013 at the Swiss TPH travel 
clinic. This part of the study was approved by the local ethical 
committee (Ethikkommission Nordwest- und Zentralschweiz 
ref. no. EKNZ: 2014–159). 
9.4.4. Data analysis 
9.4.4.1. Costs per patient treated 
Differentiating by patient management model (models A–D), 
we evaluated the costs for consultations, medication, laboratory 
tests and hospitalization until conclusion of medical treatment. 
For all patient management models we defined two scenarios 
to account for some of the heterogeneity of the patients and the 
case management strategies within a given model: a minimal 
and an extended or prolonged scenario. The proportions of pa-
tients treated with the minimal and the extended scenario were 
estimated based on results of the case-control (e.g. proportion 
of patients treated with antibiotics) [29] and the Sentinella 
study (e.g. number of consultations; Supplementary material of 
Schmutz et al. (2017b)). Afterwards, experts were asked 
whether they considered the estimated proportions reasonable. 
The two scenarios do not imply any chronology of the steps 
involved.  
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Estimates for patient management model C were validated us-
ing real patient records of the Swiss TPH travel clinic. Patient 
invoices were entered in an electronic database and analysed 
using Stata v. 13 (StataCorp., USA). Costs for laboratory tests 
or medication not primarily associated with AG were excluded, 
i.e. tests for Echinococcus, Filaria, flavivirus and Plasmodium, 
vaccines for rabies and tetanus, and electrocardiograms. Labor-
atory tests performed in external laboratories were invoiced by 
these laboratories and could, hence, not be considered in our 
analysis. However, we added costs for one positive stool test 
for Campylobacter spp. as patients were selected based on hav-
ing laboratory-confirmed campylobacteriosis. 
  
Figure 9.1: Overview of data sources used for (a) extrapolation of 
treatment costs and (b) for cost estimation for acute gas-
troenteritis and campylobacteriosis patients 
a
Qualitative study about case management of campylobacteriosis patients 
among 69 general practitioners in Switzerland (Supplementary material).  
b
Study on acute gastroenteritis conducted within the Swiss Sentinel Surveil-
lance Network ‘Sentinella’ (www.sentinella.ch) in 2014 (Supplementary 
material).  
c
Study on laboratory positivity rates of Campylobacter, Salmonella and 
Shigella diagnostic tests in Switzerland (Supplementary material). 
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9.5. Results 
9.5.1. Frequency of different patient management models in 
Switzerland 
In the NNSID, 8480 cases of campylobacteriosis were 
registered in 2012 [1]. Preliminary results from the Positivity 
study showed that 10.9% of all campylobacteriosis tests were 
positive (Supplementary material of Schmutz et al. (2017b)). 
Consequently, we estimated that 77 798 tests for 
Campylobacter spp. were made in 2012, of which 69 318 had a 
negative test result (patient management model B). Estimates 
of the Swiss GP study indicated that one in four AG patients 
has a stool test performed (Supplementary material of Schmutz 
et al. (2017b)), suggesting that 233 394 patients consult a 
physician each year without further stool testing (patient 
management model A). However, preliminary results from the 
Sentinella study suggest that only 11% (420/3794) of patients 
had stool testing performed (Supplementary material of 
Figure 9.2: Number of hospitalizations due to ICD-10 code A04.5 
‘Campylobacter enteritis’ in Switzerland from 2004 to 
2012 (blue dotted line with circles, left axis, [31]) 
Number of hospitalizations extrapolated from results of 
a case-control study in Switzerland [29] assuming hospi-
talization of 14.5% of cases registered in the National 
Notification System for Infectious Diseases (NNSID) 
(green dashed line with triangles, left axis) 
Number of case notifications from the NNSID [1] (black 
solid line with squares; right axis). 
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Schmutz et al. (2017b)). In this case a total of 629 457 patients 
would be in patient management model A.  
The number of hospitalizations due to ‘Campylobacter enteri-
tis’ (ICD-10 code A04.5) as reported in the official Swiss 
hospital statistics increased steadily since 2004. In 2012, 1348 
hospitalizations were reported which is the maximum so far 
(Figure 9.2). For comparison, 14.5% (23/159) of interviewed 
patients in the recent case-control study, with laboratory-
confirmed campylobacteriosis, reported hospitalization due to 
their illness [29]. Considering the case notification numbers of 
2012 (8480 cases), this proportion would result in 1230 hospi-
talizations (patient management model D). Patient management 
model C includes all notified cases except those being hospital-
ized (1348), resulting in 7132 patients annually in Switzerland. 
9.5.2. Individual case management costs for AG and campyl-
obacteriosis patients 
The costs per case are highly variable ranging from €30 (pa-
tient management model A) to €4828 (patient management 
model D). The cost items attributed to the different patient 
management models and scenarios and associated costs are 
presented in . (For a list of unit costs see Supplementary Table 
S2 of Schmutz et al. (2017b))  
The healthcare costs of 41 patients with laboratory-confirmed 
Campylobacter spp. infection were analysed. Costs for those 
19 male and 22 female patients aged between 1 and 72 years 
were in the range of €179–1033 (median €464). The number of 
consultations varied between 1 and 8 per patient (median 2), 
the number of blood samples taken between 0 and 4 (median 1) 
and the time between the first and the last consultation between 
0 (only one consultation) and 65 days (median 3). Consultation 
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costs and costs for laboratory testing of real patient data were 
higher than estimated costs for patient management model C 
(Supplementary Table S3 of Schmutz et al. (2017b)). 
9.5.3. Healthcare costs due to AG and campylobacteriosis 
Total healthcare costs for the management of the four different 
patient management models combined in Switzerland in 2012 
were estimated at €29.5–44.7 million (). Costs for the different 
patient management model groups (A–D) were €9.0–24.2, 
€12.3, €1.8 and €6.5 million, respectively (Supplementary Fig-
ure S1 of Schmutz et al. (2017b)). 
Costs separated by type/provider were: €11.1–20.6 million for 
GPs’ services (including medical assistants), €7.7–9.1 million 
for laboratory diagnostics, €4.4–8.6 million for medications 
and €6.4 million for hospitalizations (Supplementary Figure S2 
of Schmutz et al. (2017b)). 
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Table 9.3: Health care costs associated with the management of 
acute gastroenteritis and campylobacteriosis for four pa-
tient management models with two scenarios each. 
(Values reflect costs in Euro) 
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Table 9.3 continued 
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Table 9.4: Estimated health care costs for the treatment of acute gas-
troenteritis and campylobacteriosis in Switzerland. Costs 
for individual cases are based on resource use estimates 
presented in Table 9.3. 
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9.6. Discussion 
This study provides for the first time an assessment of total 
Swiss healthcare costs due to AG and campylobacteriosis by 
estimating the individual costs of four types of patient man-
agement models and their frequency: patients suffering from 
AG and seeking medical care without being tested (model A); 
patients seeking medical care and having a Campylobacter-
negative stool test (model B); patients seeking medical care 
and having a Campylobacter-positive stool test (model C); and 
patients with a severe course of campylobacteriosis requiring 
hospitalization (model D). 
Cases of campylobacteriosis increased in the last decade 1.5-
fold, implying a contemporarily relevant public health prob-
lem. We estimated that in Switzerland, each year 311 192–707 
255 patients consult a physician due to AG or campylobacteri-
osis, leading to annual healthcare costs ranging from €29 to 
€45 million. 
The calculations were based on several assumptions as this 
study provides the first estimates of healthcare costs due to AG 
and campylobacteriosis in Switzerland. The country has no 
central database which is based on diagnostic codes and where 
healthcare costs from outpatient care are systematically record-
ed. Therefore, we tried to cross-validate our estimates 
whenever possible by combining different data sources. The 
real patient data which we used for comparison with cost esti-
mates for patient management model C originated from our 
own institution’s (Swiss TPH) travel clinic. These real patient 
data suggested higher costs for laboratory-confirmed, ambula-
tory patients than we used for our calculations. Possibly 
consultation time in returning travellers was longer because of 
the travel anamnesis and laboratory tests were more extensive. 
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Nevertheless, returning travellers are likely to be overrepre-
sented also in the patients with AG seen by GPs. When using 
the median total costs of the real patient data of the travel clinic 
for patients in management model C, the costs for this group 
would be €3.3 million (instead of €1.8 million; Supplementary 
Figure S1 and S2 of Schmutz et al. (2017b)). Hence, we be-
lieve the cost estimates used for patient management model C 
are conservative. 
Some physicians reported performing a second stool test after a 
positive result for certain patient groups (e.g. working in the 
food sector) before allowing the patients to return to work. A 
few experts claimed that the consultation times we applied in 
our models were rather short. They suggested consultation 
times of 5–10 min longer for selected (but not for all) consulta-
tions. The case-control study [29] found that about 10% of 
campylobacteriosis patients in outpatient treatment received 
intravenous therapy, which was not considered in our models. 
Furthermore, patients requiring hospitalization may be trans-
ferred to the hospital by ambulance causing additional costs. 
Taking all these points into account, we believe that our esti-
mates reflect rather conservative approximations. 
9.6.1. Healthcare costs of laboratory-confirmed campylobac-
teriosis patients 
Campylobacteriosis cases as registered in the NNSID were 
estimated to cost around €8.3 million/year (patient manage-
ment models C and D). The majority of these costs are 
attributable to hospitalizations. Comparison of our estimates 
with actual patient data suggests that our estimates (at least for 
patient management model C) underestimated actual costs oc-
curring in the health system. The number of hospitalizations 
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due to ‘Campylobacter enteritis’ (ICD-10 code A04.5) matches 
well with the calculated number of hospitalized patients using 
the official notification data together with the hospitalization 
rate found in the case-control study (1348 vs. 1230 cases). The 
hospitalization costs, which are based on DRG flat rates, in-
clude all costs occurring during the hospital stay. This flat rate 
is independent of the length of stay as long as it is within 2–11 
nights (for DRG code G67B, according to DRG v. 1.0 [36]). 
9.6.2. Healthcare costs of AG patients 
The costs for AG patients without laboratory-confirmed cam-
pylobacteriosis varied significantly depending on the 
proportion of stool testing we used to calculate patient numbers 
for patient management model A. The proportion of stool test-
ing is highly variable also in other countries: it was found to be 
12% in The Netherlands [38], 19–44% in the United States [39, 
40] and 27% in England [41]. Even though our estimate of 
11% from the Sentinella study is lower compared to the pro-
portions reported in other countries we believe that this number 
is more accurate than the semi-quantitative estimates obtained 
from the Swiss GP study. Moreover, the figure from the Senti-
nella study represents the proportion of patients for which the 
physician initiated stool testing. It is likely that not all patients 
actually provided a stool specimen. Hence, using the propor-
tion of actually completed stool tests would increase case 
numbers in model A and our cost estimates. Additionally, our 
calculation for patient management model A is based on the 
estimated number of tests for Campylobacter spp. This may in 
fact underestimate the total number of stool tests as in some 
instances physicians might only test their patients for viruses, 
for example. In this case, the number of patients in manage-
ment models A and B would be even larger. 
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Apart from Campylobacter both Salmonella and Shigella 
infections are notifiable in Switzerland. Usually, basic stool 
bacteriology involves testing for these three pathogens [42]. 
Under this assumption and ignoring the chance of mixed 
infections, all Salmonella- or Shigella-positive patients were 
assigned to management model B (patients with 
Campylobacter-negative stool test). This leads again to a rather 
conservative estimate of costs since stool cultures with a 
positive result are more expensive than negative stool cultures 
(€64.74 vs. €128.65) [34]. Additionally, salmonellosis and 
shigellosis patients may also need hospitalization and those 
patients are, therefore, more likely to create costs similar to 
those estimated for campylobacteriosis patient management 
models C and D. In 2012, 1243 cases of salmonellosis and 159 
cases of shigellosis were reported [43, 44]. Moreover, AG 
patients with viral infections and patients without an identified 
causative agent might be hospitalized. The hospitalization costs 
for these patients were not considered in our study.  
Patients consulting a physician not at all or only by phone and 
patients seeking help in a pharmacy have not been considered 
in this study. Up to 60% of gastroenteritis patients calling the 
medical practice are managed by phone, according to the Swiss 
GP study (Supplementary material of Schmutz et al. (2017b)). 
Individual (healthcare) costs for these patients may be low. 
However, the high quantity of these patients might still lead to 
considerable costs. 
9.6.3. Comparison of cost estimates for Switzerland with es-
timates of other countries 
Various studies have been conducted in several countries to 
estimate costs for gastrointestinal infections or campylobac-
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teriosis (Table 9.1 and Table 9.2). However, comparison of 
costs is very difficult due to varying case definitions used, het-
erogeneity in costs included, differences in health systems and 
health-system use and time. We estimated that a case of labora-
tory-confirmed campylobacteriosis costs on average €975 
(average per case for models C and D). The extent of underre-
ported campylobacteriosis infections – defined as infections in 
individuals who seek healthcare but whose infection is not cap-
tured by the surveillance system [45] – is unknown for 
Switzerland. The multiplication factor due to underreporting of 
campylobacteriosis was estimated at 1.3 in the UK [46] and at 
2.0–5.6 in The Netherlands [6, 47]. Applying the same factors 
to Swiss data would result in 2544–39 008 additional campylo-
bacteriosis cases. Assuming that underreporting was due to 
under-diagnosis (as opposed to under-notification), these cases 
are automatically included in our patient management model A 
(where model A represents all consulting AG patient without 
stool diagnostics.) Hence, costs in model A attributable to un-
der-diagnosed campylobacteriosis cases would range between 
€0.98 and €1.50 million. Total costs attributable to campylo-
bacteriosis would then range between €8.4 and €9.8 million in 
Switzerland (representing 19–33% of total AG costs) or €206–
759/case. Healthcare costs per case are higher than Dutch 
(€82–280/case, Table 9.2) or US estimates (€163–253/case). 
However, the latter two were based on the yearly estimated 
number of campylobacteriosis cases in the population while we 
considered only campylobacteriosis cases presenting to the GP 
or being hospitalized. 
On average, a case of AG (including campylobacteriosis) in 
Switzerland was estimated at €63–95. Again, our cost estimates 
are based on cases presenting to the GP while estimates from 
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other countries usually are presented for cases in the communi-
ty. Hence, values are not comparable even though our cost 
estimates are within the range of cost estimates from other 
countries (€3–155 [9–20], Table 9.1). 
9.6.4. Unknown socioeconomic burden 
We only assessed direct healthcare costs for AG and campylo-
bacteriosis. The average hospital stay of three nights and the 
median disease duration of 7 days of campylobacteriosis pa-
tients which were found in the case-control study [29] suggest 
that the socioeconomic burden due to productivity loss and 
home care is a multiple of the healthcare costs. Additionally, 
we neither considered costs arising from complications of the 
disease (e.g. Guillain–Barré syndrome, reactive arthritis or irri-
table bowel syndrome) nor did we include out-of-pocket 
expenses for medications of patients not consulting a physician 
or costs arising of patients consulting the physician exclusively 
by phone. This further underscores the conservative nature of 
our overall healthcare cost estimated at €29–45 million. 
The disease burden and economic consequences are further 
increased by years of life lost due to premature mortality. The 
ICD-10 codes A02 ‘other Salmonella infections’ and A04.5 
‘Campylobacter enteritis’ were recorded only for four patients 
in 2011 as the main cause of death (Swiss Federal Statistical 
Office, personal communication). When considering also sec-
ondary causes of deaths, 104 deaths were registered in 2011. 
For influenza it was shown that mortality is underreported in 
official statistics [48]. We assume that such underreporting is 
also the case for deaths due to campylobacteriosis (and salmo-
nellosis). 
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AG and campylobacteriosis cause a marked public health prob-
lem generating considerable costs. To our knowledge, this is 
the first study investigating healthcare costs due to AG and 
campylobacteriosis in Switzerland. Further research is needed 
for more accurate cost estimation. In order to reduce the finan-
cial burden and suffering of patients, there is a need for 
implementing health policy measures, sectorial and inter-
sectorial public health interventions and increasing awareness 
in the population at all levels. 
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10. General discussion 
Human campylobacteriosis and acute gastroenteritis (AG) due 
to infectious intestinal diseases (IID) received little attention in 
Switzerland so far. Despite campylobacteriosis case notifica-
tions are increasing since 2005 and show a distinct winter peak 
whose determinants are unclear. The aim of this doctoral re-
search is to contribute to a better understanding of the 
epidemiology of human campylobacteriosis and AG and to 
improve the interpretation of routine surveillance data from the 
Swiss National Notification System for Infectious Diseases 
(NNSID). The six research components conducted appropriate-
ly addressed this aim and the underlying objectives from a 
human and health system’s perspective along the burden-of-
illness pyramid (see Chapter 3).  
The case-control study identified the consumption of meat fon-
due especially if consumed with chicken meat as a major risk 
factor for contracting campylobacteriosis in Switzerland over 
Christmas and New Year (Chapter 4). Hence, its consumption 
is largely responsible for the winter peak of cases observed in 
the NNSID. Moreover, the consumption of meat fondue is like-
ly to play a similar role in other European countries with a 
winter peak in surveillance data (Chapter 5). An analysis of 
laboratory positivity rates from Campylobacter and Salmonella 
infections confirmed the epidemiological observations made in 
the NNSID and thereby increased the validity of surveillance 
data from the NNSID (Chapter 6). 
The disease burden and presentation of campylobacteriosis and 
AG, and determinants of the NNSID at the primary care level 
were investigated by a mixed methods approach (Chapter 7 and 
8). The qualitative study among general practitioners (GPs) 
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generated knowledge on health care seeking, clinical presenta-
tion and case management of patients suffering from 
campylobacteriosis and AG in Switzerland (Chapter 7). The 
following quantitative study within the Sentinel Surveillance 
Network Sentinella showed that the disease burden of AG due 
to IID is comparable to the burden of influenza-like illnesses 
(ILI) and estimated determinants of the burden-of-illness pyr-
amid such as stool testing rates (Chapter 8). Finally, the 
generated knowledge on case management and disease burden 
together with official rates for consultations, hospitalisations, 
diagnostics and drugs was used to estimate health care costs of 
campylobacteriosis and AG in Switzerland (Chapter 9). 
The following chapter compiles and discusses the estimated 
disease burden and health care costs of campylobacteriosis and 
AG along the burden-of-illness pyramid in Switzerland (ad-
dressing general objective 1). Subsequently, the usefulness and 
validity of the disease burden measured by the NNSID and 
implications of current and upcoming diagnostic practices and 
methods on measuring the disease burden by the NNSID are 
highlighted (addressing general objective 2). The need for an 
assessment of IID and AG at the community level to even bet-
ter understand the disease and economic burden along the 
burden-of-illness pyramid is emphasised. Additionally, a future 
monitoring of non-notifiable IID and AG is proposed. The 
presentation and case management of patients suffering from 
campylobacteriosis and AG at the primary care level is dis-
cussed considering specifically the increasing resistance to 
antibiotics among bacterial IID and changes in diagnostic 
methods to come (addressing general objective 1 and 2). The 
current control measures and prevention campaigns for cam-
pylobacteriosis in Switzerland are reviewed in the light of 
Along the burden-of-illness pyramid 
279 
determinants assessed to acquire a Campylobacter infection 
(addressing general objective 1). Finally, promising interven-
tions to reduce the burden of campylobacteriosis in the future 
are highlighted. 
10.1. Campylobacteriosis and acute gastroenteritis along 
the burden-of-illness pyramid 
10.1.1. Disease burden and health care costs 
Results of the Sentinella study showed that around 175,000 
cases of AG consulted at the primary care level in Switzerland 
in 2014 (Chapter 8). This is comparable to the consultation 
numbers due to ILI during an influenza season (107,000 – 
276,000 ILI cases during the seasons 2013 - 2016) which is 
estimated by the same method as the burden of AG (BAG 
2014, 2015a, 2016). The study on health care costs estimated 
that between 311,192 and 707,255 cases of AG and campylo-
bacteriosis occur annually at the primary care level (Chapter 9).  
The estimated 175,000 to 707,255 cases correspond to a prima-
ry care attendance rate due to AG of 21 to 87 cases per 1000 
person-years. These estimates are close to estimates from the 
UK (18 per 1000 person-years), the Netherlands (13.0 per 1000 
person-years) and France (110 per 1000 person-years) 
(Havelaar et al. 2012, Tam et al. 2012c, van Cauteren et al. 
2012). Yet, it is remarkably lower than estimates from Germa-
ny (395 per 1000 person-years), Italy (389 per 1000 person-
years), Poland (266 per 1000 person-years) and Norway (200 
per 1000 person-years) (Kuusi et al. 2003, Baumann-Popczyk 
et al. 2012, Scavia et al. 2012, Wilking et al. 2013). This com-
parison should be interpreted with caution as consultation rates 
originate from studies with different study designs and case 
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definitions. All remarkably higher consultation rates originate 
from retrospective studies which relied on self-reporting of AG 
episodes by participants, often with a 4-week recall period. The 
Sentinella study and the study estimating the rate for the UK 
used a prospective study design generating similar results (21 
and 18 consultations per 1000 person-years).  
Retrospective study designs on disease burden are prone to a 
special recall bias known as “telescoping” (Wheeler et al. 
1999). Thereby, participants believe that a disease episode oc-
curred more recently than it actually did. This recall bias can 
lead to an overestimation of the disease burden in the recall 
period and is maybe more prevalent among AG cases consult-
ing a physician than cases not consulting. Another possibility is 
that AG cases consulting a physician are likely to better re-
member their disease episode. Hence, they could be more 
likely to report their episode than cases with a mild episode not 
leading to a consultation. This would point towards an underes-
timation of cases with a mild episode leading to an 
overestimation of the proportion of cases consulting a physi-
cian. 
Estimating case numbers by two different approaches (Senti-
nella study and study on health care costs) provided the 
possibility to cross-validate individual estimates. The differ-
ence between the two estimates can partially be explained by 
the different methods used to estimate case numbers. Annual 
AG case numbers at the primary care level in the Sentinella 
study were calculated based on consultation and population 
numbers stratified by temporal and spatial determinants and 
also patient characteristics (sex, age) (Altpeter et al. 2013). The 
estimation of health care costs used annual rates (stool test, 
positivity and hospitalisation rates) and case numbers from the 
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NNSID without stratification by temporal, spatial or patient 
characteristics to calculate case numbers for the different case 
models. Yet, the analysis of positivity rates showed that test 
numbers and positivity rates vary among sex, age groups and 
over the year (Chapter 6). Similarly, stool testing rates are 
pathogen-specific and depend on patient characteristics such as 
age or exposure to risk factors (Chapter 7 and 8). 
The estimated case numbers of the Sentinella study are likely 
also influenced by reporting fatigue. Participating physicians 
indicated in a survey that the reporting of AG cases is com-
paratively time-consuming and hence, could have had reported 
less cases leading to a lower number of estimated cases. An-
other important fact is that the upper estimate of the study on 
health care costs (707,255 cases) is based on the stool testing 
rate estimated from the quantitative Sentinella study. This stool 
testing rate (11.6%) is significantly lower than the one of the 
qualitative GP study (25.0%) used to calculate the lower esti-
mate (311,192 cases). It can be assumed that the stool testing 
rate of the quantitative Sentinella study is more reliable given 
the methodological advantages of the study design to quantita-
tively assess outcomes. 
It is difficult to judge which of the two estimates reflects the 
true disease burden better as both approaches have their limita-
tions. Assuming the stool testing rate from the Sentinella study 
reflects the reality better, the true burden of AG at the primary 
care level per year is likely between the 175,000 cases of the 
Sentinella study and the 707,255 cases of the study on health 
care costs (upper estimate). 
It also needs to be added that a considerable proportion of the 
cases observed at the primary care level were admitted to hos-
pital. The Sentinella study and the case-control study showed 
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that 2.7% of AG patients and 14.5% of campylobacteriosis 
patients needed to be hospitalised during their illness (Chapter 
4 and 8). Among elderly patients (>60 years) even 7.0% of AG 
patients and 33.0% of campylobacteriosis patients were admit-
ted to a hospital. The majority of health care costs associated 
with campylobacteriosis cases notified in the NNSID were at-
tributable to hospitalisations (€6.5 million). The health care 
costs caused by AG and campylobacteriosis patients admitted 
to hospitals should therefore not be neglected. The disease bur-
den and health care costs at the hospital level could even 
increase in the future considering that the Swiss population is 
ageing. 
The study on health care costs estimated the costs due to AG 
and campylobacteriosis at the primary care level in Switzerland 
at €29–45 million per year. A considerable proportion of these 
costs can be attributed to campylobacteriosis: €1.8 million to 
campylobacteriosis patients at the primary care level and €6.5 
million to hospitalised campylobacteriosis patients. A compari-
son of the estimated health care costs due to AG and 
campylobacteriosis in Switzerland with other (neighbouring) 
countries can be found in Chapter 9. Yet, such a comparison is 
challenging given varying case definitions used, heterogeneity 
in costs included, differences in health systems and health-
system use and time. 
The approach used to estimate health care costs relied on esti-
mated case numbers, official rates for health care services and 
expert opinions. The estimation of case numbers was based on 
determinants of the burden-of-illness pyramid (stool testing, 
positivity and hospitalisation rates) which are influenced by 
temporal and spatial factors and patient characteristics as men-
tioned before. A possible new estimation of health care costs 
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for AG and campylobacteriosis using the same approach 
should thus consider stratifying the calculation of case numbers 
by temporal, spatial and patient characteristics. Estimated 
health care costs per case were based on official rates and ex-
pert opinions. Only health care costs for patients with 
campylobacteriosis were validated with real patient data from 
the Swiss TPH’s Department of Medicine. Hence, assessing the 
health care costs per case management model with real patient 
data is recommended for a future assessment. More accurate 
estimates for case numbers and health care costs per case will 
lead to a more precise estimate of health care costs due to AG 
and campylobacteriosis in Switzerland. 
In summary, the studies conducted showed that the burden of 
AG and campylobacteriosis at the primary care level and in 
hospitals in Switzerland is considerable and results in substan-
tial health care costs requiring public health action to reduce 
the associated burden. 
10.1.2. Usefulness and validity of the disease burden of cam-
pylobacteriosis and salmonellosis measured by the 
National Notification System for Infectious Diseases 
The rise in campylobacteriosis and the decrease in 
salmonellosis case notifications in the NNSID between 2003 
and 2012 as observed by Schmutz et al. (2016) could be 
confirmed as real epidemiological trend in the population by 
the analysis of positivity rates (Chapter 6). During the same 
time period, the number of tests conducted for Campylobacter 
spp. and Salmonella spp. increased and the rise in 
campylobacteriosis case numbers can be interpreted as an 
actual rise in the number of cases combined with increased 
testing. In contrast, the decline in salmonellosis case 
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notifications represents a strong decrease of human 
salmonellosis in Switzerland as case numbers decreased even 
in the light of increasing test numbers i.e. lower positivity rates 
(positive tests / total test numbers). Similar trends observed in 
case notifications for both diseases on the European level seem 
to confirm the observations made (EFSA and ECDC 2016). 
The new Epidemics Act was implemented together with a new 
ordinance on the reporting of infectious diseases in Switzerland 
at the beginning of 2016 (Die Bundesversammlung 2012, EDI 
2015). The ordinance requires all medical laboratories to report 
annually the total number of tests conducted for 
Campylobacter spp. and Salmonella spp. including the number 
of positive results as aggregated numbers, stratified by month 
and test method. This summary measure of denominator data 
allows now for a continuous but basic temporal assessment of 
positivity rates to interpret trends in the NNSID. Yet, the 
aggregated numbers do not allow calculating age- or sex-
specific positivity rates for an accurate interpretation of NNSID 
data stratified by age or sex. 
The analysis of positivity rates showed once again the need of 
analysing denominator data (total number of tests conducted) 
for the interpretation of trends in NNSID case numbers (cf. 
Schmutz et al. (2013)). The importance of analysing denomina-
tor data for the interpretation of trends in passive surveillance 
systems has also been highlighted by others (van Pelt et al. 
2003, Janiec et al. 2012, Franklin et al. 2015). Why denomina-
tor data is important could be directly shown by the qualitative 
GP study (Chapter 7) and the Sentinella study (Chapter 8). 
They showed that the primary care level is very important for 
two determinants of the burden-of-illness pyramid. First, in 
many primary care practices the GP or a nurse filters patients 
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and provides them with medical advice at the telephone de-
creasing the number of patients that are seen by the GP. 
Second, the decision to conduct a stool test or not is strongly 
influenced by disease progression, reported exposure to risk 
factors (e.g. travel abroad) and the GP’s personal experiences 
and opinions. Analysing positivity rates helps detecting chang-
es among these determinants which can affect the number of 
cases registered in the NNSID in different ways. 
Hence, cases of notifiable IID registered in the NNSID repre-
sent the more severe cases and risk groups rather than the 
average individual affected by IID. This is also supported by 
the case-control study conducted among campylobacteriosis 
cases registered in the NNSID (Chapter 4). Cases in this study 
rated the disease severity with a median of 8 on a rating scale 
from 1 (very mild) to 10 (very severe). As a result, the infor-
mation on and about mild and short episodes of notifiable IID 
does simply not reach the NNSID. This leads to a clear under-
estimation of the incidence of notifiable IID at the primary care 
level and in the Swiss population as a whole by the NNSID. 
IID case numbers observed in the surveillance system represent 
only the tip of the iceberg of cases occurring in the community 
(Allos et al. 2004). 
10.1.3. Influence of diagnostic practices and methods on the 
disease burden measured by the National Notification 
System for Infectious Diseases 
In Switzerland physicians generally order basic stool culture 
for Campylobacter, Salmonella and Shigella for their patients 
suffering from AG with a suspected bacterial infection e.g. 
based on increased C-reactive protein levels (Chapter 7). Stool 
tests for viral or parasitic causes were often only ordered with a 
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distinct suspicion about an exposure during an outbreak or for 
travelling abroad. In 2011, the first diagnostic laboratories in 
Switzerland started to offer stool-based multiplex PCR panels 
for the detection of gastrointestinal pathogens in routine diag-
nostics which are commonly used today (Hächler and Stephan 
2015). These PCR panels are able to detect a wide range of 
gastrointestinal pathogens including viruses, bacteria and para-
sites with a high sensitivity and specificity (Binnicker 2015, 
Spina et al. 2015).  
Notification rates of EHEC in Switzerland increased 2.5-fold 
from 2014 (1.5 per 100,000 population) to 2015 (3.5 per 
100,000 population), while the notification rate of the haemo-
lytic-uremic syndrome remained rather stable (BAG 2015b, 
Hächler and Stephan 2015). Multiplex PCR panels for gastro-
intestinal pathogens often include EHEC (Binnicker 2015, 
Spina et al. 2015) and, hence, every patient suffering from AG 
and undergoing stool testing with PCR panels will be tested for 
EHEC independent of the clinical suspicion. This likely in-
creases EHEC notification rates due to its detection in cases 
where previously only basic stool culture was ordered by the 
physician and performed (Hächler and Stephan 2015).  
Hence, it should be taken into account that the introduction of 
multiplex PCR panels as routine diagnostic for gastrointestinal 
pathogens likely increases test numbers for pathogens that are 
not the primarily suspected cause of disease from a clinical 
point of view. This could lead to an increase of pathogen-
specific notification rates. As a result, positivity rates of 
gastrointestinal pathogens will likely decrease due to increased 
test numbers and a lower pre-test probability. It is likely that 
positivity rates of Campylobacter spp., Salmonella spp. and 
Shigella spp. in Switzerland will only be slightly affected by 
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this phenomenon as these pathogens belonged already 
previously to standard stool diagnostics. Since the introduction 
of the new Epidemics Act in 2016, it is possible to assess these 
developments in Switzerland as the monthly number of tests 
conducted (incl. test results) for Campylobacter spp. and 
Salmonella spp. must be reported to the FOPH (Chapter 1.6.3). 
Such assessments are highly recommended for an appropriate 
interpretation of NNSID data considering the current changes 
in the diagnostic sector. 
Most recent European notification rates declined for 
Campylobacter and slightly increased for Salmonella from 
2013 to 2015 (EFSA and ECDC 2016). Therefore, an 
important question from an epidemiological point of view is to 
understand if such increases or decreases in notification data 
are real trends requiring public health action or just an artefact 
of the transition from single and often culture-based methods to 
multiplex molecular diagnostics (Langley et al. 2015, Marder 
et al. 2017). The assessment of corresponding positivity rates is 
a solid method to investigate this issue. Further should be 
considered that physicians’ testing behaviour and patient’s 
health care seeking likely have a much bigger influence on 
surveillance data than diagnostic technologies (Cronquist et al. 
2012, Doorduyn et al. 2012, Janiec et al. 2012, Langley et al. 
2015). Diseased individuals that do not seek health care or do 
not get tested have no chance to be recorded by the 
surveillance system. 
10.1.4. Monitoring the disease burden of non-notifiable infec-
tious intestinal diseases and AG in Switzerland 
Laboratory-confirmed infections by bacterial IID 
(Campylobacter spp., Salmonella spp., Shigella spp., Vibrio 
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cholerae, Listeria spp., EHEC) are monitored on a regular 
basis by the NNSID (Chapter 1.6.3). Viral or parasitic IID are 
not regularly monitored by the NNSID. They have only to be 
reported to the cantonal health department if an excess of case 
numbers (more than expected in time and place) i.e. an 
outbreak are observed by physicians or diagnostic laboratories 
(EDI 2015). The consequences thereof are twofold: (i) only 
obvious outbreaks are detected and (ii) conclusive estimates on 
the national burden of viral and parasitic IID are lacking for 
Switzerland so far. 
In contrast, Germany monitors a subset of viral and parasitic 
IID causing AG by a similar mandatory notification system as 
in Switzerland (RKI 2016). France as another example moni-
tors AG (and other diseases) at the population level through the 
sentinel system French GPs Sentinelles network and results of 
this national surveillance are made available for the public on 
the network’s website (Flahault et al. 2006, Réseau Sentinelles 
2017). The National Outbreak Reporting System (NORS) in 
the US monitors AG outbreaks of any cause and provides valu-
able information of the aetiological agents involved (Hall et al. 
2013). Additionally, the laboratory surveillance Network 
“CaliciNet” collects norovirus sequences and epidemiologic 
outbreak data and allows investigating spatial and temporal 
trends and identifying and linking clusters of norovirus out-
breaks in the US (Vega et al. 2011). Switzerland does not have 
any surveillance data on AG or single viral and parasitic IID 
while other countries do. So there is a clear potential for ex-
panding the surveillance of AG and IID in Switzerland. 
The surveillance of ILI during the influenza season has already 
been part of the Sentinella network since many years. The Sen-
tinella study provides solid evidence that AG could also be 
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monitored through the network (Chapter 8). A possible routine 
monitoring of AG within Sentinella would profit from the 
methodologies developed for ILI (e.g. estimation of national 
disease burden) and could be based on an already existing sys-
tem likely not generating considerable additional costs. Hence, 
the Sentinella network would provide an excellent system to 
monitor the burden of AG at the Swiss primary care level simi-
lar to the French GPs Sentinelles network. Also this network 
monitors cases of ILI and AG side by side based on the clinical 
presentation of cases. Information gained from such a surveil-
lance of AG could include its incidence and presentation at 
primary care level and stool testing and hospitalisation rates. 
Integrating AG monitoring into Sentinella would allow as-
sessing spatial and temporal trends of AG on a regular basis 
and thereby provide valuable epidemiological information (e.g. 
for outbreak detection) for cantonal and federal health authori-
ties. 
The Sentinella study showed that the Sentinella network is cur-
rently only of limited value - if at all - for the surveillance of 
specific IID (Chapter 8). A major limitation is that only around 
12% of cases suffering from AG undergo stool testing in daily 
practice. This limits the detection rate of specific IID if they are 
tested at all and results in small case numbers of laboratory-
confirmed IID. Hence, reliable estimates for the disease burden 
of specific IID at the primary care level can currently not be 
made from the Sentinella Network especially not for rather rare 
IID. A solution could be to increase the number of physicians 
participating in Sentinella as currently a small proportion 
(2.5%) of all physicians practicing in the ambulatory care sec-
tor participate. This would likely result in an increased number 
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of laboratory-confirmed IID cases making estimates of the 
primary care burden more reliable. 
Another possibility to improve the surveillance of specific IID 
within Sentinella would be to test all or a defined proportion of 
consulting AG cases for a defined set of IID. This would likely 
increase case numbers of laboratory-confirmed IID for the es-
timation of the primary care burden and allow determining the 
aetiology of AG at the primary care level. Diagnostic costs 
associated with such an approach are presumably too high for 
routine surveillance (3,900 AG cases were reported in the Sen-
tinella study). However, a one-time assessment for research 
purposes i.e. assessing the aetiology of AG at the primary care 
level would be desirable as this has not been done within the 
Sentinella study. 
Compared to other European countries or the US (Flahault et 
al. 2006, Vega et al. 2011, Hall et al. 2013, RKI 2016), surveil-
lance data on viral IID of public health importance such as 
norovirus or rotavirus are currently lacking in Switzerland. In 
Germany the viral and parasitic IID norovirus, rotavirus, giar-
diasis and cryptosporidiosis are also notifiable besides some 
bacterial IID (RKI 2016). This allows Germany to investigate 
unusual observations in the epidemiology of these IID in more 
detail e.g. the sudden increase of human norovirus infections at 
the end of 2016 (Niendorf et al. 2017). The introduction of a 
mandatory reporting for selected viral and parasitic IID in 
Switzerland would: (i) increase the knowledge on how these 
diseases present in the population and (ii) allow a better detec-
tion of outbreaks caused by these diseases than with the current 
procedures i.e. reporting of unusual observations by physicians 
and laboratories. 
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The identification of infectious causes of AG in stool was done 
by pathogen-specific diagnostics with different methodologies 
until the development of multiplex PCR panels for IID at the 
end of the 2000s (Chapter 1.5.3). Today, human stool speci-
mens can be tested for a variety of IID with a single test. 
Multiplex PCR panels for the diagnosis of IID are becoming 
increasingly popular. The Swiss NNSID could profit of this 
development by including so far non-notifiable IID in the man-
datory reporting system which are part of such panels. These 
non-notifiable IID are now tested with such panels anyway 
while in the past specific single tests had to be conducted. At 
least norovirus and rotavirus could be easily monitored in 
Switzerland as they are part of most commercially available 
multiplex PCR panels (Binnicker 2015, Spina et al. 2015). In 
summary, it would be clearly beneficial for Switzerland to 
monitor some currently non-notifiable IID given the resulting 
knowledge gain and the recent developments in the diagnostic 
sector. Yet, the increasing use of multiplex PCR panels likely 
leads to a decrease in the number of pathogen isolates available 
for outbreak investigations or antimicrobial susceptibility test-
ing which needs to be considered for corresponding 
surveillance systems (Langley et al. 2015). 
10.1.5. Case management of patients suffering from acute gas-
troenteritis and campylobacteriosis 
Results of the Sentinella study showed that around 12% of AG 
patients consulting at the primary care level have a stool test 
performed compared to a median of 18% in the qualitative GP 
study (Chapter 7and 8). From the perspective of the NNSID i.e. 
surveillance it would be much more beneficial if every patient 
would get tested. This way, notified cases would likely be more 
representative for the primary care level. Yet, conventional 
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diagnostic methods such as stool cultures or single PCRs can 
fail to detect an infectious agent in more than 50% of faecal 
specimens from AG patients (Huhulescu et al. 2009, Karsten et 
al. 2009, Tam et al. 2012b). Hence, such an approach is only of 
limited benefit as there are considerable costs associated with 
stool diagnostics (Chapter 9).  
As discussed earlier, multiplex PCR panels for the detection of 
IID in faecal specimens advance and are now frequently of-
fered for routine diagnostics. They have the potential to replace 
culture, microscopy and antigen methods for the detection of 
IID in the clinical setting due to the faster availability of results 
and the lower labour costs (Schreckenberger and McAdam 
2015, Rochat et al. 2017). This could lead to an increase in the 
number of AG patients tested for IID. However, these panels 
are not beneficial to every AG patient (passage and non-viable 
pathogens) and their deployment or not should be carefully 
considered by the physician in charge (Schreckenberger and 
McAdam 2015, Rochat et al. 2017). 
The treatment by antibiotic therapy is only recommended for 
very severe cases of AG with e.g. inflammatory and invasive 
bacterial IID while symptomatic treatment incl. oral rehydra-
tion therapy or antidiarrhoeals belongs to the standard 
treatment approach for AG patients (DuPont 2009, 2014, 
Zollner-Schwetz and Krause 2015). The vast majority of AG 
patients consulting at the Swiss primary care level requires 
supportive symptomatic treatment and around 1 out of 10 pa-
tients is additionally treated with antibiotics (Chapter 7 and 8). 
A Polish study found that 15.6% of AG cases visiting a GP 
received antibiotic therapy (Stefanoff et al. 2013). Close to 
two-third of laboratory-confirmed and registered campylobac-
teriosis cases are treated with antibiotics in Switzerland 
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(Chapter 4). Cases suffering from severe campylobacteriosis 
are more likely to be tested and hence, are more likely to be 
registered in the NNSID. This puts the antibiotic treatment rate 
of campylobacteriosis cases into perspective. 
In Switzerland, roughly 60% of AG patients and 50% of cam-
pylobacteriosis patients receiving antibiotic therapy are treated 
with quinolones (Chapter 8). This practice is highly questiona-
ble as human Campylobacter isolates show high levels of 
resistance to fluoroquinolones in Switzerland and Europe in 
general (FOPH and FSVO 2016, EFSA and ECDC 2017). 
Niederer et al. (2012) also showed that in Switzerland re-
sistance to quinolones is higher among Campylobacter isolates 
from travel-associated cases (56%) than from domestic cases 
(39%). The ECDC does not anymore recommend fluoroquin-
olones for the empirical treatment of campylobacteriosis due to 
the high level of resistance (EFSA and ECDC 2017). AG – if 
clinically indicated – and campylobacteriosis are nowadays 
best treated with azithromycin (macrolide) (Zollner-Schwetz 
and Krause 2015). Considering that mostly elderly suffer from 
severe campylobacteriosis the treatment with effective antibiot-
ics is important to reduce morbidity among the elderly 
(Chapter 4 and 8). 
The Strategy on Antibiotic Resistance Switzerland calls for a 
prudent use of antibiotics: they should be used carefully and if 
really indicated (The Federal Council 2015). The results of the 
studies conducted indicate that there is likely a potential to fur-
ther reduce the use of antibiotics for the case management of 
patients suffering from AG and bacterial IID. Consequently, 
antibiotic treatment practices for AG and campylobacteriosis 
patients in Switzerland should be re-considered and routine 
antibiotic resistance testing for bacterial IID would be advisa-
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ble for an effective case management. The development of na-
tional guidelines for the case management of AG and 
campylobacteriosis cases appears to be necessary given these 
circumstances. 
The high rate of resistance against quinolones among 
Campylobacter spp. highlights the need for a routine antibiotic 
resistance monitoring of bacterial IID. In Switzerland, 
antibiotic resistance monitoring of Campylobacter spp. and 
Salmonella spp. (and many other human pathogens) is already 
done by the Swiss Centre for Antibiotic Resistance in Bern 
(FOPH and FSVO 2016). The centre compiles the results from 
antibiotic resistance testing of the major diagnostic laboratories 
and hospitals in Switzerland resulting in a comprehensive and 
representative overview. Similarly, the ECDC collects 
antibiotic resistance monitoring data of EU member states and 
publishes the results of the monitoring in an annual report 
(EFSA and ECDC 2017). National guidelines for the case 
management of AG and campylobacteriosis could be adapted 
based on this surveillance if necessary. 
Antibiotic resistance is currently assessed by the phenotype of 
bacterial isolates which are collected during the application of 
conventional diagnostic methods such as stool cultures (Platts-
Mills et al. 2013). So how can isolates of IID for antibiotic 
resistance monitoring be acquired if the future diagnostic of 
choice could shift to multiplex PCR panels? A possibility is the 
antimicrobial susceptibility testing of isolates gained from stool 
samples tested positive by multiplex PCR panels. A recent 
study showed that this is a very promising approach and 
isolates for antimicrobial susceptibility testing could be 
recovered from 71% of stool samples tested positive for 
Campylobacter jejuni, Salmonella spp., Shigella spp., 
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enteroinvasive Escherichia coli and Yersinia enterocolitica by 
multiplex PCR (van Lint et al. 2016). 
In the future, the detection of antibiotic resistance genes by 
PCR or WGS together with knowledge on the phenotypic ex-
pression could provide a very fast tool for the identification of 
clinically relevant antibiotic resistance (Platts-Mills et al. 
2013). Yet, this approach will still rely on the relationship of 
genes and phenotypic expression and hence, will likely com-
plement and not replace phenotypic testing (Platts-Mills et al. 
2013).
10.2. Control measures to reduce the burden of human 
campylobacteriosis in Switzerland 
Human campylobacteriosis is a known public health problem 
in Switzerland since many years but received little attention so 
far. The FSVO launched the so-called “Campylobacter 
platform” to tackle the problem by a One Health approach in 
December 2008 (FVO 2009). The multi-sectoral platform 
consisted of federal and cantonal authorities, researchers, 
scientist and the poultry industry and “was established to 
identify and close any gaps in knowledge, to re-launch the 
control of Campylobacter and finally to reduce the disease 
burden in humans” (FVO 2009). In 2016, the platform was 
abolished and the focus lies now on distinct interventions to 
reduce the disease burden (BLV 2016b). 
Studies initiated by the platform included the case-control 
study on risk factors for contracting campylobacteriosis of this 
thesis (Chapter 4) and others (Kittl et al. 2011, Kittl et al. 
2013a, Jonas et al. 2015). These studies collectively showed 
that the majority of human campylobacteriosis cases in Swit-
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zerland is related to the poultry reservoir confirming results 
from other studies from Europe (EFSA Panel on Biological 
Hazards 2010, Domingues et al. 2012). Specifically, the case-
control study of this thesis could epidemiologically proof that 
the consumption of meat fondue – especially if consumed with 
chicken meat – is an important risk factor for a Campylobacter 
infection in Switzerland over Christmas and New Year when 
case notifications show a distinct increase (Chapter 4). Also in 
other European countries an increase in the number of notified 
cases is observed at this time and the consumption of meat 
fondues or table top grillings appears to be a considerable risk 
factor given the increasing use of inexpensive poultry meat 
(Chapter 5). 
Bearth et al. (2013, 2014b, a) showed that poultry consumers 
in Switzerland are generally well aware of the microbial con-
tamination of poultry meat (e.g. Campylobacter) and 
associated mitigation measures for the preparation of poultry 
meat. However, food safety behaviour especially regarding the 
avoidance of cross-contamination is often insufficient due to 
misconceptions and knowledge gaps. Exact adherence to miti-
gation measures is even lower at special occasions such as 
barbecues or meat fondues. 
The Swiss poultry industry’s own efforts to tackle the problem 
included implementing stricter biosafety measures to prevent 
the infection of flocks on broiler farms or hygiene measures to 
prevent the contamination of chicken meat with 
Campylobacter at the slaughter and processing levels (FVO 
2009). Unfortunately, these efforts were of rather limited 
success. Campylobacteriosis case numbers notified to the 
NNSID continued to rise during this time (Schmutz et al. 
2016). Consequently, measures to reduce the exposure to 
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Campylobacter spp. targeting the slaughter, processing, 
preparation and consumption of chicken meat were promoted 
by the platform: 
 Freezing of chicken liver from campylobacter-positive 
flocks 
 Process hygiene criterion for the Campylobacter load 
on broiler carcasses 
 Hygiene note on the packaging of fresh chicken meat 
products 
 Information campaign on the safe preparation and con-
sumption of chicken meat for consumers 
As already mentioned, several studies proved that the major 
source for human campylobacteriosis in Switzerland is chicken 
meat. Hence, control measure to reduce the human campylo-
bacteriosis burden need to focus on the transmission of 
Campylobacter spp. along the farm-to-fork chain i.e. from 
broiler farms over slaughter and retail levels to the consumer 
level.  
10.2.1. Control measures along the poultry production chain 
Biosafety measures e.g. ante-rooms and disinfection for boots 
for personnel aim at preventing the introduction of pathogens 
such as Campylobacter spp. into broiler flocks (Wagenaar et 
al. 2013). Fly screens at possible entry points for flies e.g. ven-
tilation systems lead to a reduced prevalence of campylobacter-
positive flocks, too (Hald et al. 2007). But even with the appli-
cation of strict biosecurity measures broiler flocks can become 
campylobacter-positive until slaughter as Campylobacter spp. 
is present all over in the environment of broiler houses 
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(Wagenaar et al. 2013). The implementation of stricter biose-
curity measures by the Swiss poultry industry did also not have 
the desired effects as previously mentioned (FVO 2009).  
A vaccine preventing the colonisation of broilers by 
Campylobacter spp. would be an ideal solution to reduce the 
disease burden in humans (Wagenaar et al. 2013, Johnson et al. 
2017). Several vaccine candidates are currently tested but until 
today there is no vaccine on the market to reduce the load of 
Campylobacter spp. in broilers (Johnson et al. 2017). Trials 
with a vaccine candidate for broilers are on the way in 
Switzerland (Malcisbo AG 2017). Yet, the development is still 
at the beginning and further trials will have to be conducted to 
prove effectiveness on the farm level. 
Another approach would be to eliminate Campylobacter spp. 
from broiler flocks by phage therapy with specific bacterio-
phages but this approach still needs further research before it 
can be applied on broiler farms (Janez and Loc-Carrillo 2013). 
Broiler carcasses after slaughter or chicken meat before pack-
aging can already be treated with bacteriophages in some 
countries (Endersen et al. 2014). However, different risk as-
sessments suggest that a reduced prevalence of 
Campylobacter spp. among broiler flocks does only lead to a 
minor reduction of the incidence in humans (Golz et al. 2014). 
Since January 2014, only chicken liver originating from cam-
pylobacter-negative flocks can be sold fresh in Switzerland 
while the one from positive flocks needs to be frozen prior to 
be sold at retail (EDI 2016a). Freezing chicken meat has been 
proven several times to be effective in lowering the quantita-
tive load of Campylobacter on the meat and thereby reducing 
the risk for consumers (EFSA Panel on Biological Hazards 
2011). 
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Additionally, a process hygiene criterion for the 
Campylobacter load on broiler carcasses at the end of the 
slaughter process (after chilling) was introduced with the new 
hygiene ordinance at the beginning of May 2017 including a 
transition period until 30 April 2018 (EDI 2016a). The limit for 
the process hygiene criterion is 2.5 log10 colony-forming units 
(CFU) of Campylobacter per gram (g) of broiler skin and 
applies to the arithmetic mean of the log10 of a minimum of 5 
pooled samples (10g of neck skin and 10g of breast skin per 
carcass from 3 carcasses per flock) per day. If the measured 
value is above the limit the slaughterhouses have to adopt 
measures such as improvements of slaughter hygiene, measures 
for germ reduction, and reviewing the process control, the 
origin of broilers and biosafety measures on the farms of 
origin. Distinct control measures are not mandatory at the 
slaughter stage and chicken meat producers can decide by 
themselves how they want to reduce contamination levels of 
Campylobacter spp. as long as they reach acceptable 
contamination levels.  
The EU adapted a similar process hygiene criterion incl. the 
adoption of measures for improvement if the criterion is not 
met which enters into form as from 1 January 2018 (The 
European Commission 2017). The proposed limit of 3 log10 
CFU/g could lead to a public health risk reduction of more than 
50% if carcasses comply with this limit (EFSA Panel on 
Biological Hazards 2011, The European Commission 2017). 
The Swiss limit is even lower (2.5 log10 CFU/g) and a decrease 
of campylobacteriosis case numbers can theoretically be ex-
pected within the coming years. 
Reducing the faecal leakage from and avoiding cross-
contamination of carcasses during the slaughter process and 
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subsequent carcass processing steps are important points for 
low loads of Campylobacter spp. on chicken meat (Golz et al. 
2014). Possibilities for the decontamination of carcasses at the 
end of the slaughter process include chemical decontamination 
(e.g. by lactic acids, acidified sodium chlorite, peracetic acid), 
freezing of broiler carcasses or irradiation (e.g. gamma rays) 
(EFSA Panel on Biological Hazards 2011, Golz et al. 2014). 
Most effective is irradiation leading to a risk reduction of 100% 
while chemical decontamination leads to a 50-90% risk reduc-
tion in regard to public health (EFSA Panel on Biological 
Hazards 2011). According to the federal law, only the chemical 
decontamination of bovine carcasses with lactic acids is cur-
rently allowed in Switzerland (EDI 2016c). Yet, it is in the 
responsibility of the FSVO to approve processes and chemicals 
for broiler carcass decontamination such as irradiation or 
chemical decontamination by acidified sodium chlorite or 
peracetic acid (Der Schweizerische Bundesrat 2016, EDI 
2016c). 
In summary, it appears to be most feasible today to decrease 
the Campylobacter spp. load on chicken meat below the limit 
of the hygiene criterion by chemical decontamination or irradi-
ation at the end of the slaughter process. Especially considering 
that the implementation of stricter biosecurity measures on 
farms by the Swiss poultry industry was not successful in the 
past. Unfortunately Swiss consumers’ preferences and ac-
ceptance are currently not well compatible with chemical 
decontamination. The Swiss and also the European consumers 
are rather opposed to the so-called “Chlorhühnchen” (Jordan 
and Stockley 2010, Baumgartner et al. 2012). Yet, in the ab-
sence of vaccines or phage therapies to eliminate 
Campylobacter spp. from broiler flocks, chemical decontami-
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nation or irradiation seems the only promising way to reduce 
the burden of campylobacteriosis in Switzerland. An additional 
benefit of these decontamination methods would be the reduc-
tion of antibiotic resistant bacteria e.g. extended-spectrum beta-
lactamase-producing E. coli which are frequently found on 
Swiss chicken meat (FOPH and FSVO 2016). Additionally, 
contamination limits for imported chicken meat should be con-
sidered in Switzerland despite imported chicken meat is 
significantly less contaminated with Campylobacter spp. than 
domestic chicken meat (Baumgartner and Felleisen 2011). 
10.2.2. Prevention measures at the consumer and household 
level 
The ordinance on food of animal origin obliges the producers 
in Switzerland to put a hygiene note on the correct handling of 
fresh poultry meat products on their packaging since January 
2014 (EDI 2016b). The note informs the consumer that the 
fresh poultry meat products need to be thoroughly cooked be-
fore consumption and how they can be handled in a hygienic 
manner at home.  
The information campaign “Richtig zubereiten - sicher genies-
sen” (Prepare properly – enjoy safely, see 
www.sichergeniessen.ch) is run by the FSVO and partners 
from the meat industry and retail business since 2016 (BLV 
2016a). It covers all aspects in regard to the storage and prepa-
ration of raw foods such as meat, eggs, fish or seafood. The 
aim is to better prevent foodborne diseases especially campyl-
obacteriosis by making 4 basic rules for kitchen hygiene 
known countrywide (heat properly, separate properly, wash 
properly, cool properly).  
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Further, the FSVO currently runs an annual campaign for the 
safe preparation and consumption of meat fondue before the 
festive season at the turn of the year which is similar to the 
campaign “Richtig zubereiten - sicher geniessen”. One of the 
main recommendations is the use of two separate plates for raw 
and cooked meat to avoid cross-contamination (BLV 2017) 
which is supported by the case-control study results of this the-
sis (Chapter 4). Also before the barbeque season during 
summer the main hygiene messages of the campaign are com-
municated to the public. 
10.2.3. Impact of measures implemented on the number of no-
tified campylobacteriosis cases 
All the aforementioned measures along the farm-to-fork chain 
are earliest in place since 2014 and the process hygiene criteri-
on for the Campylobacter load on broiler carcasses – a very 
promising control measure – only since 20175. The number of 
notified campylobacteriosis cases slightly increased from 2014 
(7647 cases) to 2016 (7810 cases) with less notified cases in 
2015 (6705 cases) (BAG 2017b). The campylobacteriosis win-
ter peak that is observed around the turn of the year and which 
is related to the consumption of meat fondue was less pro-
nounced in 2016/2017 compared to 2014/2015 and 2015/2016 
(BAG 2017a). There is no direct evidence that this can be at-
tributed to the campaign for the safe preparation and 
consumption of meat fondue and the information campaign 
“Richtig zubereiten - sicher geniessen” by the FSVO. Yet, an 
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impact of these campaigns appears to be likely. The results of 
the case-control study of this thesis received nationwide media 
attention (see Appendix 14.3) which likely also contributed to 
the risk awareness of the Swiss population. 
However, it is too early to make a reliable statement on the 
influence of all the measures on the human disease burden of 
campylobacteriosis. A successful implementation of these 
measures should theoretically lead to a decrease in campylo-
bacteriosis case numbers observed within the NNSID in the 
coming years. This effect was also observed when control 
measures for salmonellosis (e.g. mandatory screening of layer 
hens) were implemented in the 1990s (Schmutz et al. 2016). 
The success of the control measures for Salmonella spp. in the 
poultry sector showed that Switzerland has the potential to con-
trol zoonotic diseases with a One Health approach. A reduction 
of campylobacteriosis case numbers should also be possible 
with the control measures implemented for campylobacteriosis. 
Costs and benefits of the cross-sectorial approach to 
Campylobacter mitigation by the Campylobacter platform 
were assessed for the first time by Babo Martins et al. (2017). 
Costs for the overall mitigation activities – mainly 
commissioned research and surveillance activities in humans 
and animals – between 2009 and 2013 were estimated at 1.85 
million CHF (370,000 CHF per year) (Babo Martins et al. 
2017). The estimated human disease burden of 
campylobacteriosis in Switzerland increased from 1609–2756 
DALYs in 2008 to 1751–2852 DALYs in 2013 (Babo Martins 
et al. 2017). As mentioned before, Campylobacter control 
measures targeting the food chain are in place earliest since 
2014. A cross-sectorial economic assessment using the same 
methodological framework should be performed again in the 
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coming years to assess the cost and benefits of control 
measures implemented along the farm-to-fork chain. 
Case notifications at the end of 2019 should be compared with 
the previous years as the process hygiene criterion for 
Campylobacter spp. will then be in place nationwide for more 
than a year
6
 and case numbers could be already declining. 
When assessing the impact of measures implemented by the 
analysis of NNSID case notifications positivity rates and 
diagnostics applied (culture methods vs. PCR) should be 
considered (Chapter 10.1.3). Unfortunately the NNSID does 
not collect any information that would allow distinguishing 
between autochthonous and travel-associated 
campylobacteriosis cases. This would be ideal to gather a better 
picture of the impact of the control measures applied on 
NNSID case numbers. 
Currently, 40 to 84% of human campylobacteriosis cases in 
Switzerland originate from the poultry reservoir (Kittl et al. 
2011, Kittl et al. 2013a, Jonas et al. 2015). If control measures 
are successful, the proportion of chicken-associated cases will 
likely decrease and hence, a decline in case numbers can be 
expected. Sources of infections should be assessed in the future 
by genetic source attribution studies as already previously done 
in Switzerland. Although the majority of human campylobac-
teriosis cases in Switzerland currently originates from the 
poultry reservoir other sources of infection such as raw milk or 
contaminated drinking water should not be neglected. These 
sources will likely require more attention to decrease the dis-
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ease burden in Switzerland further if the control measures in 
the poultry sector have the desired effect. 
10.3. Strengths and limitations of the research conducted 
Each research component was conducted in the most appropri-
ate way considering given financial, administrative, personal 
and temporal limitations. They were often implemented within 
running systems such as the NNSID or Sentinella which was 
often not straightforward and required reasonable compromises 
for implementation. On the other hand, this allowed gaining 
reliable and valid results for and insights into these systems for 
public health authorities and researchers. Major strengths and 
limitations of the chosen research approach are outlined below 
and detailed strengths and limitations of individual research 
components can be found in the corresponding result chapters 
(Chapter 4 to 9). 
The case-control study (Chapter 4), the analysis of TESSy sur-
veillance data (Chapter 5), the analysis of positivity rates 
(Chapter 6) and the estimation of health care costs (Chapter 9) 
(partially) relied on notified and laboratory-confirmed campyl-
obacteriosis cases. These cases represent only a subgroup of 
campylobacteriosis cases as cases with mild disease progres-
sion are less likely to consult a physician or to be tested for 
campylobacteriosis and, hence, less likely to be notified. 
Therefore, generated research results are often highly reliable 
for laboratory-confirmed cases while the results might not al-
ways be directly transferable to cases with mild disease. 
Laboratory-confirmed cases for the case-control study and la-
boratory data for the analysis of positivity rates originated from 
private laboratories which operate on a regional or national 
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level and predominantly serve the practices of GPs and medical 
specialists. The catchment population of the participating la-
boratories was not known and hospital-based laboratories were 
not included. As a result, the hospitalisation rate and the pro-
portion of patients approaching emergency departments and 
policlinics directly as estimated by the case-control study may 
be underestimated. An estimation of stool sampling rates and 
an assessment of the representativeness of the patient popula-
tion could not be done given the aforementioned 
circumstances. Cases included in the analysis of positivity rates 
and notified cases were comparable and hence, estimated posi-
tivity rates are likely to represent accurately the 
epidemiological trends and situation in Switzerland. 
A mainly descriptive approach was chosen for the analysis of 
positivity rates and for the analysis of TESSy surveillance data. 
This approach produced reliable and solid descriptive results 
for the understanding of Campylobacter transmission dynamics 
and the disease presentation at the laboratory and surveillance 
level. However, more sophisticated analysis by a time-series 
model taking into account endemic and epidemic behaviours 
and seasonality of laboratory and surveillance data would have 
been an option, too. This was previously done for Swiss cam-
pylobacteriosis notification data but results were similar to 
another descriptive analysis (Wei et al. 2015, Schmutz et al. 
2016). In summary, using a time-series model like suggested 
would likely not have added new insights compared to the ap-
proaches applied. 
The combination of a qualitative and a quantitative study at the 
primary care level (Chapter 7 and 8) provided an ideal and 
unique opportunity to assess the presentation and case man-
agement of campylobacteriosis and AG patients and the 
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associated disease burden at the primary care level. First, a 
qualitative approach was chosen due to the lack of knowledge 
on AG and campylobacteriosis at the primary care level in 
Switzerland. This first approach generated valuable results for 
the planning, design and content of the following quantitative 
approach. Yet, it only allowed for first semi-quantitative esti-
mates on the disease burden and important determinants for the 
NNSID such as the stool testing rate by GPs. The disease bur-
den and determinants for the NNSID at the primary care level 
were subsequently quantified by the quantitative study within 
Sentinella. The combination of these approaches allowed to 
cross-validate study results increasing their reliability and sig-
nificance. 
The estimation of health care costs due to campylobacteriosis 
and AG (Chapter 9) was the first of its kind done so far for 
Switzerland. Only direct health care costs of campylobacterio-
sis and AG were considered. Costs associated with patients not 
consulting at the primary care level, hospitalisations due to 
other IID than campylobacteriosis or sequela (e.g. Guillain–
Barré syndrome, reactive arthritis or irritable bowel syndrome) 
were not considered as corresponding information was often 
lacking. The calculations performed were based on several 
assumptions and own (preliminary) research results leading to 
a rather wide range of estimated costs. Estimates were cross-
validated whenever possible by combining different data 
sources e.g. official hospital statistics or real patient data from 
the Swiss TPH’s travel clinic. As a result, the estimated costs 
are rather conservative i.e. likely underestimate the real health 
care costs for campylobacteriosis and AG. 
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11. Conclusion 
This is the first comprehensive assessment of the epidemiology 
of human campylobacteriosis and AG in Switzerland consider-
ing also related data from the NNSID. The consumption of 
meat fondue especially if consumed with chicken meat and 
travelling abroad are important drivers for the observed cam-
pylobacteriosis peak around the turn of the year. The 
consumption of meat fondues or table top grillings is likely to 
play a similar role in other European countries with increased 
case numbers during this period of time. Human campylobac-
teriosis and AG cause a considerable disease burden in the 
primary care setting and at the hospital level. Epidemiological 
trends of campylobacteriosis are accurately reflected by sur-
veillance data from the NNSID. The number of annually 
notified campylobacteriosis cases remains on a high level alt-
hough the Campylobacter problem figures high on the agenda 
of the Swiss authorities and poultry industry since many years. 
This high disease burden within the Swiss health system results 
in substantial health care costs. Yet, the exact burden of AG 
and campylobacteriosis in the community and the specific dis-
ease burden of other IID than campylobacteriosis remain 
largely unclear. Hence, there is a clear need to assess the 
presentation and disease and economic burden of AG and IID 
at the community level given the unknown situation at this lev-
el of the burden-of-illness pyramid.  
Swiss public health authorities should regularly re-assess de-
terminants of the burden-of-illness pyramid (health care 
seeking, stool testing and positivity rates) to strengthen the 
surveillance of IID by the NNSID especially considering the 
ongoing changes in diagnostics applied and test numbers ob-
tained. Additionally, the sentinel surveillance network 
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Sentinella would provide an ideal tool for the routine surveil-
lance of AG at the Swiss primary care level. Yet, it is currently 
not suitable for the surveillance of specific IID. 
Laboratory-confirmed campylobacteriosis cases and many AG 
patients suffer from a severe course of disease and a 
considerable proportion - especially elderly - requires 
hospitalisation and/or antibiotic therapy. Around 60% of AG 
patients and 50% of campylobacteriosis patients receiving 
antibiotic therapy are treated with quinolones although more 
than 50% of Campylobacter spp. – the most common cause of 
bacterial AG in Switzerland - are resistant to fluoroquinolones. 
Public health authorities in partnership with medical 
associations should consider developing national case 
management guidelines including antibiotic therapy 
recommendations for patients suffering from AG and IID. 
  
Recommendations 
311 
11.1. Recommendations 
 The epidemiology and disease and socioeconomic 
burden of AG and IID at the community level in 
Switzerland should be assessed e.g. by a population-
based longitudinal study. 
 Sporadic cases of viral IID – at least due to norovirus 
and rotavirus – should be notifiable and reported to the 
NNSID as surveillance data on viral IID of public 
health importance is lacking so far. 
 AG at the primary care level should be monitored 
through the Sentinella network similar to ILI. This 
would allow a regular assessment of the burden and 
epidemiology of AG which are not well known so far. 
 If the current control measures do not lead to the de-
sired reduction of human campylobacteriosis in 
Switzerland stricter or additional control measures 
along the food chain need to be considered e.g. a lower 
limit for the process hygiene criterion or mandatory 
chemical decontamination or irradiation. 
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12. Outlook 
The research approach applied in this PhD was not conceptual-
ised to assess the presentation and the disease and 
socioeconomic burden of AG, campylobacteriosis and other 
IID at the community level in Switzerland. The Sentinella 
study provides only an estimate for the disease burden at the 
Swiss primary care level (Chapter 8). Many cases suffering 
from AG or IID will not contact a GP during their course of 
illness but are also significantly contributing to the overall na-
tional disease and socioeconomic burden. To know how AG 
and IID present at the community level is crucial to strengthen 
the interpretation of surveillance data from the NNSID and to 
estimate the overall national disease and socioeconomic burden 
of IID. 
A longitudinal population-based study would be the ideal study 
design to close this knowledge gap. A study protocol for such a 
study was developed within the Household Health Systems 
Research Group during this PhD and funding from the FOPH 
and FSVO was already in parts received to conduct the study. 
The findings of this PhD work in concert with the forthcoming 
results and lessons learnt from the said population-based cohort 
study on AG will soon contribute to an even better understand-
ing of the epidemiology and the disease and socioeconomic 
burden of AG and IID in Switzerland. 
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